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People with serious mental illness (SMI, including schizophrenia and bipolar disorder) 
experience adverse health and premature mortality. Higher incidence and/or worse 
outcome of acute myocardial infarction (AMI) may partly underlie this. 
Objectives:   
1. To investigate the relative risk of AMI in adult patients with SMI 
2. To compare receipt of invasive coronary intervention, inpatient mortality, and 
recurrence of cardiovascular diseases following AMI between patients with and 
without SMI 
3. To investigate the association between AMI and recent antipsychotic exposure 
among people with SMI 
Design: Historic cohort study for the first two objectives and a case-crossover design 
for the third objective. 
Setting: The Taiwan National Health Insurance Research Database (NHIRD). 
Participants: For the first two objectives, adult patients with diagnoses of 
schizophrenia or bipolar disorder were compared to general population controls. For 
the third objective, a ‘case-crossover design’ was utilized, with antipsychotic exposures 
compared between a ‘case period’ (proximal to the index AMI) and a ‘control period’ 
(more distal to the index AMI). 
Main Outcome Measures: Adjusted hazard ratios of AMI were calculated using Cox 
regression. Invasive coronary interventions and outcomes were compared in logistic 
regression models. Odds of antipsychotic exposure in case and control time periods 
were compared within individuals using conditional logistic regression models.  
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Results: Overall, no increased risk of AMI was found in people with SMI, apart from 
in sub-group analyses (suggesting an excess SMI-associated risk in younger women). 
Patients with schizophrenia and bipolar disorder were less likely to receive invasive 
coronary interventions following AMI episode compared to controls, and inpatient 
mortality was higher in patients with schizophrenia compared to controls. AMI was 
significantly associated with more recent antipsychotic exposure in schizophrenia but 
not in bipolar disorder.  
Conclusion: Schizophrenia and bipolar disorder were only associated with raised risk 
of AMI in young women, but post-AMI care was less adequate in both conditions. A 
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CHAPTER 1  
INTRODUCTION: SERIOUS MENTAL ILLNESS AND GENERAL HEALTH
  
2
1.1 Serious Mental illness  
The term “serious mental illness” (SMI) was initially defined and measured by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) in 1996 
for the purpose of investigating the prevalence, characteristics, and utilization of 
mental health treatments in people with SMI and/or those with co-occurring 
substance use disorders among all persons aged 18 or older (Epstein, 2004). Criteria 
for SMI were first addressed in the National Survey on Drug Use and Health 
conducted by SAMHSA and were listed as follows (SAMHSA, 1993; Kessler et al., 
2003): 
- ‘A mental, behavioral, or emotional disorder (excluding developmental and 
substance use disorder),  
- Diagnosable currently or within the past year, 
- Of sufficient duration to meet diagnostic criteria specified within the 4th edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)(APA, 
1994), 
- Resulting in serious functional impairment, which substantially interferes with 
or limits one or more major life activities’ (NIMH, 2008).  
 
In 2003, the prevalence of SMI was 9.2 percent among the population aged 18 or 
older in the United States (SAMHSA, 2003). Disorders encompassed within these 
criteria were estimated to account for 14% of the burden of disease world wide, and 
up to half of all disability-adjusted life-years (the sum of years lived with disability 
and years of life lost) (Mathers & Loncar, 2006; Murray & Lopez, 1996; Prince et al., 
2007). 
 
Different studies have included different mental disorders such as schizophrenia, 
schizoaffective disorder, bipolar disorder, and/or major depressive disorder ((Chang 
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et al., 2010; Chang et al., 2011; Hayes et al., 2012; Kessler et al., 2003; Kessler et al., 
2001; Wang et al., 2002) into definitions of SMI. In this thesis, diagnoses of 
schizophrenia and bipolar disorder were investigated specifically within this category 
as the major component mental disorders, following the majority of research in this 
field, and because they both typically involve psychosis, tend to be more chronic and 
severe, and require high levels of care due to mental or physical consequences 
(Chang et al., 2010; Hayes et al., 2012; Kessler et al., 2003).  
 
Schizophrenia is a debilitating mental disorder of the brain with characteristic 
symptoms of auditory hallucinations, bizarre or paranoid delusions, or disorganized 
speech or thinking for at least one month. Bipolar disorder is characterized by 
episodes of mood swings alternate from baseline to mania or depression. For a 
formal diagnosis, a person with schizophrenia or bipolar disorder must be 
experiencing significant impairment in their social, interpersonal, or occupational 
functions for at least six months. There are about 24 million people suffering from 
schizophrenia (WHO, 2001), and 27 million people with bipolar disorder worldwide 
(WHO, 2003). Lifetime prevalences have been estimated as 0.3 to 0.7% for 
schizophrenia (van Os & Kapur, 2009) and 2 to 5% for bipolar disorder (Ketter, 
2010).  
 
Schizophrenia and bipolar disorder have been estimated to result in 2.3~2.8 % of the 
total ‘years lost due to disability (YLD)’, respectively ranking fifth and seventh in 
men, and sixth and eighth in women, with respect to the ten leading global causes of 
YLD in 2004 (WHO, 2008a). They are associated with more severe disability: 
bipolar disorder has a disability class of V, and active psychosis due to schizophrenia 
or schizoaffective disorder fall into the most severe class of VII on the Disability 
classes for Global Burden of Disease study (WHO, 2008a). Moreover, people with 
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these disorders have a reduced life expectancy compared to the general population 
(Brown, 1997), and are more likely to suffer from a range of physical disorders 
including respiratory diseases, infectious diseases, digestive diseases and 
cardiovascular diseases (Dickey et al., 2002; Oud & Meyboom-de Jong, 2009), as 
well as being less likely to receive standard care (Bradford et al., 2008; Desai et al., 
2002; Kisely et al., 2007; Oud & Meyboom-de Jong, 2009).  
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1.2 Excessive mortality due to natural causes in people with SMI compared with 
the general population  
People with SMI experience significant functional decline and premature mortality 
(Kisely et al., 2005; Murray & Lopez, 1996). Recent literature has demonstrated 
significantly increased overall mortality in people with SMI with mortality rate ratio 
ranging from 1.74 to 2.57 (Kisely et al., 2005; Lawrence D et al., 2000). In addition, 
excess mortality for specific causes of death has been reported, including that from 
cardiovascular diseases, with standardized mortality ratios ranging from two- to 
six-fold excess risk (Kamara et al., 1998; Osby et al., 2001; Osby et al., 2000; 
Rasanen et al., 2003; Valenti et al., 1997), as well as coronary heart disease (adjusted 
hazard ratios (HRs) ranging from 1.04 to 2.88 across different age groups), and 
stroke (adjusted HRs ranging from 1.33 to 2.39 across different age groups) (Osborn 
et al., 2007).  
 
Considering specific diagnoses within SMI, research worldwide has consistently 
found that people with schizophrenia have two to three times higher mortality rates 
for almost all causes of death (Allebeck & Wistedt, 1986; Babigian & Odoroff, 1969; 
Berren et al., 1994; Brown, 1997; Felker et al., 1996; Harris & Barraclough, 1998; 
Koranyi, 1979; M et al., 2011; Mortensen & Juel, 1990, 1993; Newman & Bland, 
1991; Saha et al., 2007; Tsuang & Simpson, 1985; Tsuang et al., 1980). It is 
estimated that schizophrenia is associated with a 20% reduction in life expectancy 
(which translates to a 13 years of shortened life expectancy) compared with the 
general population (Chang et al., 2011; Hennekens et al., 2005). Although SMI is 
associated with a raised risk of unnatural causes of death, such as suicide (Brown, 
1997), deaths from natural causes have been estimated to be responsible for eighty 
percent of deaths in people with schizophrenia: about 1.4 times higher than expected 
(Harris & Barraclough, 1998), and account for about 59% to 62% of the excess 
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mortality compared with general population (Brown, 1997; Harris & Barraclough, 
1998). A meta-analysis of 9 studies published between 1982 to 1993 (encompassing 
a total population of nearly 6000) estimated that the standardized mortality ratio 
(SMR) from natural causes of death was 134 (95% CI: 131~137) (Brown, 1997). An 
SMR within a similar range (SMR=137, 95% CI: 134~141) was estimated in another 
meta-analysis based on 20 studies published from 1973 to 1995 (Harris & 
Barraclough, 1998). Although the distributions of causes for these natural deaths in 
people with schizophrenia were broadly similar to general population, the SMRs for 
particular causes have been found to be significantly higher. For instance, the SMR 
for infectious disease mortality was 944 (95% CI: 851~1045) for schizophrenia; 
those for respiratory disease mortality ranged from 226~230; that for gastrointestinal 
disease mortality was around 185; that for cardiovascular or circulation disease 
mortality was 104~110. However, SMRs for neoplastic disease mortality have either 
not been found to be significantly elevated, or have been found to be significantly 
lowered in men (Brown, 1997; Harris & Barraclough, 1998). 
 
Much less research has investigated mortality associated with bipolar disorders or 
affective psychosis compared to schizophrenia. A meta-analysis based on 6 studies 
of bipolar disorder with a total population size of over 4500, reported an associated 
SMR of 150 (95% CI: 137~164) for natural death, accounting for 46% of the excess 
death compared with general population (Harris & Barraclough, 1998). The main 
causes of excess mortality from natural deaths were respiratory diseases (SMR: 1034, 




1.3 Worse general health in SMI and reasons 
The excess mortality from natural causes in people with SMI may be explained by a 
higher prevalence of physical comorbidities than in the general population 
(Hennekens et al., 2005; Kisely et al., 2005; Laursen et al., 2007; Lawrence DM et 
al., 2003; Osby et al., 2001; Roshanaei-Moghaddam & Katon, 2009). A wide range 
of studies have confirmed this with respect to different physical disorders including 
cardiovascular disease, infectious diseases, diabetes, respiratory diseases, and some 
forms of cancer (Jeste et al., 1996; Kilbourne et al., 2004), with prevalence of 
physical illness ranged from 9~74% in people with SMI, much higher than the 
general population (Oud & Meyboom-de Jong, 2009). Odds ratios (OR) for such 
associations have ranged from 1.1 to 1.8 for cardiovascular diseases (Bresee et al.; 
Callaghan et al., 2009; Hayward, 1995; Osborn et al., 2007), and 1.8 to 3.8 for 
diabetes. Other disorders where higher than expected comorbidity has been found 
with SMI include obesity (1.5~2-fold) (Daumit et al., 2002; Lambert & Newcomer, 
2009; Newcomer, 2007), hypertension (1.6-fold) (Goff et al., 2005), malignant 
neoplasm (1.2~1.4-fold)(Dickey et al., 2002; Lichtermann et al., 2001), 
gastrointestinal disorders (1.6-fold) (Dickey et al., 2002), HIV (1.4-fold) (Gearon & 
Bellack, 1999; Stoskopf et al., 2001), dyslipidaemia (5-fold) (Lambert & Newcomer, 
2009; Newcomer, 2007), and both acute and chronic respiratory disease (1.2-fold) 
(Dickey et al., 2002). Most of the above studies either focused on people with 
schizophrenia (Bresee et al., 2010; Curkendall et al., 2004; Lambert et al., 2003; 
Lichtermann et al., 2001) or a broader category of psychotic disorder or SMI (Dickey 
et al., 2002; Osborn et al., 2006). Much less attention has been given into 
investigation of medical comorbidity in people with bipolar disorder and inconsistent 
findings have been reported. For instance, some studies have found an elevated risk 
of cardiovascular diseases in people with bipolar disorder, 1.3~1.6 times higher than 
that in the general population (Callaghan & Khizar, 2009; Kilbourne et al., 2007); 
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whereas Lin et al. found no significantly increased risk of acute myocardial 
infarction (Lin et al., 2008). 
 
Previous research has suggested that such worse physical health in people with SMI 
might be conceptualized in terms of unwanted events, environmental or economic 
risks, and health and lifestyle risks (Kilbourne et al., 2006). An example is the 
relatively high prevalence of respiratory disease in people with SMI. One study 
found that 15% of people with schizophrenia and 25% of those with bipolar disorder 
had chronic bronchitis; with 16% and 19% respectively having asthma: all 
significantly higher than matched controls (Sokal et al., 2004). Such phenomena may 
reflect the high frequency of smoking or passive smoking among people with mental 
disorders (Druss et al., 2001a). Another example is cancer in people with SMI. 
Although studies of lung cancer risk in people with schizophrenia have remained 
inconsistent in their findings (Brown et al., 1999; Lichtermann et al., 2001; 
Mortensen, 1994), other research has more consistently found higher risks of 
digestive and breast cancers associated with schizophrenia (Schoos, 2003), 
understandable when risk factors of cancer such as tobacco use, unhealthy diet, and 
physical inactivity, are also known to be more prevalent in people with SMI (Brown 
et al., 1999; Diaz et al., 2009).  
 
Besides the aformentioned risk health behaviors, recent research has also suggested 
that people with SMI and physical comorbidity may receive less adequate medical 
care when judged against clinical standards, with odds ratios for individual 
recommended preventive physical care or treatments associated with presence of a 
SMI ranging from 0.35~0.85 (Druss et al., 2001a; Mitchell et al., 2009). However, 
studies investigating this face substantial methodological challenges. In particular, 
the prevalence of SMI is quite low, and it is therefore difficult to identify databases 
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with sufficient numbers of people who have both SMI and a given physical illness to 
investigate these questions (Cohen et al., 2002).  
 
Of the aforementioned physical comorbidities suggested to have higher prevalence 
among people with SMI, cardiovascular disease (CVD, a class of disease that involve 
the heart or blood vessels, with hypertension, ischemic heart disease, coronary heart 
disease, or acute myocardial infarction as the most common disorders (Harrison's 
Principles of Internal Medicine 17th Edition, 2008) is already the leading cause of 
death in the world population. CVD was deemed to be responsible for 29.2% of all 
deaths in the world (WHO, 2004). Among all CVD, ischemic heart disease (IHD, 
which includes acute myocardial infarction (AMI), angina pectoris, and heart failure 
when preceded by AMI) alone accounts for nearly 13% of the total deaths worldwide 
(7.3 million out of total deaths of 57 million people) (WHO, 2008b). In addition, 
IHD was estimated to rank 4th among the leading causes of burden of disease, 
contributing a total of 62.6 million DALYs (Disability-adjusted life years, one DALY 
representing the loss of the equivalent of one year of full health): 4.1% of the total 
(WHO, 2008a). While IHD is suggested to cause substantial burden in the general 
population, reports have also shown that IHD accounts for more than 10% of DALYs 
in people with SMI (Prince et al., 2007). IHD has also been found to be the major 
cause of excess mortality in psychiatric patients (Lawrence DM et al., 2003). 
However, despite the gradual decline in IHD mortality in Australia, droping from 
139~209 per 100,000 person-years to 117~143 per 100,000 person-years over the 
past 20 years, it remained approximately constant (at an average of 280 per 100,000 
person-years) in male patients with mental disorders, and has shown an 81 per 
100,000 person-years increase in female patients thus affected (Lawrence DM et al., 
2003). With higher prevalences of many risk factors of IHD in people with SMI, 
such as cigarette smoking (Brown et al., 1999; Dixon et al., 1999; Druss et al., 2001a; 
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Hennekens et al., 2005; Lambert & Newcomer, 2009; McCreadie, 2003; Newcomer, 
2007), sedentary lifestyle (Brown et al., 1999), poor diet (McCreadie, 2003), obesity 
(Fontaine et al., 2001; Manson et al., 1987), hypertension (Collins et al., 1990; 
Rosner et al., 1977), and hyperlipidemia (Wilson et al., 1998) (Robson & Gray, 2007),  
and lower receipt of adequate cardiac intervention (Mitchell & Lawrence, 2011), 
there is a pressing need to understand more about the IHD risk and outcome facts 
among patients with SMI. 
 
IHD can be categorized into two groups: (1) chronic coronary artery disease (CAD), 
most commonly presenting as stable angina; (2) acute coronary syndromes (ACS), 
composed of acute myocardial infarction (AMI) with ST-segment elevation (STEMI) 
on the electrocardiogram (ECG), unstable angina (UA), and non-ST-segment 
elevation myocardial infarction (NSTEMI) (Harrison's Principles of Internal 
Medicine 17th Edition, 2008). Most individuals with IHD show no symptoms or 
signs until the disease progresses to ischemia, when the blood supply to the tissue 
fails to meet its demand due to the restriction caused by atherosclerotic plaque on the 
wall of the blood vessel. AMI occurs when an atherosclerotic plaque ruptures and 
occludes the coronary artery causing reduced oxygen supply and subsequent tissue 
death (Cotran RS, 1994; Graham et al., 2007). AMI is diagnosed from complaints of 
chest pain or discomfort not relieved by rest, findings from the 12-lead ECG, and 
serum cardiac biomarkers of creatinine kinase-MB (CK-MB) or troponin to 
distinguish UA from NSTEMI. For patients with ACS, initial treatments should 
include bed rest, nitrates, beta-blockers, and oral or intra-venous anti-thrombotic 
therapy. Invasive coronary interventions including coronary arteriography or 
diagnostic catheterization carried out within 48 hours of admission have been shown 
to benefit high-risk patients, i.e. patients with multiple clinical risk factors, 
ST-segment deviation, and/or positive biomarkers. Decisions regarding coronary 
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revascularization, such as percutaneous transluminal coronary angioplasty (PTCA) or 
coronary artery bypass surgery (CABG) are then made depending on findings of 
multiple blockage in coronary arteries investigated by coronary angiography 
(Harrison's Principles of Internal Medicine 17th Edition, 2008; Van de Werf et al., 
2008). Prognosis of AMI depends greatly on the person’s own health, the extent of 
myocardial damage, and the treatments given (Krumholz et al., 2009). However, a 
meta-analysis of studies encompassing 825,754 individuals concluded that, in people 
with defined mental disorder, not only is the mortality up to one year after AMI 
higher than comparison groups (OR = 1.11, 95%CI: 1.00~1.24, p=0.05), but also the 
receipt of diagnostic and treatment interventions are significantly lower (OR ranged 
from 0.85~0.87)(Mitchell & Lawrence, 2011).  
 
Moreover, while some of the excess risk of AMI is likely to be explained by adverse 
lifestyle factors such as smoking and physical inactivity (Robson & Gray, 2007), 
potential adverse effects of antipsychotic agents have also attracted extensive 
attention (Brauer et al., 2011; Foley & Morley, 2011). As well as associations with 
obesity and impaired glucose tolerance as predisposing factors for cardiovascular 
outcomes (Newcomer, 2004), antipsychotic agents may also have a range of 
shorter-term adverse cardiovascular effects including QT interval prolongation 
(Stollberger et al., 2005; Trojak et al., 2006; Vieweg, 2002), ventricular arrhythmia 
(Gury et al., 2000; Wang et al., 2007), and sudden cardiac death described in 
schizophrenia (Straus et al., 2004), as well as potential ischemic stroke risk in 
dementia (Douglas & Smeeth, 2008; Pariente et al., 2012; Rochon et al., 2008). 
However, research findings in this field are still inconclusive. For instance, Honkola 
et al.(Honkola et al., 2012) found that use of an antipsychotic was significantly 
associated with the risk of sudden cardiac death during an acute coronary event, with 
an OR of 3.4 (95% CI 1.8~6.5) in a case-control study. On the other hand, Osborn et 
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al. (2007) investigated antipsychotic prescription as a potential mediator but found 
that this did not explain wholly the elevated risk of cardiovascular diseases, although 
the association between antipsychotic use and mortality from cardiovascular diseases 
and stroke was found to show a dose-dependent relationship with hazard ratios 
ranging from 1.40 to 4.11 (Osborn et al., 2007). A recent systematic review reported 
a range of both significant and absent associations between antipsychotic exposure 
and occurrence of AMI among studies in heterogenous clinical settings or using 
different methodology (Brauer et al., 2011). 
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1.4 Structure of the thesis 
The focus of this thesis is on the relationships between schizophrenia, bipolar 
disorder and acute myocardial infarction (AMI). Chapters 2~4, provide a 
background to the thesis. Chapter 2 reviews studies investigating the risks of 
cardiovascular diseases, coronary heart disease, or AMI in people with and without 
SMI. Chapter 3 reviews literature on intervention receipt following AMI in people 
with and without SMI. In Chapter 4, literature on studies to date investigating 
associations between antipsychotic exposure and AMI are summarized. Gaps from 
literature review, objectives and specific hypotheses of this thesis are described in 
Chapter 5.  
 
Chapter 6 describes the materials, database, measurements, independent and 
outcome variables, and processes of data management applied in this study. 
Chapters 7~9 then describe in detail the particular statistical analyses used to 
examine individual hypothesis and summarize the results from the study followed by 
individual discussion of inferences arising from these. Chapter 7 describes and 
compares the risk of AMI in two cohorts of people with and without SMI stratified 
by age and gender. Chapter 8 compares the odds of intervention receipt and 
inpatient mortality following an AMI in people with or without SMI. In Chapter 9, 
associations between AMI and antipsychotic exposure as a potential precipitating 
factor are investigated. Finally, in Chapter 10, the findings from the three preceding 
chapters are brought together, discussed further, and potential implications are 





SYSTEMATIC REVIEW ON THE RISK OF ACUTE MYOCARDIAL 
INFARCTION IN PEOPLE WITH SERIOUS MENTAL ILLNESS
  
15
As mentioned in Chapter 1, relatively high morbidity and mortality for almost all 
causes of death have been found in people with serious mental illness (SMI), 
especially schizophrenia. Although previous research has investigated prevalent 
cardiovascular or coronary heart disease among people with schizophrenia, the risk 
of acute myocardial infarction (AMI) in patients with schizophrenia and bipolar 
disorder is less well documented. The first part of the literature review in this thesis 
therefore focuses on studies which have compared AMI comorbidity between people 
with and without SMI.   
 
2.1 Search strategy 
To encompass all literature comparing incidence of AMI in people with or without 
SMI, a broad category of cardiovascular or coronary heart disease was included in 
this review. Individual articles were searched on Pub Med and Ovid Medline using 
the following search strings:  
(Schizophrenia OR bipolar disorder) AND (myocardial infarction OR cardiovascular 
disease) 
or 
(Schizophrenia OR bipolar disorder) AND (somatic disease) 
or 
(Schizophrenia OR bipolar disorder) AND (comorbidity) 
or 
(Schizophrenia OR bipolar disorder) AND (physical) 
(Prevalence OR incidence OR comorbidity) AND (myocardial infarction OR 
coronary heart disease OR cardiovascular disease) AND (mental illness OR schizo* 
OR bipolar* OR psych*) 
 
(Astrix ‘*’ in search term searches any ending to the word such as ‘psychiatric’ or 
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‘psychotic’; or ‘schizophrenia’ or ‘schizoaffective’). 
 
2.2 Selection criteria for studies reviewed 
Searches were restricted to studies involving human subjects over 18 years of age; as 
well as to those carried out in the most recent ten years using large databases 
(because, since the prevalence of SMI comorbid with AMI is low, large samples are 
required in order to draw meaningful conclusions). A search for review articles was 
carried out before searching for individual articles. Two recent reviews were found 
(Oud & Meyboom-de Jong, 2009; Weiner et al., 2011). Titles of articles identified 
from Pub Med or Ovid Medline which were not on the reference list of these two 
review papers were further examined. Due to the large amount of literature obtained 
from PubMed and Ovid Medline, the custom filter on Pub Med was also used in 
addition to manual checking to exclude articles that did not match the purpose of 
search. Abstracts of articles not written in English or Chinese were further examined 
and excluded if the contents were not relevant to the objective of search. The 
searches were performed initially in September 2009, with the main database of 
searches updated in October 2012. Additional articles appearing in the reference lists 
of papers found from the original search were tracked or located from additional 
book chapters or conference papers. Full texts of relevant articles were accessed and 
those that matched the search purpose were summarized. 
 
The main outcomes of interest were the odds of prevalence or incidence of an AMI 
episode expressed as relative risks (RRs), rate ratios, odds ratios (ORs) or hazard 
ratios (HRs) compared between people with and without SMI. Both crude and 




Articles that matched the above search string but were not relevant to the objective of 
this study, and were therefore excluded from this literature review, are categorized 
and listed as follows: 
1. Studies investigating cardiovascular diseases in relation to central nervous system 
stimulants or tobacco.  
2. Reviews or studies not focusing on patients with or without SMI.  
3. Studies lacked data on the prevalence or incidence of AMI or coronary heart 
disease.  
4. Studies focused on the relationships between depression, cognitive functions, 
health behaviors, or quality of life and AMI.  
5. Studies focused on the prevalence or incidence of cardiovascular risk factors or 
levels of blood markers (eg. c-reactive protein or creatinine kinase-MB).  
6. Studies focused on risk of AMI with antipsychotic use, but not with serious 
mental illness.  
The systematic reduction of articles was described in Figure 2.1. 
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Figure 2.1 Flow chart of study selection for literature review  








Excluded titles or 
abstract not containing 
any of the search terms 









Full text assessed 
n=53 
Excluded studies not 
focusing on people with 
schizophrenia or bipolar 
disorder (n=12), or risk 
of AMI (n=6)  
Discarded studies that 
were more than 10 
years old or with 
irrelevant titles 
(n=2,150) 
Full text assessed 
n=48 
Excluded studies only 
about cardiovascular 
risk factors (n=24) or 
risk estimates (n=4) 
Excluded studies 
focused on the risk of 
AMI with antipsychotic 
use without a general 
population comparison 
group (n=5) 




2.3 Search findings 
Of the 2,656 articles identified, 2,020 were discarded because they were conducted 
and published more than ten years ago, did not use large computerized 
population-based databases, or whose title or abstract did not contain any of the 
search terms following manual checking and using the custom filter of PubMed. 
Most of these 2,020 were initially identified because they contained just ‘risk’, 
‘morbidity’, ‘prevalence’, OR ‘incidence’; AND ‘somatic’, ‘physical’, OR ‘vascular’; 
AND ‘illness’. Of the remaining 506 papers, abstracts were assessed and the 
aforementioned exclusion criteria were applied. A total of 13 studies were included in 
addition to the two reviews. Fourteen papers compared people with and without SMI. 
One study focused on the rather broader category of ‘patients with diagnosis of 
psychosis’ (Truyers et al., 2011). Seven of these papers analyzed specific psychiatric 






Table 2.1 Studies of acute myocardial infarction (AMI) or coronary heart disease (CHD) among people with SMI (mainly schizophrenia if not 
specified) 
              




Age or mean age of inclusion; 
Design of study; Control for 
confounders 
Main findings: (adjusted odd ratios (aOR), 
hazard ratios (HR), or incidence rate ratio 
(IRR), with 95% confidence interval)  
Dickey  
(Dickey et al., 2002), 
US 
- Total 26,332 Medicaid beneficiaries 
aged 18~64 in Massachusetts 
- 11,185 patients has been treated 
with severe mental illness2 
- One year prevalence 
- Mean age: 40 (SD 11) and 32 
(SD10) for those with or without 
mental disorders, respectively 
-Cross-Sectional study 
- Adjusted for age, gender, and race or 
ethnicity 
People with severe mental illness had an increased 
risk of heart disease with an adjusted odds ratio of 
3.19 (95%CI 2.51~4.07) 
Curkendall 
(Curkendall et al., 
2004), Canada 
-3,022 patients with schizophrenia 
- Four age- and gender- matched 
controls for each individual 
- Mean age: 49.6 (SD 17.8) and 49.6 
(SD17.7) for those with or without 
schizophrenia, respectively 
- Cohort study 
- Prevalence of cardiovascular 
morbidity during 1994 and 1995 
- Incidence of cardiovascular morbidity 
from 1996~1999 
- Adjusted for age, sex, and medical 
risk factors 
- Associations between schizophrenia and 
prevalence of AMI: aOR=1.3, 95%CI 0.9~1.9;  
- Associations between schizophrenia and 
prevalence of ischemic heart disease: aOR=1.1, 
0.9~1.3  
- Associations between schizophrenia and 
incidence of AMI: aOR=0.9, 95%CI 0.6~1.4 
- Associations between schizophrenia and 





(Goff et al., 2005), 
US 
-689 Schizophrenia patients 
recruited from 54 clinical sites 
- Age and gender matched controls 
- Mean age: 40.4 (SD 11.2) and 40.4 
(11.2) for those with or without 
schizophrenia, respectively 
- Cohort study 
- Incidence of CHD morbidity from 
1999~2004 
People with schizophrenia had a significantly 
higher ten-year risk of coronary heart disease in 
both male (9.4% vs. 7.0%) and female (6.3% vs. 
4.2%) compared to controls (p < 0.001). 
Kilbourne 
(Kilbourne et al., 
2007), Canada 
- 7,529 male Veteran Administration 
patients of different psychiatric 
diagnoses 
- Mean age: 54.5 years 
- Cross-sectional study 
- Adjusted for or stratified by age 
- People with bipolar disorder were 44% more 
likely to have CHD than patients with 
schizophrenia 
Lin 
(Lin et al., 2008), 
Taiwan 
-1429 hospitalized patients with 
bipolar disorder,  
-Compare with patients receiving 
appendectomy (n=4993) 
-1997~2001 
-Mean age: 54.8 (SD 9.6) and 60.0 
(11.6) for those with or without 
schizophrenia, respectively 
- Cohort study 
- Adjusted for age and comorbid 
medical disorders 
- OR of developing AMI comparing patients with 
bipolar disorder and patients receiving 
appendectomy: aOR= 1.31(0.87~1.97) 
Callaghan 
(Callaghan et al., 
2009), Canada 
- 9,815 patients with schizophrenia 
- Matched with appendicitis-related 
diagnoses on sex, age, average 
neighbourhood income level, and 
amount of follow-up time available
- 2002~2006 
- Mean age before matching: 41.0 
(SD 14.0) and 38.6 (15.1) for those 
with or without schizophrenia, 
respectively 
- Mean age after matching: 40.3 (SD 
13.8) and 40.2 (15.2) for those with 
or without schizophrenia, 
respectively 
- Cohort study 
- Adjusted for age, sex, neighbourhood 
income level, tobacco 
related-problems, and comorbid 
medical disorders 
People with schizophrenia had a greater risk of 
readmission for cardiovascular events, with an 
adjusted hazard ratio of 1.43 (95% CI 1.22~1.69) 




(Callaghan & Khizar, 
2009), Canada 
- 5,999 patients with bipolar disorder
- Matched with appendicitis-related 
diagnoses on sex, age, average 
neighbourhood income level, and 
days from index admission to study 
end 
- 2002~2006 
- Mean age before matching: 42.9 
(SD 15.0) and 38.6 (15.1) for those 
with or without schizophrenia, 
respectively 
- Mean age after matching: 42.0 (SD 
14.4) and 42.1 (15.3) for those with 
or without schizophrenia, 
respectively 
- Cohort study 
- Adjusted for age, sex, neighbourhood 
income level, tobacco 
related-problems, and comorbid 
medical disorders 
People with bipolar disorder had a greater risk of 
readmission for cardiovascular events, with an 
adjusted hazard ratio of 1.66 (95% CI 1.36~2.03) 
compared to the appendicitis group. 
Laursen  
(Laursen et al., 2009), 
Denmark 
- 4,997 patients with severe mental 
disorder3 from a 4.6 million 
population cohort  
- 1994~2007 
-Cohort study 
- Adjusted for or stratified by age, and 
gender 
People with severe mental disorder had a slightly 
increased incidence rate ratios of heart disease at 
1.11 (95%CI 1.08~1.14).  
Lin (Lin et al., 
2010b), Taiwan  
- 7,353 patients hospitalized with 
diagnosis of schizophrenia 
- Matched with 22,059 enrollees 
from general population on age and 
gender 
- 2000~2006 
- 47.3% of the sample were <35 
years of age 
-Cohort study 
- Adjusted for comorbid medical 
disorder 
People with schizophrenia had a significantly 
higher risk of AMI (adjusted hazard ratio of 1.83, 
1.62~2.05) than the comparison group.  
Bresee et al 
(Bresee et al., 2010), 
Canada 
- 28,755 patients identified with 
schizophrenia 
- Compared with 2,281,636 control 
patients without schizophrenia  
- 1995~2006 
- Mean age before matching: 47.6 
(SD 16.7) and 45.3 (16.6) for those 
with or without schizophrenia, 
respectively 
- Cross-sectional study 
- Adjusted for age, sex, socioeconomic 
status, and GP visits 
- Stratified by age and gender 
People with schizophrenia had a significant higher 
risk of acute coronary syndrome (unadjusted odds 
ratio 1.09, 1.01 ~1.18), ischemic heart disease 
(1.52, 1.48 ~1.56), and cardiovascular disease 
(1.76, 1.72~1.81). Risks were different across 
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different age groups, with younger groups of 
people with SMI at higher risk of cardiovascular 
diseases. 
Truyer 
(Truyers et al., 2011), 
Belgium 
- A total of 197,000 patients that 
covered 1.5% of population from 
Flanders, north Belgium 
-  894 patients with diagnosis of 
psychosis 
- 4010 non-psychotic controls were 
matched (1:5) with age (+ 5 years), 
gender, within a practice 
- 1994~2007 
- Mean age at the diagnosis of 
psychosis: 48.8 (SD 21) 
- Mean age of control group: 
45.5(SD19) 
- Retrospective cohort study 
- Adjusted for age, gender, and frailty 
model (which characterizes the 
relationship or dependence of 
corrected failure times). 
- No significant higher risk of cardiovascular 
disease in people with diagnosis of psychosis, 
adjusted HR : 1.02 (0.70~1.47) 
Laursen 
(Laursen et al., 2011), 
Denmark 
- A total of 2,450,812 persons 15~52 
years old, at risk for admission 
with one of the 19 somatic diseases
- 16,079 and 6,215 patients have 
been in contact with a psychiatric 
hospital for schizophrenia or 
bipolar disorder, respectively 
- 1995~2006 
- Population-based cohort study 
- Adjusted for or stratified by gender, 
calendar time, and age (made in 
5-year groups) 
- Incidence rates of hospital contacts for AMI 
were higher (IRR >1) in people with 
schizophrenia, but not significant in bipolar 
disorder. (no actual numbers shown in figures) 
Lahti 
(Lahti et al., 2012), 
Finland 
- A total of 12,939 people born in 
1934~1936, 1940, and 1944 from 
the Helsinki Birth Cohort Study 
- 117 men and 87 women were 
- Followed up  between 1969~ 2002
- The median age at first 
hospitalization for schizophrenia was 
35.3 years (SD9.7), and 55.6 years 
- Population-based cohort study 
- Stratified for sex and year of birth; 
-Adjusted for socio-economic position 
in childhood, lipid-lowering, and 
- Risk of hospitalization for coronary heart disease 
was significantly higher in people with 
schizophrenia: adjusted HR: 2.00 (1.25~3.21) 
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diagnosed with schizophrenia 
- 86 men and 96 women were 
diagnosed with non-schizophrenic 
psychotic disorder 
(7.9) for coronary heart disease antihypertensive agents,  
1Mainly adapted from Oud et al. (Oud & Meyboom-de Jong, 2009)   
2Severe mental illness: Dickey et al. selected disabled beneficiaries who had at least one claim for the treatment of schizophrenia, bipolar disorder, or another psychotic disorder 
(Dickey et al., 2002) 
3Severe mental disorder: Laurson et al. included patients with bipolar disorder, schizophrenia, and schizoaffective disorder (Laursen et al., 2009)
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Search results in this literature review were similar to the two aforementioned 
reviews (Oud & Meyboom-de Jong, 2009; Weiner et al., 2011). As shown in Table 
2.1, there were substantial variations in sampled populations, exposure categories, 
and outcome measures between these studies. Three studies examined risks of 
cardiovascular diseases within composite groups of patients with diagnoses of 
psychotic disorder or SMI without further subgroup analysis (Curkendall et al., 2004; 
Dickey et al., 2002; Laursen et al., 2009; Truyers et al., 2011). Two studies revealed 
elevated risk of heart disease (Dickey et al., 2002; Laursen et al., 2009) or 
cardiovascular disease (Callaghan et al., 2009; Callaghan & Khizar, 2009; Truyers et 
al., 2011) in people with SMI, without mentioning specific risks of AMI or coronary 
heart disease. One study did not have a control group from general population, and 
just compared the risk of coronary heart disease between patients with schizophrenia, 
schizoaffective, and bipolar disorder (Kilbourne et al., 2007). As for outcome 
measures, most studies described odds ratios or hazard ratios for coronary heart or 
cardiovascular diseases. One study just described incidence of ten-year risk of 
coronary heart disease and no odds ratio was calculated (Goff et al., 2005).  
 
Regarding main findings, two studies mentioned excessive risk of heart disease in 
people with diagnosis of severe mental illness (Dickey et al., 2002; Laursen et al., 
2009) with odds ratios or incidence ratios ranged from 1.11~3.19; whereas Truyer et 
al. found no significant elevated risk of cardiovascular disease in people with 
diagnosis of psychosis. Most studies reported increased likelihood of AMI (odds 
ratios 1.09 to 1.83), coronary heart disease (odds ratios 1.43 to 2.00), or 
cardiovascular disease (odds ratios 1.11 to 3.19) in people with schizophrenia. One 
study reported elevated risk readmission due to cardiovascular events in bipolar 
disorder compared to controls (Callaghan & Khizar, 2009). The study that didn’t 
have a comparison group from general population reported a 44% increased 
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likelihood of coronary heart disease in people with bipolar disorder than in 
schizophrenia. However, there were three studies other than the aforementioned 
research from Truyer et al. that found insignificant associations of AMI in people 
with schizophrenia (Curkendall et al., 2004) and bipolar disorder (Laursen et al., 
2011; Lin et al., 2008), respectively. Among these four studies with null associations, 
Truyers et al. discussed that the surprisingly lower cardiovascular morbidity after 
psychosis might be due to the relatively short follow-up time before cardiovascular 
diseases actually emerge (Truyers et al., 2011). Curkendall et al. emphasized that 
despite insignificant findings in AMI, all the other cardiovascular comorbidies 
including arrhythmia, heart failure, stroke, and diabetes had significantly higher 
prevalence and incidence compared to controls (Curkendall et al., 2004). Laursen et 
al. suggested that the reason for the decreased likelihood of somatic contacts due to 
heart disease in people with SMI was probably owing to the severity and symptoms 
of mental disorders. However, Laursen et al. and Lin et al. (Lin et al., 2008) both 
mentioned that considering the 1.9~3-folds of excessive mortality due to 
cardiovascular disease being reported in people with SMI (Laursen et al., 2009) or 
bipolar disorder (Angst et al., 2002; Osby et al., 2001), it is in fact more important to 
notice the insufficient health contacts or physical care being provided to those people 
(Laursen et al., 2009; Lin et al., 2008).  
 
Age and gender differences on the risks of coronary heart disease were found 
following stratification, with women (Bresee et al., 2010; Lahti et al., 2012), or 
patients of younger age (Bresee et al., 2010; Laursen et al., 2009) reported to be at a 
particularly high risk. In the study conducted by Laursen et al (2009), elevated 
incidence rate ratios (IRR) of medical contacts due to overall heart disease were 
significantly higher in patients with severe mental disorder less than 70 years of age 
and not in those older than age 70. However, medical contacts due to AMI were not 
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significantly higher in the same age range. Finally, among the seven papers reporting 
specific psychiatric diagnoses, most studies found significantly elevated risks of AMI 
or coronary heart disease comparing patients with and without schizophrenia (odds 
ratios 1.09~2.00). However, two out of three studies reported no significant 





Although studies have found associations of schizophrenia and bipolar disorder with 
elevated risk of death from cardiovascular disease (see Chapter 1), morbidity risks 
of AMI or coronary heart disease have mostly focused on people with schizophrenia, 
reporting increased risk compared with the general population. Associations between 
bipolar disorder and AMI have received much less attention and findings have been 
inconsistent. All findings to date have predominantly analysed combined samples, 
rather than looking at modifying effects by age or gender. Only one study has 
reported elevated risk of cardiovascular disease (but not specifically AMI) in people 
with schizophrenia across different age groups (Bresee et al., 2010) but did not 
investigate bipolar disorder. Further investigation on exploring the modification by 
age and gender on risk of AMI between schizophrenia and bipolar disorder is 
therefore needed.  
 
Finally, it is important to bear in mind that inclusion or exclusion criteria of this 
review were just agreed by the candidate and the supervisor and not by two 
independent raters. In addition, due to the large numbers of articles identified using 
PubMed or Ovid Medline, selections by custom filter in addition to manual checking 
were carried out, and only full texts of studies using large database conducted in 
recent ten years, published in English or Chinese language were obtained and 
summarized by the candidate. Thus, it should be borne in mind that this literature 
review did not include relatively old studies, those judged as using too-small samples, 
and articles in Korean or Japanese (although the candidate did not identify any 
evidence of important missing literature from East Asia in the process of checking 




LITERATURE REVIEW ON THE INVASIVE CORONARY 
INTERVENTIONS AND TREATMENT OUTCOME FOLLOWING ACUTE 




Research investigating excess risk of acute myocardial infarction (AMI) in people 
with serious mental illness (SMI) has been summarized in Chapter 2. The objective 
of the second part of the literature review was to summarize the literature on 
intervention receipt and treatment outcomes following AMI in this group. 
 
3.1 Search strategy  
The literature search was carried out on Pubmed and Ovid Medline using the 
following strings:  
(intervention AND receipt) AND (myocardial infarction OR coronary heart disease) 
AND (mental illness OR schizo* OR bipolar* OR psych*) 
or  
(catheterization) AND (myocardial infarction OR coronary heart disease) AND 
(mental illness OR schizo* OR bipolar* OR psych*) 
or  
(revascularization) AND (myocardial infarction OR coronary heart disease) AND 
(mental illness OR schizo* OR bipolar* OR psych*) 
or 
(mortality OR prognosis) AND (myocardial infarction OR coronary heart disease) 
AND (mental illness OR schizo* OR bipolar* OR psych*) 
or 
(recurrence) AND (myocardial infarction OR coronary heart disease) AND (mental 
illness OR schizo* OR bipolar* OR psych*) 
or 
(second) AND (myocardial infarction OR coronary heart disease) AND (mental 




The searches were restricted to studies of human subjects over 18 years of age, and 
without restrictions on lengths or timing of studies, nor on geographical locations. A 
search for review articles was carried out before searching for individual articles. 
One systematic review (Mitchell, 2009) and one meta-analysis (Mitchell & Lawrence, 
2011) were found (Oud & Meyboom-de Jong, 2009; Weiner et al., 2011). Titles of 
articles identified from PubMed or Ovid Medline which were not on the reference 
list of these two review papers were further examined. Abstracts of articles not 
written in English or Chinese language were further examined and excluded if the 
contents were not relevant to the objective of search. The searches were performed 
initially in January 2010, then updated in September 2012. Full texts of relevant 
articles were accessed and those that matched the search objectives were 
summarized. 
 
3.2 Selection criteria of studies 
Studies that reported intervention receipt or treatment outcome following AMI in 
patients with SMI were included. Of the standard post-AMI interventions mentioned 
in Chapter 1, invasive coronary interventions were chosen as the main search 
outcomes in this literature review because most literature focused on these (Mitchell 
& Lawrence, 2011) and investigation of these interventions was considered to be 
most feasible in the study to be described. In terms of outcome following AMI, 
studies were reviewed which compared mortality or recurrence following an AMI 
episode in people with or without SMI. Crude and adjusted results expressed as 
relative risks (RR), rate ratios, odds ratios (OR) or hazard ratios (HR) were studied.  
 
The following exclusions were applied:  
1. Comments or author’s reply.  
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2. Studies exclusively investigating depression, cognitive functions, or quality 
of life as outcomes.  
3. Studies of mortality or recurrence of AMI just among general population but 
not those with schizophrenia or bipolar disorder.  
4. Studies lacking a non-psychiatric comparison group.  
5. Studies of cardiac rehabilitation (e.g. exercise programmes, health education, 
or counseling sessions offered to survivors of AMI) or those which 
compared the efficacy or safety profiles of pre- or post-operative statin use.  
6. Studies evaluating levels of blood markers (e.g. c-reactive protein or 
creatinine kinase-MB) without assessing the delivery of medical services.  
7. Studies solely focused on cardiovascular medications as outcomes (eg. 
aspirin, anticoagulant, antihypertensive) rather than invasive coronary 
procedures.  
References of related articles were scrutinized and potentially relevant publications 
that were not included in the original search were accessed. The systematic selection 
of articles is described in Figure 3.1.
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Excluded studies not 
focusing on people with 
schizophrenia or bipolar 
disorder (n=16) or 
literature that was 
comments or reply (n=1)
Excluded studies 
focusing on the effect of 
pre- or post-AMI 
depression on the 
outcome of mortality of 
re-hospialization (n=10) 
Full text assessed 
n=40 
Full text assessed 
n=23 
Excluded studies whose 
outcome was about 
psychological prognosis 
after AMI (n=3)  
Discarded studies 
applying the exclusion 
criteria (n=173) 




medications use in the 







3.3 Summary of search findings 
Of the 224 papers that were initially identified using the search strings, 208 were 
excluded applying the aforementioned criteria. Among the remaining 16 papers, 
there was one systematic review of the quality of medical care on general internal 
medicine, cardiovascular, diabetes, infection, and cancer for people with or without 
mental illness (Mitchell et al., 2009) which reviewed ten studies, examining a broad 
category of cardiac care (including pharmacotherapy and invasive coronary 
interventions), and found seven out of ten reporting lower quality of care in people 
with mental illness. Another meta-analysis specifically focused on invasive coronary 
interventions treatments and mortality following acute coronary syndrome in people 
with mental disorders (Mitchell & Lawrence, 2011) (as summarized in Table 3.1). 
The other fourteen studies compared likelihood of intervention receipts in people 
with and without mental disorder. Among them, six analyzed subgroups with 
schizophrenia or affective disorder.  
 
Results comparing receipt of cardiovascular procedures and mortality following AMI 
between people with or without mental disorder have been inconsistent. Reasons for 
inconsistencies have been suggested to include variations in study populations and 
health care systems sampled (Kisely et al., 2009). As shown in Table 3.1, reduced 
likelihood of catheterization or revascularization (67~90% odds of receipts compared 
with those in the general population) in people with mental disorder have been 
reported, mostly focusing on people aged 65 years or over, and using large databases 
such as the US Medicare system (Druss et al., 2000; Druss et al., 2001a), the 
Healthcare Investment Analysts (HCIA) Sachs Projected Inpatient database (Young 
& Foster, 2000), or Veteran Health System in the US (Petersen et al., 2003); as well 
as 35~92% reduced likelihood in studies using population-based health services 
research databases in West Australia (Lawrence DM et al., 2003), Canada (Kisely et 
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al., 2009), and Denmark (Laursen et al., 2009). However, there were also some 
studies that have found no significant differences in intervention receipt in people 
with or without mental illness using the US Veterans Health Administration (Abrams 
et al., 2009; Plomondon et al., 2007), the US Medicaid claims (Jones DR et al., 2004), 
or New York Sate hospital discharge records (Li et al., 2007), although these have 
tended to have smaller sample sizes.  
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Table 3.1 Summarizing studies comparing medical care receipt and outcome following AMI in people with or without SMI   
        
Study, author, 
and country 
Sample members  
Study years; 
Age or mean age of 
inclusion; 
Control for confounders 
Principal findings on 
procedure receipt in people 
with any mental disorder 
compared to the general 
population 
Principal findings on 
procedure receipt in people 
with specific psychiatric 
diagnoses compared to the 




Outcomes of mortality 
or AMI recurrence 
 
Druss  
(Druss et al., 
2000); US 
- Patients over 64 years 
of age from Medicare 
with confirmed 
diagnosis of AMI 
- 5,365 patients with 
mental disorder 
- 108,288 patients 
without mental 
disorder 
- Patients were hospitalized 
for AMI between February 
1994~July 1995 
- Mean age: 79.5 (SD 6.9) 
years;  
- Controlled for 
demographic, clinical, 
hospital, and regional 
variables 
People with any mental 
disorder were significantly 
less likely to undergo: 
- Catheterization (RR 0.72*2)
- PTCA3: (RR 0.75*) 
- CABG4:(RR 0.68*) 
People with schizophrenia and 
affective disorders were 
significantly less likely to 
undergo: 
- Catheterization: RR 0.41* for 
schizophrenia; 0.65* for 
affective disorder; 
- PTCA : RR 0.55** for 
schizophrenia; 0.51** for 
affective disorder; 
- CABG:RR 0.27* for 
schizophrenia; 0.63** for 
affective disorder  
No significant difference 
between people with or 
without mental disorders 
(p=0.12 for PTCA; p=0.06 
for CABG), schizophrenia 
(p=0.36 for PTCA; p=0.08 
for CABG), or affective 
disorder (p=0.07 for PTCA; 
p=0.12 for CABG) 
No significant difference 
in the likelihood of 
30-day mortality adjusted 
for all variables including 
PTCA and CABG for: 
- Any mental disorder: 
p=0.22;  
- Schizophrenia: p=0.18; 
- Affective disorder 
p=0.20. 
Young 
 (Young & 
- 354,195 patients with 
diagnosis of AMI 
- 1998 
- 40.5% of patients were 
People with any mental 
disorders were significantly 
People with schizophrenia and 
affective disorders were 
Not mentioned 
- In the subgroup aged 65 













younger than 65 years 
- Stratified by younger and 
older age groups 
- Unable to adjust for 
admission characteristics 
or left ventricular function
less likely to undergo: 
(1) Age >=65 years:  
- catheterization: RR=0.77, 
95% CI(0.75~0.80) 
- PTCA : 0.68 (0.65~0.72) ; 
- CABG : 0.67 (0.62~0.72) 
(2) Age <65 years :  
- catheterization : 0.88 
(0.86~0.90) 
- PTCA: 0.70 (0.68~0.73) 
- CABG: 0.79 (0.75~0.84) 
significantly less likely to 
undergo: 
(1) Age >=65 years:  
- Catheterization: RR=0.51 
(0.42~0.62) in schizophrenia; 
0.80 (0.71~0.88) in affective 
disorder;  
- PTCA : 0.32 (0.21~0.47) in 
schizophrenia; 0.78 
(0.65~0.92) in affective 
disorder; 
- CABG: 0.67 (0.46~0.95) in 
schizophrenia; 0.61 
(0.47~0.80) in affective 
disorder; 
(2) Age<65 years:  
- Catheterization: 0.70 
(0.63~0.77) in schizophrenia; 
0.93 (0.87~0.99) in affective 
disorder;  
- PTCA: 0.55 (0.46~0.65) in 
schizophrenia; 0.79 
with mental illness have 
21% lower risk-adjusted 
likelihood of death 
compared with the 
reference group 
(p<0.001). 
- In the subgroup of 
younger than 65 years 
of age, people with 
schizophrenia have an 
86% increased 
risk-adjusted likelihood 
of death (p<0.001) 
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(0.70~0.88) in affective 
disorder; 
- CABG: 0.71 (0.54~0.92) in 
schizophrenia; 0.78 
(0.62~0.97) in affective 
disorder. 
Druss (Druss 
et al., 2001a); 
US 
- 88.241 patients over 
64 years of age from 
Medicare with 
confirmed diagnosis of 
AMI 
- 4,664 patients with 
mental disorder 
- 108,288 patients 
without mental 
disorder 
- Patients were hospitalized 
for AMI between 
February 1994~July 1995
- Mean age: 76.0 (SD 7.3) 
and 76.1 (SD7.1) for 
those with or without 
mental disorders, 
respectively 
- Controlled for 
demographic 
characteristics, cardiac 
risk factors, cardiac 
history, admission 
characteristics, and left 
ventricular function 
-Patients with mental disorder 
were less likely to receive 
reperfusion therapy: 0.74 
(95%CI 0.56~0.95)* 
-Patients with schizophrenia 
were less likely to receive 
reperfusion therapy: 0.52 
(0.26~0.90) 
- Patients with affective disorder 
were less likely to receive 
reperfusion therapy: 0.71 
(0.45~0.99) 
 
- Patients with any 
mental disorder had an 
increased likelihood of 
mortality compared to 
rest of the population 
during the year after 
hospital discharge: HR 
1.19 (1.04~1.36) 
- Patients with 
schizophrenia 
(compared to the rest of 
the population): HR 
1.34(1.01~1.66) 





- But in the model 
adjusting for quality 
measures and all 
covariates, the 
associations between 
mental disorder and 
1-year mortality was no 
longer significant 
(p=0.17); similar for 
schizophrenia: HR 1.23 
(0.96~1.26); affective 




et al., 2003); 
Australia 
- 44,767 deaths due to 
ischemic heart 
disease (IHD) from 
the West Australia 
Linked Database 
(population-based) 
- 3796 deaths occurred 
in users of mental 
health services 
- 1980~1998 
- Unable to adjust for 
demographic and clinical 
characteristics 
 
People with schizophrenia and 
affective psychosis were 
significantly less likely to 
undergo revascularization: 
- Schizophrenia, male: 0.31 
(0.21~0.45); female:0.34 
(0.18~0.64) 
- Affective psychosis, male:0.77 
(0.64~0.93); female: 0.79 
Not mentioned   
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al., 2003); US 
- Patients treated for 
AMI from Veterans 
Health 
Administration 
- 859 patients with 
mental illness 
- 3,481 patients without 
mental illness 
- January 1994~September 
1995 
- Mean age: 63.0 (SD 12.0) 
in the SMI group; 66.5 
(10.2) in the non-SMI 
group 
- Adjusted for age 
People with any mental 
disorders were significantly 
less likely to receive  
- diagnostic angiography:0.90 
(0.83~0.98) 
- PTCA: 0.92 (0.76~1.11) 
- CABG: 0.80 (0.60~1.07) 
 Not mentioned 
- 30-day mortality: 0.80 
(0.47~1.35) 
- 1-year mortality: 1.26 
(0.94~1.68) 
Jones (Jones 
LE & Carney, 
2005); US 
- Patients aged 18~64 
hospitalized for AMI 
from the Blue cross/ 
Blue Shield of Iowa 
administrative claims 
data (Medicaid) 
- 1,342 patients with 
mental disorder 
- 2026 without mental 
disorder 
- 1996~2001 
- Mean age: 53.4 (SD7.7) 
in the SMI group; 54.8 
(7.4) in the non-SMI 
group 
- Controlled for age, 
gender, number of days 
hospitalized, residence 
(rural, urban), hospital 
transfer, cardiovascular 
risk factors, and other 
The odds ratio for receiving 
PTCA and CABG were not 
significantly different in 
people with any mental 
disorders compare with 
general population (odds ratio 
for receiving PTCA: 1.10 
(0.95~1.29); CABG 0.89 (0.71
~ 1.11) 
 
- Significant predictors of 
demographic variables 
and specific cerebro- or 
cardiovascular conditions.
-  Age, gender, and race 
were not significantly 









et al., 2007); 
Canada  




- 17,665 deaths from 
circulatory disease 
- 2,839 were people 
with psychiatric 
problems 
- January 1, 1995 and 
December 31, 2001 
- Adjusted for principal 
psychiatric diagnosis, age, 
sex, social economic 
status, treatment setting, 
residence and medical 
comorbidity 
People with any mental 
disorder were significantly 
less likely to receive 
catheterization (RR 0.92, 95% 
CI 0.86 ~0.98); but not PTCA 
(0.97, 0.86 ~1.09), CABG 
(0.92, 0.83~1.02).  
- 
Note: Psychiatric hospital 
inpatients had significantly 
lower rate ratios of receiving 
same procedures than patients 
from outpatient settings. 
Adjusted rate ratios for inpatient 
vs. outpatient settings 
respectively: 
- Catheterization :0.41 
(0.26~0.65) vs .0.56 
(0.44~0.70); 
- PTCA: 0.22 (0.07~0.69) vs. 
0.59 (0.39~0.89) 
- CABG: 0.34 (0.15~0.77) vs. 
0.66 (0.47~0.93) 
 
For first hospital 
admissions (mostly due to 
ischemic heart disease), 
the age-standardized rate 
ratio of deaths was 1.34 
(1.32~1.37). 
- Significantly higher for 
patients treated under 
specialist services 
(1.74, 1.68~1.81) vs. 
primary care (1.29, 
1.26~1.31)  









Li (Li et al., 
2007); US  
- Total 39,839 patients 
receiving CABG  
- 3,211 patients had 
diagnosis of any 
mental disorder 
- 36,628 patients 
without diagnosis of 
mental disorder 
- 2001~2003 
- Mean age: Patients with 
psychiatric disorder: 67.5 
(SD 11.2); Patients 
without: 67.1 (10.8)  




surgeon work volume 
- Patients with mental illness 
had an odds of 1.28* for 
receipt of care from a high 
mortality surgeon. 
- No evidence suggests that 
these patients are 
disadvantaged in access to 
high-quality cardiac 
surgeons 





- 14,194 patients with 
acute coronary 
syndrome presenting 
to Veterans Health 
Administration 
- 2,623 patients had a 
diagnosis of serious 
mental illness (SMI) 
- 11,571 patients 
without 
- October 2003~September 
2005 
- Mean age: 64.0 (SD 11.7) 
and 69.6 (11.5) for 
patients with or without 
SMI, respectively 
- Adjusting for 
demographic, cardiac, and 
non-cardiac comorbidieis, 
presentation factors, 
in-hospital procedures and 
discharge medications 
No significant difference 
between people with or 
without SMI in the rates of 
receipt of: 
- Diagnostic catheterization: 
p=0.14 ; 
- Percutaneous coronary 
interventions: p=0.10 
- CABG: p=0.61  
  
Between people with or 
without SMI, the 
following outcomes were 
not significantly different 
after adjustments:  
- 1-year all- cause 
mortality: HR 0.91 
(95%CI 0.81~1.02) 
- The combined endpoint 
of all-cause mortality 
and re-hospitalization 
for AMI: in people with 
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any SMI: HR 0.99 
(0.90~1.10); in people 
with schizophrenia: HR 
0.83 (0.60~1.15); in 
people with mood 




(Abrams et al., 
2009); US 
- 21,745 patients 




- 5,887 patients were 
identified as having 
psychiatric diagnosis 
- 2004~2006 
- Mean age: 68.5 (SD 11.6)
- Adjusted for age, race, 
gender, marital status, 
VHA eligibility criterion, 
comorbid medical 
condition, mechanical 
ventilation on day of 
admission, location of 
infarction, and 9 selected 
lab results within 48 hours 
of admission time.  
Patients with psychiatric 
comorbidity had lower receipt 
of revascularization based on: 
- outpatient codes: 0.92( 0.85 
~ 0.99) 
- but similar receipt based on 
inpatient codes 1.00 ( 0.91 to 
1.10). 
  
Patients with psychiatric 
comorbidity had higher 
adjusted 30- and 365-day 
mortality, based on  
- outpatient psychiatric 
codes , with odds ratios 
1.19 (95% CI, 1.09 ~ 
1.30), and 1.12 (1.03~ 
1.22), respectively;  
- but similar mortality 
based on inpatient 
codes: 0.89 (0.69~ 
1.01) and 0.93 (0.82 ~ 




(Laursen et al., 
2009); 
Denmark 
- All persons born in 
Denmark before 
January 1, 1994 from 
the Danish Civil 
Registration System 
- Among the 605, 649 
patients who had a 
diagnosis of heart 
disease, 4,997 
persons had diagnosis 
of severe mental 
disorder prior to their 
diagnosis of heart 
disease 
- Followed until January 1, 
2007 
- Adjusted for age, sex, and 
calendar period 
People with SMI were 
significantly less likely to 
receive invasive procedures 
for heart disease within 5 
years after their first contact 
(7.04% vs. 12.27% in people 
with and without SMI, 
respectively) 
  
Mortality rate ratios 
(MRR) of myocardial 
infarction in patients : 
- With mental disorder 
vs. people without 
mental disorder: 2.81 
(95%CI: 2.50~3.17); 
 
1-year mortality of heart 
disease after the first 
heart disease contact was 
2.80% and 1.00% for 
people with or without 
previous psychiatric 
admissions respectively  
 
Mortality of heart disease 
within 5 years after the 
first heart disease contact 
was 8.26% and 2.86% for 






et al., 2009); 
Canada 





Health Research Unit 
in Nova Scotia 








- Mean age: 65.4 (SD 13.6)
- Adjusted for psychiatric 




score), and place of 
residence 
Adjusted odds ratio (95%CI) 
of receiving: 
Catheterization: 0.47 (0.38 
~0.58) 
PTCA: 0.41 (0.29 ~0.59) 
CABG: 0.35 (0.25~0.49) 
  
Adjusted OR (95%CI) 
for: 
- Unadjusted 28-day 
mortality: 1.56 
(1.32~1.86) 




et al., 2012); 
Canada 
- A total of 2,310,391 
people from the 
Alberta Health and 
Wellness databases 
- 5,673 patients were 
schizophrenia and 
had coronary heart 
 
Patients with schizophrenia and 
coronary artery disease were less 
likely to undergo coronary 
revascularization (6% versus 






- 318,145 were people 
without schizophrenia 









- A total of 825,754 
individuals identified 
from 22 analyses 
Pooled hazard ratios of in 
people with any mental 
disorders: 
- Overall relative risk of 
receiving comparable 
procedures: RR=0.86 (95% 
CI 0.80-0.92)  
- Catheterization: RR=0.85 
(0.76~0.95) 
- PTCA: RR=0.87 (0.72~1.05)
- CABG: RR = 
0.85(0.72-1.00)  
Pooled hazard ratios of in people 
with schizophrenia: 
- Overall relative risk of 
receiving comparable 
procedures: RR=0.53 (95% CI 
0.44-0.64)  
- PTCA: RR=0.50 (0.34~0.75) 
- CABG: RR = 0.69(0.55-0.85)
 
Pooled hazard ratios 
(95%CI) of one-year 
mortality for those with 
mental illness: 
- RR=1.11 (1.00~1.24, P 





- 69,911 people with 
incident AMI who 
were alive at 
hospitalization 
discharge from 
- January 1, 2002 to 
December 31, 2006 
- Mean age: 66.1(SD 14.7) 
and 67.7 (14.0) for 
patients with or without 
 
Adjusted odds ratios (95%CI) 
for 
- cardiac procedures: 0.48 
(0.40~0.56) 
 
Adjusted odds ratios 
(95%CI) for 











- Adjusted for age, sex, rural 
residence, income, length 
of stay, frequency of 
primary care visits, 
whether subjects had any 
cardiologist visit in the 
year prior to admission for 
AMI, and medical 
comordities 
1Based on Mitchell et al’s systematic review (Mitchell et al., 2009). 
2* p< 0.001; ** p<0.01; *** p<0.05   
3 PTCA: Percutaneous transluminal coronary angioplasty  
4CABG: Coronary artery bypass graft 
    
  
48
Six studies have focused on schizophrenia and four on the broad category of 
affective disorder (included affective psychosis, bipolar disorder, and major 
depressive disorder; not specifically bipolar disorder). Compared to counterparts 
without mental illness, patients with schizophrenia or affective disorder had a 
significant 41~88% and 51~93% reduced likelihood of receiving cardiac 
catheterization, respectively. The likelihood of receiving revascularization were even 
lower in patients with schizophrenia (27~71% odds of receipt compared with the 
general population) and affective disorder (51~79 % odds of receipt compared with 
general population).  
 
Nine studies reported outcomes of mortality or recurrence. Among these, significant 
excess risks of 28-day (56% increased risk)(Kisely et al., 2009), 30-day (19~56% 
increased risk)(Abrams et al., 2009; Kurdyak et al., 2012), or one-year mortality 
(12~34% increased risk)(Abrams et al., 2009; Druss et al., 2000; Kisely et al., 2009; 
Kisely et al., 2007; Laursen et al., 2009) were found in patients with any mental 
disorder. However, other studies found no difference in 30-day (Druss et al., 2000; 
Petersen et al., 2003) or one-year mortality (Plomondon et al., 2007). In subgroup 
analyses patients with schizophrenia or affective disorder had a higher one-year 
mortality (11~78%)(Abrams et al., 2009; Druss et al., 2001a), which was found to be 
reduced by adjusting for measures of cardiac care quality (Druss et al., 2001a). 
Additional analyses stratified by age or psychiatric outpatient or inpatient diagnosis 
further revealed that people with schizophrenia younger than 65 years of age (Young 
& Foster, 2000) and psychiatric patients identified based on outpatient codes 
(Abrams et al., 2009) have an increased likelihood of deaths following an AMI.
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3.4 Conclusion  
Although findings of population-based studies from Canada (Kisely et al., 2009; 
Kisely et al., 2007), Australia (Lawrence DM et al., 2003), or Denmark (Laursen et 
al., 2009) have more generalisability because of national healthcare systems, most 
research has either grouped mental illness into very broad categories (e.g. affective 
or non-affective psychoses) or has focused on schizophrenia specifically (Druss et al., 
2000; Jones LE & Carney, 2005; Kisely et al., 2007; Lawrence DM et al., 2003; 
Petersen et al., 2003). Given the significant heterogeneity (I= 98.1%) reported in a 
meta-analysis to quantify differences of invasive coronary intervention rates in 
people with any mental disorder or severe mental illness (Mitchell & Lawrence, 
2011), and although previous research has reported reduced likelihood of receiving 
invasive procedures and increased mortality rates following an AMI in people with 
schizophrenia, very little is known specifically about bipolar disorders in this respect. 
Finally, as described in the previous chapter, it should be borne in mind that only 
relevant studies published in English or Chinese language were included; although 
through a process of checking through titles and abstracts lists from Pubmed or Ovid 




LITERATURE REVIEW OF THE ASSOCIATION BETWEEN 




The risk of acute myocardial infarction (AMI) among patients with serious mental 
illness (SMI) has been discussed in the previous chapters. Another important 
question arising concerns the degree of association between antipsychotic 
exposure and risk of AMI. This chapter reviews studies that investigated this 
question and summarizes their findings.  
 
4.2 Literature search 
4.2.1 Search strategy  
The main purpose was to identify research investigating associations between 
antipsychotic agents and myocardial infarction; therefore individual articles on 
Pubmed and Ovid Medline were extracted for review using the following search 
strings:  
 
(antipsychotic* AND agents) AND (myocardial infarction OR coronary heart 
disease) 
or (neuroleptic* AND agents) AND (myocardial infarction OR coronary heart 
disease) 
or (major AND tranquiliz*) AND (myocardial infarction OR coronary heart 
disease) 
or (psych*) AND (myocardial infarction OR coronary heart disease).  
 
The searches were restricted to studies of human subjects over 18 years of age, 
and did not restrict on duration or timing of studies, or on geographical location. 
A search for review articles was carried out before searching for individual 
articles, and one systematic review was found (Brauer, 2011). Titles of articles 
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identified from Pubmed or Ovid Medline which were not on the reference list of 
the review were further examined by candidate. Abstracts of articles not written in 
English or Chinese language were further examined and excluded if the contents 
were not relevant to the objective of search. The searches were performed initially 
in July 2011, with the main database searches updated in August 2012. Abstracts 
and full text from research papers or review articles that contained any of the 
above keywords were assessed. References from these articles that were 
potentially relevant to the search topic were also accessed.  
 
4.2.2 Selection of studies 
Studies that reported any study population with measures of past, current or 
cumulative prescription instances of any antipsychotic agent and used AMI or 
coronary heart disease as the main outcomes of interest were included. The main 
outcome of interest was the association between antipsychotic agents and the 
incidence of AMI expressed as relative risk (RR) or hazard ratio (HR), or the 
association between AMI and prior antipsychotic exposure expressed in odds 
ratios (ORs). Both unadjuted and adjusted results were considered. Findings 
assessing dose–response relationships or results of sub-analyses comparing gender, 
age and history of cardiovascular disease strata were also reviewed. 
 
Studies not associated with antipsychotic agent, or solely about clinical 
monitoring suggestions over antipsychotic use were not included. A previous 
review (Brauer et al., 2011) had restricted their search criteria to studies with 
exposures to antipsychotic or placebo or other alternative medication for at least 
12 months, but since the short-term effect of antipsychotic agent was also of 
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interest, no restriction rules were made for the time of exposure. The systematic 
reduction of articles was described in Figure 4.1.
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investigating other non 
coronary heart disease 
as outcome measures 
(n=59) or not related to 
antipsychotic use (n=33)








Excluded studies with 
irrelevant titles (n=26) 
Unavailable or 




4.3 Summary of search findings 
Of the initial 152 articles identified, titles and abstracts were screened first, 
followed by full text review. There were 141 studies that were not relevant or not 
matching search criteria which were discarded. 
 
Previous investigations of the association between AMI and antipsychotic 
exposures have used following study designs summarized briefly below: 
a) ‘Case control’ studies have been conducted which have selected groups with or 
without a diagnosis of AMI and compared the odds of antipsychotic exposure.  
b) Cohort studies have been reported where the outcome of developing an episode 
of AMI or not has been investigated among groups of people with or without the 
exposure to antipsychotic. 
c) ‘Self-controlled case series’ have been conducted, comparing the relative 
incidence estimates of high- risk period with low- risk period from exposed cases 
to eliminate control-selection bias. 
 
Results from the above designs are summarized in the following sections: 
 
4.3.1 Findings from case control studies 
Three case control studies were found which compared the exposure of 
antipsychotic between groups with or without AMI. Among them, sources of 
medication records and types of medication covered were quite heterogeneous. As 
summarized in Table 4.1, the following two studies found a 1.5~6.2 times 
increased odds of exposures of antipsychotic or neuroleptic agents in people with 
AMI. Thorogood et al. specifically focused on thioxanthene and phenothiazine 
agents by interviewing general practitioners and using patient records (Thorogood 
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et al., 1992) but included only fatal AMI. One study investigated patient records 
for neuroleptic use among incident cases of AMI that were either hospitalized or 
died because of AMI (Penttinen & Valonen, 1996). However, the exposure was 
quite rare (4 cases of AMI vs. 6 non-AMI controls were exposed to antipsychotic). 
In addition, the generalisability of the above two studies might be limited because 
Thorogood et al. only focused on female and Penttinen et al. focused on male 
subjects. The study reported by Nakagawa had the largest sample size, making use 
of a population-based prescription database (Nakagawa et al., 2006), but only 
investigating first-time hospitalizations for AMI. Cumulative doses of 
antipsychotic were only analyzed in Nakagawa’s study.   
 
In Table 4.1, two case-control studies found higher frequencies of exposure to 
antipsychotic agents among patients with AMI, reporting ORs or RRs ranging 
from 1.5 to 6.2 (Penttinen & Valonen, 1996; Thorogood et al., 1992). However, 
the largest, with the highest internal validity reported by Nakagawa et al. found 
negative associations between myocardial infarction and antipsychotic exposures 
although not to a statistically significant extent (Nakagawa et al., 2006). These 
authors further reported that there were no clear trends in a dose-response analysis, 
indicating that the risk of AMI was not influenced by the cumulative defined daily 





Table 4.1 Summarizing case control studies reporting associations between AMI and antipsychotic use1   
                
Study, author, 
and country 
Sample members of 
AMI cases and 
non-AMI controls  
Study years; 







Numbers of exposure 
in AMI cases or non- 
AMI control groups 
Control for confounding factors 







- Women aged 16 to 
39;  
- 161 AMI cases and 
309 non-AMI 
controls;  
- 1986 ~ 1988 
- Not given 
- Compared recent 
users and ever 
users vs. non-users 
of antipsychotic. 
- AMI cases exposed to 
antipsychotic: 25;  
- Non-AMI controls 
exposed to 
antipsychotic: 13. 
- 1:2 matching by age, marital status, 
and general practitioner.  
-  
Relative risk (RR) for ever use of:  
-Thioxanthene: 4.6 (0.90~ 24).  
-Phenothiazine: 6.2 (2.0~ 19.1).  






- 83 AMI cases and 
249 non-AMI 
controls among 
3172 male farmers 
 
- 1980~1992 
- Not given 
- Compared ever 
users vs. non-users 
of antipsychotic 
- AMI cases exposed to 
antipsychotic: 4;  
- Non-AMI controls 
exposed to 
antipsychotic: 6.  
- 1:3 matching by age, smoking, 
social status, and country of 
residence.  






21,377 AMI patients 
matched with 
106,885 non-A MI 
population controls 
- 1992~2004 
- Mean age: 69.4 
- Compared low, 
moderate, or high 
cumulative dose on 
users vs non-users 
of antipsychotic 
- AMI cases exposed to 
antipsychotic: 1024;  
- Non-AAMI controls 
exposed to 
antipsychotic: 4511. 
- 1:5 matching by age, sex, and 
residence.  
Adjusted OR of MI:  
- For current users of atypical antipsychotic: 
0.98 (0.88~1.09)  




- For current users of both: 0.92 (0.71~1.20) 
- For current female users of atypical 
antipsychotic: 1.02 (0.88~1.18)  
- For current male users of atypical 
antipsychotic: 0.94 (0.81~1.09)  
- For current female users of typical 
antipsychotic: 0.99 (0.94~1.04)  
- For current male users of typical 
antipsychotic: 1.004 (0.94~1.06) 




4.3.2 Findings from cohort studies 
 
Seven cohort studies were identified which reported the risk of AMI either among 
patients with or without antipsychotic exposure, or users with typical vs. atypical 
antipsychotic (summarized in Table 4.2).  
 
As shown in Table 4.2, sources of subjects varied in these research. There were 
studies that focused on patients with schizophrenia (Enger et al., 2004; Jerrell & 
McIntyre, 2007; Osborn et al., 2007)) or other severe mental illness (Osborn et al., 
2007); as well as studies only focusing on older people with mental disorders (Barak 
et al., 2007; Mehta et al., 2011; Pariente et al., 2012), including a cohort of older 
patients with dementia who had recently initiated acetyl cholinesterase inhibitor 
treatment (Pariente et al., 2012). Exposure status and outcome measures among these 
studies were quite heterogeneous. Pariente et al. (2012) and Enger et al. (2004) 
compared incident AMI among users and non-users of typical or atypical 
antipsychotic. Pratt et al. (1996) only focused on the risk of incident AMI among 
those exposed or not exposed to phenothiazine agents; while Jerrell et al. (2007) and 
Mehta et al. (2011) compared the risk of incident AMI or serious cardiac events 
(AMI included) between users of typical or atypical antipsychotic agents. Similar to 
Mehta, the outcome that Barak et al. (2007) measured was also a wide group of 
cardio- or cerebrovascular events that included AMI among patients with or without 
antipsychotic exposure. There have also been limitations of loss to follow-up in 
previous research; it was reported that almost half of the sample members in Pratt et 
al’s (1996) cohort either died or were lost to follow up; 40% of the sample members 





The study reported by Osborn et al., (2007) was also included as relevant literature, 
which compared mortality due to coronary heart disease among patients with SMI 
with or without exposures to antipsychotic. Concerning the dose-response 
relationship, Enger et al. (2004) calculated ratios of dispensed days to total days 
(lowest exposure as reference) representing the intensity of dose, whereas Osborn et 
al. (2007) compared total dose of antipsychotic prescribed among different age 
groups of patients with SMI.  
 
Accepting these differences in methodology, among the seven studies, an increased 
risk of AMI was found in people with antipsychotic use compared to those without in 
three historic cohort studies with odds ratios (OR) or hazard ratios (HR) ranged from 
1.15 to 5.34 (Enger et al., 2004; Pariente et al., 2012; Pratt et al., 1996). Osborn et al. 
(2007) found that the excess risk of coronary heart disease associated with 
antipsychotic use in SMI ranged from 0.98 in patients older than 75 years of age, to 
3.13 in patients aged between 18~49, with the greatest risk in the highest dose group. 
However, Enger et al. (2004) found an inverse dose-response relationship. Barak et 
al. (2007) and Jerrell et al. (2007) found no significant association between risk of 
AMI and antipsychotic exposures, but they either did not measure the effects of 
relative risks (Barak et al., 2007), or just compared the risk of AMI among users of 





Table 4.2 Summarizing cohort studies reporting associations between antipsychotic use and AMI      
              
Study, author, 
and country 
Sample members   
Study years; 
Age or mean age of 
inclusion 
Compare the risk of 
AMI among the 
following subgroups 
Number of events (AMI) 
in antipsychotic exposed 
and non-exposed groups 
Control for confounding 
factors 
Main findings: (with 95% 
confidence intervals)  
 
Pratt  








- 18~29 yrs: 36% 
30~44 yrs: 38.2% 
45~54 yrs: 10.2% 
55~64 yrs: 9.4% 
≧65 yrs: 6.2% 
- Compared ‘ever users’ 
vs. non-users of 
antipsychotic 
AMI occurred among 
- Phenothiazine exposed 
patients: 8; 
- Non-exposed: 55 
- Adjusted for age, sex, 
marital status, history of 
hypertension, and history 
of major depressive 
disorder or dysphoria  




-Adjusted OR for ever use of 
-Phenothiazines: 2.92 (1.23~ 
6.98) 
Enger 




- 1920 patients with 
schizophrenia 
matched with 9,600 
people who were 
members that receive 
health care services 
from a large managed 
care organization  
- 1995~1999 
- Mean age: 38.2 
- Compared types and 
intensity of exposure to 
antipsychotics;. 
AMI occurred among 
- antipsychotic- exposed 
patients: 12; 
- Non-exposed patients: 28
- 1:5 matching by age, 
gender, date and health 
plan;  
- Adjusted for duration of 
follow-up, prior diabetes, 
prior use of antianginal or 
antihypertensive 
medications 
Adjusted relative risk (RR) of 
AMI:  
- For any antipsychotic use: 4.81 
(2.44~9.46)  
- For typical antipsychotic only: 
5.34 (1.75~16.30)  
- For atypical antipsychotic 
only: 1.66 (0.19~14.82)  
- For use of both types of 





Intensity to exposure: 
- Medium: 0.31(0.05~1.75) 
- Highest: 0.46 (0.13~1.69) 
Osborn 




- 46,136 people with 
serious mental illness 
(SMI), compared 
with 300,426 without 
 
- 1987~2002 
- Median age: 46.4 for 
SMI group; 38.0 for 
control 
Examined the risk of 
CHD mortality : 
- Among people with or 
without SMI, with or 
without antipsychotic 
exposure 
- According to terciles 
total dose of 
antipsychotic use (in 
chlorpromazine 
equivalent) among 
people with or without 
SMI 
Total numbers of deaths due 
to coronary heart disease 
(CHD): 
- In people with SMI: 618;
- In people without: 2293 
- Adjusted for age, sex, 
period, and social 
deprivation 
Risk of CHD mortality in people 
with or without SMI: 
- In SMI patients not taking 
antipsychotic: from 1.17 
(0.94~1.46) in people older 
than 75 years of age, to 2.75 
(1.17~6.44) in people aged 
between 18~49 
- In SMI patients taking 
antipsychotic: from 0.98 
(0.84~1.13) in people older 
than 75 years of age, to 3.13 
(1.11~8.55) in people aged 
between 18~49. 
- Risk of CHD mortality 
increased with total dose of 
antipsychotic use, especially in 
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patients with SMI aged 18~49. 
Barak 




- 3,111 patients 
admitted to an acute 
psychogeriatric ward 
in a mental health 
center; 
- 2,583 patients were 
exposed to 
antipsychotic 




- Mean age: 73.9 
- Compared the outcome 
of cardiovascular 
(including AMI) or 
cerebrovascular 
mortality among users 
of typical, atypical 
antipsychotic and 
non-users.  
Cardiac (including AMI) or 
cerebrovascular outcomes 
occurred among patients 
exposed to: 
- Second generation 
antipsychotic: 26 (out of 
1,402); 
- Conventional 
antipsychotic: 31(out of 
1,181) 
- No antipsychotic: 8 (out of 
528) 
- Did not control for 
confounders 
Patients exposed to 
antipsychotic did not have more 
medical adverse outcomes 
compared to those without 
antipsychotic exposure: 
- χ2 test compared 
cardiovascular and 
cerebrovascular outcomes 
among these three groups of 
typical, atypical, and no 
antipsychotic use yielded p 








- 4,375 patients with 
schizophrenia aged 
18~54 from the 
Medicaid 
- Newly prescribed 
with typical or 
- 2002~2004 
- Mean age: 40 
- Newly prescribed users 
of atypical vs typical 
antipsychotic 
Incidence of AMI and other 
ischemic heart diseases 
occurred among patients 
exposed to antipsychotic: 
0.7% (15 out of 2231) 
- Significant predictors of 
demographic variables 
and specific cerebro- or 
cardiovascular conditions.
-  Age, gender, and race 
were not significantly 
Results indicated a 
non-significant overall 
regression equation, with 
Likelihood ratio χ2=12.06; 
df=10; p=0.28. 





different across the 
antipsychotic groups 
aripiprazole 
which had a lower estimate : 
Waldχ2=7.45; p= 0.006; OR= 
-2.17; 0.26~ 0.80 compared to 
both conventional medications 
(haloperidol and fluphenazine). 
Mehta 




- 39,587 Older adults 
(>= 50 years of age) 
newly prescribed 
with atypical (12,296) 




- Mean age of 69.8 for 
atypical users; 69.4 for 
typical users after 
matching. 
- Users of typical vs. 
atypical antipsychotic 
Serious cardiac events 
(including AMI, after 
matching by propensity 
score) occurred among 
patients exposed to: 
- Atypical antipsychotic: 
11.9% (out of 5,580); 
- Typical antipsychotic: 
12.4% (out of 5,580) 
- Matched by propensity 
scores calculated on the 
basis of more than 60 
covariates 
- These covariates were 
shown to be associated 
with the assignment of 
treatments with typical or 
atypical antipsychotic 
Hazard ratios for serious 
cardiovascular events among 
patients exposed to : 
- Atypical antipsychotic: 1.00 
(reference) 
- Typical antipsychotic: 1.21 
(1.03~1.40) 
Pariente 











- After matching by 
propensity scores:  
Unexposed vs. exposed 
subcohort:  
66~74 yrs: 17.9 vs. 22.3 
% 
- Compared users vs. 
non-users of 
antipsychotic 
Incident AMI occurred 
among patients (after 
matching by propensity 
scores): 
- Exposed to antipsychotic: 
138 (out of 10,969) 
Not exposed to 
- Adjusted for sex, age, 
dementia severity, 
markers of potential 
comorbidities, and known 
or suspected risk farctors 
for AMI 
- Matched by propensity 
Hazard ratios for AMI after 
initiation of : 
- Antipsychotic treatment: 2.19 
(1.11~4.32) for the first 30 
days 
- 1.62 (0.99-2.65) for the first 
60 days,  
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- Incident antipsychotic 
users (exposed group) 
vs. non-users 
(non-exposed group) 
75~79 yrs: 25.8 vs. 27.6 
% 
80~84 yrs: 29.3 vs. 
27.3% 
≧85 yrs: 27.0 vs. 22.8 
% 
antipsychotic: 126 (out of 
10,969) 
scores  - 1.36 (0.89-2.08) for the first 
90 days, 
-  1.15 (0.89-1.47) for the first 
365 days. 




4.3.3 Findings from self-controlled case series 
One self-controlled case series reported by Pariente et al. was embedded in the 
aforementioned historic cohort of randomly-selected community-dwelling patients 
aged over 66 years with dementia, who were new users of cholinesterase inhibitors 
(Pariente et al., 2012). In this study design, all antipsychotic users with incident AMI 
during the follow up period were included. The number of outcome events (i.e. AMI) 
occurring during the time periods after the initiation of antipsychotic were compared 
to that during the reference periods when no antipsychotic was prescribed (periods 
before the initiation and after the termination of antipsychotic, see Figure 4.2 for the 
illustration of Pariente’s design). From the total 37,138 patients with dementia, 804 
new antipsychotic users with incident AMI were selected. Incident AMI occurring in 
acute (1~30 days), intermediate (31~60 days), and prolonged (61~90 days) periods 
after the initiation of antipsychotic were quantified and compared to that occurring in 
the reference periods. The authors also defined and compared AMI events occurring 
in the remaining exposure period, defined as day 91 until the end of the last 
antipsychotic dispensing; and the residual risk period (withdrawal), which covered 
the 90 days after the end date of the last antipsychotic dispensing. 
Their results showed a positive association with antipsychotic exposure: the highest 
incident ratios for AMI were reported in the acute period (1.78, 95% CI:1.26~2.52), 
followed by that in the intermediate period (1.67, 95% CI:1.09~2.56), prolonged 
period (1.37, 95% CI:0.82~2.28), the remaining exposure period (1.18, 95% 
CI:0.92~1.51), and the withdrawal period (0.80, 95% CI:0.62~1.04). Detailed 
information regarding numbers of AMI cases and confounders were summarized in 











       






 Acute risk period: 1~30 days 
 Mid-term risk periods: 31~60 days; 61~90 days 
 Remaining exposure risk period 
 Antipsychotic withdrawal risk period (90 days) 
 Baseline time 
Adapted from Pariente (Pariente et al., 2012) 
Date of entry in the 
cholinersterase 
inhibitor uses cohort 
(with dementia) 
First dispensing of 
antipsychotic 
End of data record
  
68
    
Table 4.3 Summarizing self-control case series on the association between myocardial and antipsychotic use 
    
Study, author, 
and country 
Sample members  Study years; Design 
Number of AMI cases in different 
periods 
Control for confounding 
factors 
Main findings: (with 95% 
confidence intervals)  
Pariente 
(Pariente et al., 
2012); 
Canada 
- 804 new antipsychotic 
users with incident AMI 
during the entire follow 
up period were selected 
among 37,138 
community-dwelling 





- Compare the incidence of AMI in 
acute (days 1-30 after the first 
antipsychotic dispensing), 
intermediate (days 31-60), or 
prolonged (days 61-90) period vs. 
reference period. 
- The remaining exposure period 
was defined as day 91 until the end 
of the last AP dispensing.  
- The residual risk period 
(withdrawal) covered the 90 days 
after the end date of the last AP 
dispensing 
- Day 1~30: 31 (out of 804) 
- Day 31~60: 21 (out of 804) 
- Day 61~90: 16 (out of 804) 
- Remaining exposure period: 198 (out of 
804) 
- Withdrawal period: 68 (out of 804) 
- Unexposed period: 470 (out of 804) 
(refence group) 
- Intra-individual comparisons 
- Adjusted for age at the first 
AMI to account for the aging 
of the cohort.  
- By partitioning the 
observation time in 5 age 
groups. 
Incident ratios for MI : 
- Day 1~30: 1.78 
(1.26~2.52) 
- Day 31~60: 1.67 
(1.09~2.56) 
- Day 61~90: 1.37 
(0.82~2.28) 
- Remaining exposure 
period: 1.18 (0.92~1.51) 
- Withdrawal period: 0.80 
(0.62~1.04) 
    




Inconclusive results have been reported from the research to date on the association 
between risk of myocardial infarction and antipsychotic use. Some studies have 
found a moderate to strong increase in the risk of AMI among users of typical 
antipsychotic agents; weak associations or no association have been found for 
atypical antipsychotic use as an exposure. Although the case-control study with the 
largest sample size (Nakagawa et al. 2006) found no association between exposure to 
any type of antipsychotic agent and myocardial infarction within the general 
population, a recent large cohort study (Pariente et al. 2011) reported increased risk 
of AMI in new users of antipsychotic among patients with dementia compared with 
non-users. Such increased risk seemed to be the highest during the first month of 
antipsychotic prescription. Most studies to date, however, have tended to investigate 
antipsychotic use in general population samples or older adults rather than use 
specifically in people with schizophrenia or bipolar disorder who may have particular 
dosing profiles that do not generalize. In addition, most studies regarding 
antipsychotic exposure and risks of AMI have focused on relatively long-duration 
exposures or follow-up periods and are not equipped to detect short-term effects. 
Furthermore, observational studies cannot exclude residual confounding arising from 
different characteristics of people receiving or not receiving antipsychotics while 
randomized control trials tend to focus on relatively healthy samples in relatively 
controlled clinical settings with insufficient statistical power, even when combined, 






REMAINING AREAS OF UNCERTAINTY IN THE LITERATURE, 
PRINCIPAL OBJECTIVES, AND STUDY HYPOTHESES
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5.1 Remaining areas of uncertainty 
Previous research investigating the risk of acute myocardial infarction (AMI), receipt 
of invasive coronary intervention and outcomes following AMI, and associations of 
AMI and antipsychotic use in people with serious mental illness (SMI) have been 
summarized in Chapters 2~4. Principally, studies in this field focusing specifically 
on AMI in people with SMI are relatively scant, espeically those which have defined 
subgroups of schizophrenia or bipolar disorder. This is likely to be due to 
methodological challenges since the prevalence of SMI and AMI comorbidity are 
relatively low. 
 
The background literature was concluded to be weak in the following areas:  
a) There were reasonable amount of literature comparing the risk of AMI in patients 
with and without schizophrenia, but relatively little comparing this outcome in 
people with or without bipolar disorder.  
b) Previous comparisons of AMI risk between people with and without SMI have 
used samples with broad age ranges. Little is known about modifying effects of 
age and gender on this association.  
c) The majority of analyses of invasive coronary intervention receipt have relied on 
data from health systems with incomplete and selected coverage, such as the US 
Medicaid and Veterans Health Administration systems. Alternatively they have 
been confined to specific clinical units or primary care registers. 
d) It is not clear whether any elevated risk of AMI is associated with use of 
antipsychotic agents in people with schizophrenia or bipolar disorder.  
e) Research to date has been conducted in Western or developed countries, with little 
or no evidence from East Asian countries. Results regarding the receipts of 
invasive coronary interventions in people with SMI might, in particular, vary 




To address the gaps from previous literature described above, the project was 
designed to use the specific resource of a nationwide database: the National Health 
Insurance Research Database (NHIRD), which contains in-depth anonymised data on 
diagnoses and units of healthcare (including medication receipt) for all citizens in 
Taiwan. This study selected more than 300,000 enrollees from the NHIRD with and 
without SMI chosen at random from the 1996 to 2007. Principal objectives and 
primary hypotheses are stated in the following sections. 
 
5.2 Study objectives 
As described in previous chapters of literature review, the overall objectives for this 
thesis were to study further the remaining areas of uncertainty. Therefore, the study 
objectives included:  
1. To investigate the relative risk of AMI in adult patients with SMI in Taiwan 
2. To compare the receipts of invasive coronary intervention, outcomes of inpatient 
mortality, or recurrence of cardiovascular diseases following the first AMI among 
patients with or without SMI 
3. To investigate the associations between AMI and recent antipsychotic exposure 
among people with SMI 
  
5.3 Study hypotheses related to objectives of this thesis 
5.3.1 To investigate the relative risk of acute myocardial infarction in adult 
patients with serious mental illness in Taiwan  
The hypothesis was as follows:  
(1) Compared with the national population, people with SMI will have a higher risk 
of AMI, independent of age, sex, previous history of cardiovascular risk factors, 




5.3.2 To compare the receipts of invasive coronary interventions, outcomes of 
inpatient mortality, or recurrence of cardiovascular diseases following the first 
acute myocardial infarction among patients with or without serious mental 
illness 
Comparing receipts of invasive coronary interventions and outcomes following AMI 
between people with a previous history of SMI (cases) and those without such a 
history (controls), the hypotheses were as follows:  
(1) Diagnostic catheterization will be lower in cases compared to controls. 
(2) Receipt of revascularization will be lower in cases compared to controls. 
(3) Receipt of revascularization after catheterization will be lower in cases compared 
to controls. 
(4) Inpatient complications following AMI will be higher in cases compared to 
controls. 
(5) The 30-day inpatient mortality following an AMI will be higher in cases 
compared to controls.  
(6) Recurrence of AMI within and after one year after discharge of index AMI 
episode will be higher in cases compared to controls. 
(7) Hospitalizations due to other cardiovascular diseases within and after one year 
after discharge of index AMI episode will be higher in cases compared to 
controls.  
 
5.3.3 To investigate the associations between acute myocardial infarction and 
recent antipsychotic exposure among people with serious mental illness 
Comparing a more recent (case) with a more distant (control) time period in people 
with SMI who experienced an AMI, the hypotheses were as follows:  
(1) Antipsychotic exposure will be more common in the case time period compared 
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to the control time period.  
(2) The average dose of antipsychotic will be higher in the case period compared to 
the control period. 
(3) Use of typical antipsychotic will be more common in the case period compared to 
the control period (the rationale being that a short-term relationship would 
potentially act via conduction deficits associated with typical agents rather than 







CORE MATERIALS AND METHODS
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6.1 Introduction and chapter plan 
In this study, a series of secondary analyses were carried out using historic cohorts 
derived from a nationwide database in order to test the study hypotheses. This 
chapter describes the details of the population-based datasets used, from the 
application to the assembly of the datasets, the principal data management processes, 
and the generation of variables relevant to the analyses presented in the subsequent 
three results chapters (Chapters 7~9). The overall protocol for ascertaining case and 
comparison groups, treatment receipts following acute myocardial infarction (AMI), 
and ascertainment of antipsychotic and cardiovascular medication use will be 
described in this chapter. Specific variables or covariates relevant to individual 
hypothesis and statistical approaches will be described in detail within each of the 
results chapters. 
 
6.2 Data source 
6.2.1 Relevant background information regarding health service provision in 
Taiwan 
Taiwan, an island of 36,000 square kilometers situated on the southeast of China, 
(see Figure 6.1), has a population of approximately twenty three million people in 
2001. The health care system in Taiwan currently offers nearly 1.6 physicians and 5.9 
hospital beds per 1,000 population (Taiwan country profile, 2005). The per capita 
health expenditure was around US$951 in year 2009. The overall health expenditure 
constitutes 6~7 percent of the gross domestic product (GDP)(World Economic 
Outlook Database-April 2010). The overall life expectancy in 2009 was 78 years 
(Taiwan country profile, 2005). The providers (hospitals or clinics) are accredited 
into four main categories of medical centers, regional hospitals, district hospitals, and 
others (mostly solo-practice clinics) by the Department of Health of the Executive 
Yuan according to their numbers of beds and staff, service provisions, and quality of 
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care. Patients with psychiatric disorders mostly received psychiatric or medical 
services from above the level of district hospitals. 
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(Source: Country Profile of Taiwan, The Economist Intelligence Unit, 2007)
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6.2.2 Setting: the National Health Insurance (NHI) system in Taiwan 
In order to provide people in Taiwan with equal access to medical care without 
financial burden, a single-payer medical insurance program, the National Health 
Insurance (NHI) system, was launched on March 1, 1995. All residents in Taiwan 
(except for military personnel and prisoners, whose medical expenses are paid by the 
government when needed) were required by law to join the NHI program, and by 
2001, over 99% of residents (about 22.8 million out of the total population of 23 
million) were included. The NHI system provides near-universal coverage of health 
care (comparable to the NHS model in the UK) including hospitalization, ambulatory 
care, and drugs with low fixed co-payment rate (US $5 per visit). With official 
registration, patients with severe mental or physical illness can be exempted from 
such co-payments. Under the NHI system, people in Taiwan have the option to 
access any hospital or physician at any time without maximum limits on attendances, 
nor is there the restricting requirement of visiting a gate keeper practitioner first.  
 
Each resident’s insurance premium is calculated on the basis of the ‘Insured Amount’, 
which takes individual or household income into account. The insured person, 
employer, and government have to share 35% to 100% of the premium, depending 
on the characteristics of their employer (eg. employers from private companies have 
to share 35% of their employees’ insurance premiums, whereas the government has 
to pay for 60~70% of their own employees’ premiums). People who are unemployed 
will either be insured as a family dependent or be registered with the social welfare 
system to receive benefits. People with disability or from lower income families, 
would receive 100% public subsidies from the government.  
 
Every enrollee needs to insert the Health IC smart card into the electronic card reader 
every time they see the doctor. The Health IC smart card is a credit-card-size card 
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that contains the photo of the holder and a 32 kilobytes chip that provides the 
enrollee’s profile (Name, ID number, and date of birth) for identification purposes 
(see Figure 6.2).  
 
Figure 6.2 The Health Smart IC card of the National Health System 
 
Every time physicians see a patient, they need to type the codes for diagnoses, as 
well as all medications, invasive procedures, and dates of inpatient care, into the 
computer (NHIRD, 2006). The medical service providers (hospital or clinic 
authorities) collect these information and upload the medical bills via internet to the 
Bureau of National Health Insurance every 24 hours to claim money for relevant 
treatments or procedures. The Bureau of National Health Insurance requests the 
above information to be coded using the International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM). This is a classification system 
consists of disease coding numbers, as well as surgical, diagnostic, and therapeutic 
procedures listed in tabular forms; and is based on the World Health Organization's 




6.2.3 The Taiwan National Health Insurance Research Database (NHIRD)  
The source of data for this thesis was a nationwide database, the Taiwan National 
Health Insurance Research Database (NHIRD), derived from the National Health 
Insurance (NHI) system in Taiwan for research purposes. The NHIRD includes 
records of all medical services and individual interventions received at an individual 
level, including ambulatory (outpatient and primary) care, hospitalization, emergency 
care, and drug prescriptions. Every year, the National Health Insurance Research 
Institute collects the information on service use from the Bureau of National Health 
Insurance, scrambles and de-identifies the data to form the original files of NHIRD.  
 
The NHIRD is in turn organized into different subsets, the following of which were 
used in the analyses presented here and are described in detail below-- the 
Psychiatric Inpatients Medical Claim Dataset (PIMC) and the Longitudinal Health 
Insurance Research Database 2000 (LHIRD2000). 
 
6.2.3.1 The Psychiatric Inpatients Medical Claim Dataset (PIMC) 
The Psychiatric Inpatients Medical Claim Dataset (PIMC) contains claim-related 
data on visits to hospitals (registry, ambulatory care, admissions, and drug use 
subsets) by all people in Taiwan who had ever been hospitalized within a psychiatric 
department between the years 1996 to 2001, regardless of any physical healthcare 
received. While this provides a large sample of people with relatively rare mental 
disorders, an important consideration is that people with mental disorders who have 
only attended as outpatients during the period of interest are not included in the 
PIMC. 
 




The Longitudinal Health Insurance Research Database 2000 (LHIRD2000) 
comprises original claim-related data (registry, ambulatory care, admissions, and 
drug use subsets) from the year 1996 to 2007 of 1 million individuals selected 
randomly from the 21 million total enrollees in the Taiwan NHI program in the year 
2000 (NHIRD, 2008). Of relevance to the study described in this thesis, someone 
who is completely healthy and not requiring medical review would still be eligible 
for random selection, as would people with mental disorders receiving outpatient 
care. The methodology of the random selection is described in detail on the NHIRD 
website (http://www.nhir.org.tw/nhird//date_cohort.htm) (NHIRD, 2009). No 
significant differences in age or gender distribution have been found between 
LHIRD2000, the NHIRD, and the known population distributions in Taiwan derived 
from census data (NHIRD, 2006). Records of medical service use of these selected 
people from 1996 to 2007 were available for analysis. 
 
6.3 Samples 
6.3.1 Inclusion criteria for the ‘case’ cohort 
1. People registered on either or both of the PIMC and LHIRD2000 datasets. 
2. Aged 18 and above at baseline (01.01.1996). 
3.  All people who had ever been given a diagnosis of schizophrenia (ICD-9-CM 
295.XX) and bipolar disorders (ICD-9-CM 296.XX, other than major depressive 
disorder, ICD-9-CM 296.2X~296.3X) from the year 1996 to 2007 were selected as 
the ‘study’ cohort. The ICD-9-CM codes for psychiatric diagnoses included or 




Table 6.1 Main ICD-9-CM codes for psychiatric diagnoses used in this thesis 
ICD-9-CM codes Diagnosis 
Inclusion diagnoses of the study cohort   
295.XX Schizophrenia 
    (including 295.7X) Schizoaffective disorder 
296.XX Affective psychoses 
    (including 296.4X) Bipolar affective disorder 
    (other than 296.2X~296.3X) Major depressive disorder 
Exclusion diagnoses of the study and comparison cohort  
294.XX Organic psychotic condition 
    (including 294.1X) Dementia 
297.XX Paranoid state 
 
6.3.1.1 Hierarchical algorithm of psychiatric diagnoses (‘case’ cohort) 
If people were found to have received diagnoses of schizophrenia and bipolar 
disorder, schizophrenia and organic mental disorder, or bipolar disorder and organic 
mental disorder during the follow up period, the main psychiatric diagnoses were 
then assigned by hierarchical algorithm (organic mental disorder > schizophrenia > 
bipolar disorder), in which an individual would be diagnosed with schizophrenia if 
he had received the diagnosis of schizophrenia during the 12- year period and had 
not received a diagnosis of organic mental disorder. 
 
The diagnosis of bipolar disorder would only be assigned if an individual had never 
received the diagnoses of schizophrenia, schizoaffective disorder, paranoid state, or 
organic mental disorder. People on the LHID2000 but not the PIMC who had been 
diagnosed with schizophrenia or bipolar disorder (i.e. who had only been seen as 
outpatients) between 1996 and 2007 were also included, this group being too small to 




Individuals with schizophrenia or bipolar disorder being identified from the above 
criteria are called the ‘case cohort’; and people from the rest of the population are 
called the ‘comparison cohort’ throughout this thesis. However, in Chapter 9, where 
a ‘case-crossover design’ is utilized, different nomenclatures of the ‘case period’ 
(indicating the time period proximal to index AMI episode) or the ‘control period’ (or 
the time period distal to index AMI episode) are applied.   
 
6.3.2 Inclusion criteria for the comparison cohort 
1. People registered on the LHIRD2000 dataset. 
2. Aged 18 and above at baseline (01.01.1996) 
 
6.3.3 Exclusion criteria for the comparison cohort 
1. All people who had received a diagnosis of organic mental disorder (ICD-9-CM 
294.XX), and paranoid state (ICD-9-CM 297.XX) from the year 1996 to 2007. 
2. People who had received a diagnosis of schizophrenia or schizoaffective disorder 
(ICD-9-CM 295.XX) or bipolar disorders (ICD-9-CM 296.XX) from the year 1996 
to 2007 were excluded from the comparison cohort and re-classified to the case 
cohort, as were those who overlapped on both the PIMC and the LHID2000 datasets 
 
6.4 Ascertainment of acute myocardial infarction  
First diagnosis of AMI (ICD-9-CM 410.XX) from claim data of ambulatory care, 
emergency services, and hospitalization during 1996 to 2007, was defined and is 
referred to as the index AMI episode for brevity’s sake. An important consideration 
for the study described in this thesis was that the index AMI was the first AMI 





6.5 Independent variables  
The rationale for investigating the study hypotheses is summarized in previous 
chapters. As described in Chapter 1, the following factors are widely recognised to 
be associated with increased risk of AMI and worse outcomes after AMI: diabetes 
mellitus, hypertension, hyperlipidaemia, male gender, tobacco use, family history of 
atherosclerotic arterial disease, low socioeconomic status, stress, and negative 
emotions (Cotran RS, 1994; Druss & Rosenheck, 2000; Druss et al., 2002; Lin et al., 
2006; Nyboe et al., 1989). As has also been summarised earlier, most of these risk 
factors are recognised to occur more commonly in people with SMI (Robson & Gray, 
2007) than those without. Variables used in all analyses are described here and other 
analysis-specific covariates are described later within each separate result chapter. 
Table 6.2 summarized the following measurements extracted from the dataset by the 
candidate: 
  
1. Demographic characteristics: 
(a) Age at study entry: Age at study entry was calculated from the difference between 
the date of study entry and the date of birth. For the case cohort, the date of study 
entry was defined as the date of the first diagnosis of schizophrenia or bipolar 
disorder in the dataset; for the comparison cohort, it was defined as the date of first 
medical contact on the dataset (both pertaining to a study period from 1996 to 
2007). Age at study entry was also categorised into five groups based on its 
distribution (as shown in Table 6.2) and was entered in the main analyses as 
appropriate in both continuous and categorical format. 
  
86
 Table 6.2 Summary of variables used in the study 
Variables Characteristics Measures 
Age at study entry 
*Mean age at study entry 
was also calculated as a 
continuous variable  






5= 65 and above 
 
Age at first AMI 
*Mean age at study entry 
was also calculated as a 
continuous variable 






5= 65 and above 
 
Gender 2 groups 0= Female 
1= Male 
 
Levels of monthly income 4 groups based on 
previous literature (Lin et 
al., 2010a) 
0=  NT$ 0  
1=  NT$ 1~15840 (≤USD 
528) 
2=  NT$ 15841 ~ 25000 
(USD 528~833) 
3=  ≧NT$ 25001 (≧
USD 834) 
 
Levels of urbanization of 
residence 
 
5 groups based on 
locations and population 
statistics (see following 
text for explanation) 




5= least urbanized 
 
Schizophrenia 2 groups based on having 
this diagnosis or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
Bipolar disorder 2 groups based on having 
this diagnosis or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
History of ischemic or 2 groups per each type 0 =  ‘No’ 
  
87
coronary heart disease 
(two different variables: 
one type is if the diagnosis 
was identified before 
study entry for analysis in 
Chapter 7; another type is 
if the diagnosis was 
identified before index 
AMI for analysis in 
Chapters 8 and 9). 
based on having such 
history or not (please refer 
to Table 6.1) 
1 =  ‘Yes’ 
 
History of hypertension 
(two different variables: 
one type is if the diagnosis 
was identified before 
study entry for analysis in 
Chapter 7; another type is 
if the diagnosis was 
identified before index 
AMI for analysis in 
Chapters 8 and 9). 
2 groups based on having 
such history or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
History of diabetes    
(two different variables: 
one type is if the diagnosis 
was identified before 
study entry for analysis in 
Chapter 7; another type is 
if the diagnosis was 
identified before index 
AMI for analysis in 
Chapters 8 and 9). 
2 groups based on having 
such history or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
History of hyperlipidemia 
(two different variables: 
one type is if the diagnosis 
was identified before 
study entry for analysis in 
Chapter 7; another type is 
if the diagnosis was 
identified before index 
AMI for analysis in 
Chapters 8 and 9). 
2 groups based on having 
such history or not 
0 =  ‘No’ 




History of alcohol use 
disorders 
(two different variables: 
one type is if the diagnosis 
was identified before 
study entry for analysis in 
Chapter 7; another type is 
if the diagnosis was 
identified before index 
AMI for analysis in 
Chapters 8 and 9). 
2 groups based on having 
such history or not 
0 =  ‘No’ 




2 groups based on having 
the episode or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
History of visiting 
psychiatric department 
before study entry 
2 groups based on having 
the episode or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
Levels of hospital patient 
visits before study entry 
4 groups based on the 
levels of hospital 
 
1 = Medical center 
2 = Regional hospital 
3 = District hospital 
4 = Others 
 
Levels of hospital of 
which the first AMI 
episode was diagnosed 
4 groups based on the 
levels of hospital 
 
1 = Medical center 
2 = Regional hospital 
3 = District hospital 
4 = Others 
 
Levels of urbanization in 
hospitals of which the first 
AMI was diagnosed 
5 groups based on the 
locations 




5= least urbanized 
 
Hospital teaching status 2 groups 0 =  ‘No’ 
1 =  ‘Yes’ 
Status of receiving 
particular intervention 
following AMI, or 
antipsychotic before AMI, 
2 groups for each variable 
appeared in different result 
chapters of this thesis 
0 =  ‘No’ 




or antidepressant before 
AMI, or cardiovascular 
medications before AMI 
Dates of the conditions 
listed on the right 
 • Registration to the 
National Health 
Insurance  
• First visit identified in 
the database 
• First diagnosis of 
psychiatric disorders 
• First diagnosis of AMI 
• First diagnosis of 
cardiovascular risk 
factors 
• Death during 
hospitalization or loss 
follow up (withdrawal 
from NHI register) 
during the study period 
(also refer to the 
methodology in Chapter 
7) 
• Prescriptions of 
antipsychotic, 
antidepressants, or 
cardiovascular drugs in 






(b) Age at index AMI: Age at index AMI is defined as the difference between the 
date of the index AMI (definition described above) and the date of birth. Similar 
to age of study entry, age of first AMI was also categorised into 5 groups based 
on its distribution. Reasons for adjusting age at index AMI are that the incidence 
of AMI increases with age. Studies have shown among patients hospitalized due 
to AMI, over one third aged over 70 (McMechan & Adgey, 1998; Rask-Madsen 
et al., 1997). In addition, 80% of mortality in AMI occurs in people aged over 65; 
60% in people aged over 75 (Gurwitz et al., 1992).  
(c) Gender: Gender is categorized into 2 groups. The reason for adjusting gender is 
that the prevalence of AMI is higher in men (Wilson et al., 1998). 
(d) Levels of income: The ‘Insured amount’ record applied to the individual 
beneficiary (or to the household in the case of unemployment or a lower income 
family) from the NHIRD was extracted as a proxy measure of individual and/or 
household income. Level of income was categorized into 4 groups according to 
its distribution (as shown in Table 6.2) and was entered into main analyses as a 
categorical variable. Reasons of adjusting levels of income are that not only do 
people with low income were found to have elevated risk of AMI, income level 
may also reflect the influences of education levels (Nyboe et al., 1989).  
(e) Urbanization levels of residence: For the purpose of describing socioeconomic 
status, the urbanization levels of the ‘Insured person’s Area of Residence’ was 
used as another proxy measure. The record of the ‘Insured person’s Area of 
Residence’ was extracted from the NHIRD. These ‘Area of Residence’ measures 
were further stratified into 5 different levels of urbanization (as shown in Table 
6.2) characterized using variables of population density (people per square 
kilometers), population ratio of people with education levels of college or above, 
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population ratio of people aged 65 or above, population ratio of agricultural 
workers, and numbers of physicians per 100,000 people based on the 2000 
Taiwan census data, data of Survey of Health Maintenance Organizations’ 
current status, and Health Service Utilization (conducted by Department of 
Health, Executive Yuan, R.O.C.) (Liu et al., 2006).  
2. Mental disorder diagnosis: Recorded diagnoses of schizophrenia and bipolar 
disorder (mutually exclusive, as defined in section 6.3.1) were extracted as binary 
variables.   
3.Diagnoses of cardiovascular risk factors occurring at any point during pre-defined 
periods. The definitions of time periods were different throughout Chapters 7~9. 
In Chapter 7, these diagnoses were identified as covariates if they occurred prior 
to study entry in case or comparison groups. In Chapters 8 and 9, these diagnoses 
were identified as covariates if they occurred prior to index AMI. These covariates 
were collated and coded as present/absent binary variables having extracted the 
data of diagnoses from ambulatory, admission, and emergency services used (also 
refer to Table 6.3 for ICD-9-CM codes): 
(a)  Hypertension: People with hypertension carry a six- to nine- fold risk of 
developing coronary heart disease (Kannel, 1975). In addition, increased short- 
and long- term mortality of AMI were observed in people with hypertension 
compared to those without (Dunn, 1983; Kuller et al., 1973).  
(b)  Diabetes: Patients with diabetes have twice the risk of developing AMI 
compared to the general population (Buse et al., 2007), and having glucose 
intolerance is associated with a 1.5 to 2 times increase in the likelihood of 
developing IHD (Fuller et al., 1980).  
(b)  Hyperlipidaemia: The risk of ischemic heart disease is doubled when the total 
cholesterol to high-density lipoprotein (HDL) ratio reaches 10:1. A 
meta-analysis from seventeen case-control studies among patients with 
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cardiovascular disease also reported an increased relative risk of triglycerides 
from 1.1 to 1.4 times after controlling for HDL (Hokanson & Austin, 1996). 
(c)  Alcohol use disorders (including alcohol abuse and alcohol dependence): 
ICD-9-CM diagnoses of alcohol use disorders were used as a proxy measure 
for heavy drinking. The reason for adjusting for alcohol use disorder is that 
although an inverse association of cardiovascular mortality has been found with 
light drinking, a U-shape or J-shape curve are often used to report the 
relationship between the amount of alcohol consumption and all-cause 
mortality, indicating that excessive drinking is still associated with increased 
mortality (Di Castelnuovo et al., 2006; Gaziano et al., 2000).  
4. Previous diagnoses indicating ischemic or coronary heart disease were 
ascertained within pre-defined periods and a single binary variable was defined 
according to the presence of any of the following diagnoses from datasets 
containing ambulatory, admission, and emergency services used (also see Table 
6.3):  
(a)  Ischemic heart disease  
(b)  Angina pectoris  




Table 6.3 ICD-9-CM codes for diagnoses of cardiovascular diseases or risk 
factors 
ICD-9-CM codes Diagnosis 
Diagnoses of cardiovascular diseases or risk factors  
410.XX Acute myocardial infarction 
401.XX Essential hypertension 
250.XX Diabetes mellitus 
272.XX Disorders of lipid metabolism 
431.XX~434.XX Cerebrovascular diseases (including 
intracranial hemorrhage, cerebral 
occlusions, stenosis, or thrombosis)
Diagnoses for coronary/ ischemic heart disease 
411.XX Other forms of ischemic heart disease 
412 Old myocardial infarction 
413.XX Angina pectoris 
414.XX Other forms of chronic ischemic heart 
disease 
Having any of the following 3 diagnoses were identified as having alcohol use 
disorder  
291.XX Alcoholic psychoses 
303.XX Alcohol dependence syndrome 
305.0X Alcohol abuse 
 
5. Using methods and definitions from previous research (Lin et al., 2006), the 
following characteristics of the hospital where the patient first received the 
diagnosis of AMI were classified and considered as potential confounding factors: 
(a)  Hospital level: This information was collected by merging the records of 
medical services in the study datasets described above with the registration file 
of hospitals containing information on their levels. All hospitals in Taiwan are 
classified into four different levels as follows based on their bed numbers and 
capability of providing clinical services: 
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- Medical centers are hospitals that have more than 500 beds, have 
responsibilities to provide medical services for severe or complex diseases, 
and have the capability for teaching, training, and undertaking research.  
- Regional hospitals are hospitals that have more than 250 beds. 
- District hospitals are those that have more than 20 beds. 
- ‘Other’ health care providers include solo-practice clinics (0 or less than 20 
beds), or government health centers located in remote areas. 
(b)  Levels of urbanization in the geographical location of these hospitals: 
Research showed that this may in particular affect the quality of care provision 
(Lin et al., 2006) and therefore was considered as a potential confounder. This 
information was collected by merging the records of medical services in the 
study datasets with the registration file of hospitals that contained area codes 
indicating their geographical locations. Similar to the methods of defining the 
aforementioned variable of ‘urbanization levels of residence’, the urbanization 
level of hospital was characterized into 5 levels according to the population 
statistics (Liu et al., 2006) of the hospital’s geographical location and was used 
as a categorical variable in the main analysis. 
(c)  Whether a hospital was accredited as a teaching hospital or not (Lin et al., 
2006): This status was coded as a binary variable.  
 
6.6 Outcome variables for intervention receipts of AMI 
Records of the following post-AMI procedures (also refer to Table 6.4 for 
ICD-9-CM OP codes) were ascertained and compared between the cohorts: 
catheterization (cardiac catheterization ICD-OP code: 37.21~37.23; coronary 
arteriography ICD-9-CM OP code: 88.55~88.57) and revascularizations 
(percutaneous transluminal coronary angioplasty (PTCA) with or without fibrinolytic 
therapy or intracoronary artery thrombolytic infusion ICD-OP code: 36.0X; other 
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heart revascularization ICD-OP code: 36.2X; coronary artery bypass graft (CABG) 
ICD-OP code: 36.1X). These were chosen in accordance with the American College 
of Cardiology (ACC) /American Heart Association (AHA) Guidelines for the 
Management of Patients with Acute Myocardial Infarction (Anbe et al., 1999). 
  
Table 6.4 ICD-9-CM OP codes for procedures 
ICD-9-CM OP codes Procedures 
36.XX Operations on vessels of heart 
   36.0X Removal of coronary artery obstruction and insertion of stent
36.XX Bypass anastomosis for heart revascularization 
   36.1X Coronary bypass for heart revascularization 
37.21~37.23 Diagnostic procedures on heart and pericardium 
88.55~88.57 Coronary arteriography 
 
6.7 Outcome variables for the association of antipsychotic agents and AMI 
Prescription instances of antipsychotic agents and other medications associated with 
AMI or the treatment of other cardiovascular diseases were identified from the 
datasets according to their registration numbers at the National Health Insurance 
Bureau. These medications were grouped according to the Anatomical Therapeutic 
Chemical (ATC) Classification System, a pharmaceutical coding system that divides 
different groups of medications according to the organ or system they act on (WHO, 
2009), and which was published by the WHO Collaborating Centre for Drug 
Statistics Methodology (WHOCC, 2009). To measure and compare different 
antipsychotic agents, the technical unit of measurement called the Defined Daily 
Dose (DDD, or ‘the assumed average maintenance dose per day for a drug used for 
its main indication in adults’) (WHOCC, 2009) was applied. Groups of medications 
identified from the NHIRD in this thesis are summarized in Table 6.5.  
  
96
Table 6.5 Medications relevant in this thesis by ATC grouping 
ATC codes Procedures 
N05A Antipsychotic agents 
N06A Antidepressants 
B01 Antidiabetes agents 
C03 Diuretics 
C07~C09 Antihypertensives 
C10 Lipid modifying agents 
 
The ATC classification system and the DDD have been used in Norway since the 
early 1970s and are now recommended by the WHO for international use. Decisions 
on ATC classification and DDD assignment were established by 12 members of the 
International Working Group, drawn from the WHO Expert Advisory Panels for 
Drug Evaluation and for Drug Policies and Management, which itself drew from a 
wide range of geographical and professional backgrounds, including clinical 
pharmacology, clinical medicine, international public health, drug utilization and 
drug regulation. The Working Group continues to develop, discuss, and approve all 
new ATC codes and their DDDs. In addition, all DDDs are reviewed and revised 
semi-annually considering recent literature, and details are published on the website 
of the WHO Collaborating Centre for Drug Statistics Methodology and in the 
publication WHO Drug Information (WHOCC, 2009). 
 
A DDD is usually established according to the maintenance dose of declared content 
(strength) of the product. All drugs have an individual DDD; for example, the DDD 
of chlorpromazine is 300mg, and that for haloperidol is 8mg. Thus, the ratio of DDD 
equivalent claims haloperidol be 37.5 times more potent than chlorpromazine. The 
main principle for assigning the DDDs for combinations of different 
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pharmacological products is based on counting the combination as one daily dose 
(WHOCC, 2009). An example from the WHO website for calculation of DDD for 
combination product is shown below:  
Treatment with two products, each containing one active ingredient: 
Product A: Tablets containing 20 mg of substance X (DDD = 20 mg) 
Product B: Tablets containing 25 mg of substance Y (DDD = 25 mg) 
The dosing schedule 1 tablet of A plus 1 tablet of B daily will be calculated as a 
consumption of 2 DDDs (WHOCC, 2009). 
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6.8 Application process and ethical considerations 
The application for NHIRD datasets is only open to academic researchers in Taiwan 
and for research purposes only. The application process requires completing the 
application form alongside the researcher’s personal profile, submitting the research 
proposal and lists of files requested, as well as signing an agreement to follow the 
Computer-Processed Personal Data Protection Law 
(http://www.winklerpartners.com/a/features/computerprocessed-personal-dat.php ) 
and related regulations of the Bureau of National Health Insurance and National 
Health Research Institutes (NHRI). All applications are reviewed under the 
committee of NHRI for approval of data release. Finally, analysis reported here 
received ethical approval by the Mackay Memorial Hospital Institutional Review 
Board, protocol number 10MMHIS056 (Appendix 3). 
 
6.9 Data management procedures 
The NHIRD resource provides valuable but complex datasets requiring a 
considerable degree of manipulation prior to analyses. The following processes were 
required to extract and prepare data: 
1. The author sent an application requesting the PIMC and LHIRD2000 datasets 
that contained medical claim records from year 1996 to 2007 from the Institute 
of National Health Insurance Research in Taiwan 
(http://w3.nhri.org.tw/nhird//date_01.html) in year 2009. The following data 
files relevant to the study were embedded within the PIMC and the LHID2000 
datasets: 
(a) The registration files (capital letters in the brackets are the official initials 
for the files named by the NHIRD), which include: 
•       Registry for contracted beds (‘BED’) 
•       Registry for contracted specialty services (‘DETA’) 
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•       Registry for contracted medical facilities (‘HOSB’) 
•       Supplementary registry for contracted medical facilities (‘HOSX’) 
•       Registry for board-certified specialists (‘DOC’) 
•       Registry for medical personnel (‘PER’) 
•       Registry for catastrophic illness patients (‘HV’) 
•       Registry for medical services (‘HOX’) 
•      Registry for drug prescriptions (‘DRUG’) 
•       Registry for beneficiaries (‘ID’) 
(b) The Original Claim Data, which includes: 
•     Monthly claim summary for inpatient claims (‘DT’) 
•     Monthly claim summary for ambulatory care claims (‘CT’) 
•     Inpatient expenditures by admissions (‘DD’) 
•     Details of inpatient orders (‘DO’): its content includes service use, drugs 
prescribed, and intervention receipt during each hospitalization 
•     Ambulatory care expenditures by visits (‘CD’) 
•     Details of ambulatory care orders (‘OO’): its content includes service use, 
drugs prescribed, and intervention receipt during each ambulatory visit 
•     Expenditures for prescriptions dispensed at contracted pharmacies (‘GD’) 
•     Details of prescriptions dispensed at contracted pharmacies (‘GO’) 
2. All the ‘Original Claim Data’ mentioned above were requested for every 
person registered as a PIMC beneficiary. For beneficiaries registered on the 
LHID2000, 300,000 out of the 1 million people were randomly selected (a 
simple random sample without stratification) (please see Appendix 1 for the 
detailed list of 154 compact discs of data files applied).  
3. Since each of the data files listed in Appendix 1 is a compact disc composed 
of 12 or more monthly subfiles (each of which was approximately 85MB in 
size), the Macro Language of SAS was used to read in the above datasets and 
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to transform the ASCII files into SAS files in order to be used via the statistical 
software of SAS. A total of 154 data VCDs, 1475 subfiles, approximately 
118GB were read.   
4. Managing datasets: Horizontal merging of four different types of subsets 
(including Registry for beneficiaries (‘ID’), Ambulatory care expenditures by 
visits (‘CD’), Inpatient expenditures by admissions (‘DD’), and Registry for 
catastrophic illness (severe mental or physical illness) patients subsets (‘HV’)) 
into one single large data file were carried out separately for the PIMC 
(23,163,262 observations) and LHID2000 (51,607,426 observations) datasets. 
Figure 6.3 illustrates an example of the datasets, yearly and monthly subfiles, 
and their sizes, merged from the PIMC, while Figure 6.4 summarizes the main 
tasks of data management. Appendix 2 lists the variables used for the analyses 
from the four main subsets of (‘ID’, ‘CD’, ‘DD’, and ‘HV’). Finally, Figure 
6.5 displays the variables used for merging and the merging details across 
different subsets.  
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Figure 6.3 Example of datasets and subfiles used for data merging 
 
 
*Each of these yearly files contained 12 monthly subfiles, representing medical 
services given in each month of the year 
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Figure 6.4 Procedures of data management and analysis 









5.  Multiple observations per subject in the ‘Registry for Beneficiaries (ID)’ were 
transposed into one observation per subject containing the latest information 
regarding the beneficiary’s demographic background. At this stage, two basic 
files had been created containing the subject’s identification number and their 
demographic information for the 91,104 subjects from the PIMC dataset and 
300,000 subjects from the LHID2000. These were therefore the ‘primary 
source’ for study and comparison subjects.
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Figure 6.5 Explanations of the variables needed for the merging process 




*Blue words represent variables used for merging
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6. Data cleaning process: Information on gender, date of birth, level of household 
income, and geographic location of residence from the above basic files was 
checked using the following procedures:  
(a)  Information on the above demographic characteristics was sought from the 
four subsets of ‘Registry (‘ID’)’, ‘Ambulatory care (‘CD’)’, ‘Admissions 
(‘DD’)’, and ‘Registry for catastrophic illness patients subsets (‘HV’)’. 
(b) Information was cross-checked between these four subsets.  
(c) If there was an inconsistency between subsets, the information from the 
‘Registry subset (‘ID’)’ was used as the final gold standard because it is the 
subset established to contain the basic personal profiles such as date of birth, 
status of insured or withdrawal from the registry, dates registration or 
withdrawal, the ‘insured amount’, and place of residence. 
The above procedures were performed separately in the PIMC and the LHID2000 
database. 
7. Vertical merging was carried out of the ‘Ambulatory care expenditures by visits 
(‘CD’)’ and the ‘Inpatient expenditures by admissions (‘DD’)’ files from the 
PIMC (resulting in 25,001,803 observations and 82 variables in the newly 
vertically merged file) and the LHID2000 (resulting in a total 51,998,445 
observations and 82 variables) in order to integrate all the medical services 
received either in outpatient or hospitalization sectors into one big file.  
8. Horizontal merging was then carried out of the basic files containing subjects’ 
identification numbers and demographic information with the abovementioned 
vertically-merged files containing observations of all medical visits between 
1996 and 2007. 
9. People were then identified with target diagnoses of mental disorders from the 




(a) Applying the aforementioned inclusion, exclusion criteria, and hierarchical 
algorithm of psychiatric diagnoses, patients with schizophrenia or bipolar 
disorder were selected and labelled using ICD-9-CM codes matched with the 
principal diagnoses appearing in the ‘CD’ and ‘DD’ datasets each time people 
received medical services. At this stage, people with either the diagnosis of 
schizophrenia or bipolar disorder were allocated to the case cohort, whereas 
people without those diagnoses were allocated to the comparison cohort.  
(b) Dates of receiving the first diagnoses of schizophrenia or bipolar disorder, 
or dates of first medical service received and recorded in the database were 
recorded as the date of study entry.  
10. Ascertainment of acute myocardial infarction: The first diagnosis of AMI 
(ICD-9-CM 410.XX) from claim data of ambulatory care, emergency services, 
and hospitalization between 1996 and 2007 (from the vertically merged files of 
‘CD’ and ‘DD’) was ascertained and a binary variable created.  
11. In the case and comparison cohorts, any diagnoses were ascertained of 
previous cardiovascular risk factors or previous history of ischemic or 
coronary heart diseases received during the follow up period or before the 
occurrence of AMI.  
12. The case and comparison cohorts were then vertically merged.  
13. Information was obtained on intervention receipt, service use, and drugs 
prescribed during the AMI episode by merging the ‘Details of inpatient orders 
(‘DO’) data file’ with the ‘Inpatient expenditures by admissions (‘DD’) data 
file’, and the ‘Ambulatory care expenditures by visits (‘CD’) data file’ with the 
‘Details of ambulatory care orders (‘OO’) data file’, using the identification 
number for each subject, the date of the index AMI episode, the hospital 
identification number, and the date that the hospital applied for treatment fees 
(see Figure 6.5). The above processes 9~11 involved the creation of accurate 
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and comprehensive code lists for every exposure, outcome, and covariates of 
interest, as well as searching these codes accurately to determine whether a 
subject had received a diagnosis, an investigation, or intervention, and if so, 
when.  
14. As summarized in Table 6.2, the final created data file (or ‘Total Cohort A’ as 
in Figure 6.6) contained information of 389,987 people with or without SMI, 
and had 127 necessary binary, categorical, or continuous variables. As 
illustrated in Figure 6.6, two study cohorts were derived from ‘Total Cohort A’ 
for the purpose of examining different hypotheses in this thesis. The first one 
was ‘Original Study Cohort B’, which excluded people with missing dates of 
birth and age of study entry, those under age 18, and those with diagnoses of 
organic mental disorder. This ‘Original Study Cohort B’ was used for analyses 
in Chapters 8~9. In order to use Cox regression models to investigate the risk 
of AMI in people with or without SMI, the second study cohort, ‘Study Cohort 
C’, was obtained. This cohort was derived from ‘Original Study Cohort B’ 
with further exclusions of people who had less than one year of disease history 
before study entry (in order to obtain definite predictors from at least one year 
of records on medical utilization for Cox regressions), those whose AMI 
occurred prior to the first date of their psychiatric diagnosis, and those whose 
age of first visit was less than 18 years old. Further information on specific 




Figure 6.6 Algorithm on data retrieving  





RELATIVE RISK OF ACUTE MYOCARDIAL INFARCITON IN PEOPLE 





Despite high mortality associated with serious mental illness, risk of acute 
myocardial infarction (AMI) remains unclear, especially for patients with bipolar 
disorder. The main objective was to investigate the relative risk of acute myocardial 
infarction in adult patients with serious mental illness (SMI) in a national sample in 
Taiwan after adjusting for demographic characteristics, comorbid cardiovascular risk 
factors, and stratified by propensity score. The hypothesis was that the risk of AMI 
would be higher in the cases compared to controls.  
 
7.2 Method 
7.2.1 Case cohort 
The case cohort comprised patients with schizophrenia or bipolar disorder identified 
from the PIMC and the LHIRD2000 (details of procedures for identifying the case 
cohort are described in Chapter 6.2 and 6.3). Their date of study entry was defined 
as the date of receiving their first psychiatric diagnosis. To obtain valid information 
on medical history prior to their study entry, the case cohort was restricted to those 
whose first medical visit (i.e. that which was not due to AMI) occurred at least one 
year prior to their first psychiatric diagnosis.  
 
7.2.2 Comparison cohort 
The comparison cohort were people of general population selected from the 
LHIRD2000 applying the inclusion and exclusion criteria (details described in 
Chapter 6.2 and 6.3). The time origin of study entry for the comparison cohort was 
defined as one year after the date of the first medical visit recorded in the database. 
 
7.2.3 Statistical analysis 
Statistical analyses were performed in three stages. Descriptive analyses were carried 
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out initially. Next, Cox regression models were used to compare the risk of AMI in 
people with or without serious mental illness. Third, after the primary analysis, the 
Cox regression model was performed again stratified by subgroups of propensity 
scores as a secondary analysis to control for differences in patients’ characteristics 
between ‘case’ and ‘control’ groups. This was instituted in response to comments 
from external reviewers on a submitted research paper containing these findings. 
 
As described individually in Chapter 6.5 and summarized in Table 6.2, factors 
widely recognized to be associated with increased risk of AMI include diabetes 
mellitus, hypertension, hyperlipidaemia, male gender, tobacco use, family history of 
atherosclerotic arterial disease, low socioeconomic status, stress, and negative 
emotions (Cotran RS, 1994; Druss & Rosenheck, 2000; Druss et al., 2002; Lin et al., 
2006; Nyboe et al., 1989). Although some of the above factors could not be obtained 
(such as tobacco use, family history of coronary diseases, precipitating stressors, or 
negative emotions), measurements available for extraction from this dataset were 
included and adjusted for in three different models in order to investigate individual 
effects on the association of interest. Model 1 adjusted for age at study entry; model 
2 adjusted for all demographic characteristics; and model 3 adjusted for all the 
demographic characteristics and cardiovascular risk factors. Detailed statistical 
procedures were as follows: 
 
I. Descriptive analysis 
SAS version 9 for Windows (SAS Institute, Cary, NC) was used for data 
management and analysis. The frequencies of target disorders were displayed. 
Pearson’s chi-squared tests were used for categorical variable comparisons. T-tests 
and one-way analyses of variance (ANOVA) were used to investigate mean 




II. Cox regression analyses 
Cox models were used to estimate hazard ratios for rate outcomes and to adjust for 
other covariates. The starting points were the time of first psychiatric diagnosis 
between 1996 and 2007 in the case cohort, and the time of first medical visit for the 
comparison cohort – i.e. individuals who received their first mental disorder 
diagnosis after AMI were excluded. Collinearity between variables was checked 
prior to their inclusion in regression models. Censoring points were the end of follow 
up or the date of withdrawal from the registry (a proxy for mortality). Hazard ratios 
and 95% confidence intervals were obtained for the outcome stratified by gender and 
age groups. Tests of effect modification for the associations of interest were restricted 
a priori to age and gender, age group at study entry being entered as an ordinal 
variable on one degree of freedom, on the assumption that interactions of interest 
would show linear relationships with age. Proportional hazards assumptions were 
checked from Kaplan-Meier survival curves. Sensitivity analyses were carried out, 
restricting the study sample to those who had their first AMI diagnoses occurred after 
07.01.2001 (i.e. during the latter half of the surveillance period) on the assumption 
that this would enrich the AMI outcome with ‘first ever’ events. Figure 7.1 illustrates 
the independent and outcome variables used in this part of the analysis. 
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III. Cox regression analyses stratified by propensity scores 
Further Cox regression analyses were then constructed, stratified by propensity 
scores to balance demographic and clinical characteristics between case and 
comparison cohorts (Joffe & Rosenbaum, 1999). The theory behind this operation is 
that when one case (i.e. a person with a psychiatric diagnosis) is found to have the 
same propensity score, or is within the same propensity stratum as one comparison 
subject (i.e. someone without a psychiatric diagnosis), it is assumed with more 
confidence that these two subjects have been ‘randomly’ assigned to each cohort on 
the basis of having equal chances of assignation as a case or comparison subject 
(D'Agostino, 1998). Propensity scores are generally calculated based on the 
covariates that affect the allocation to case or comparison cohorts (Millier et al., 
2011). Relevant covariates for estimating the propensity score used in this study are 
listed in Table 7.1. 
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Table 7.1 Summary of covariates used for calculating propensity scores for each 
subject 
Table 7.1 Summary of covariates used for calculating propensity scores for each 
subject 
Age at index date (i.e. the 
date one year after study 
entry) 






5= 65 and above 
 
Gender 2 groups 0= Female 
1= Male 
 
Levels of monthly income 4 groups based on 
previous literature  
0=  NT$ 0  
1=  NT$ 1~15840 
2=  NT$ 15841 ~ 25000 
3=  ≧NT$ 25001 
 
Levels of urbanization of 
residence 
 
5 groups based on the 
locations 




5= least urbanized 
 
Having received diagnosis 
of cardiovascular risk 
factors prior to index date 
2 groups on each 
diagnosis based on having 
this diagnosis or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
History of visiting 
psychiatric department 
before index date 
2 groups based on having 
the episode or not 
0 =  ‘No’ 
1 =  ‘Yes’ 
 
Hospital levels of visits 
before index date 
4 groups based on the 
levels of hospital  
 
1 = Medical center 
2 = Regional hospital 
3 = District hospital 




From the literature (Lo, 2004), the estimate of propensity score ( ) is:  




x are independent variables, eg. age, gender… 
a is the estimate of the intercept 
b is the coefficient for the interaction that achieve significant level (0.001) between 
variables  
e stands for exponent 
ln stands for natural log 
 
Referring to the functions mentioned above, the propensity score for each patient in 
this study was calculated using logistic regression based on covariates listed in Table 
7.1 as independent predictors affecting the receipt of psychiatric diagnosis (i.e. the 
allocation of case or comparison cohort). This propensity score corresponded to the 
probability of being assigned to the case or control group. Definitions for the date of 
study entry were the date of receiving the first psychiatric diagnosis for the case 
group, and the date of first medical visit appearing in the records (from 1996 to 2007) 
for the comparison group.  
 
Second, individuals were stratified by 20th, 30th, 40th percentiles of increasing 
propensity score, so that in each stratum, the probability of being assigned to case or 
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control group was similar, as well as having enough AMI subjects in each cohort to 
be able to analyze. Collinearity between variables was checked prior to their 
inclusion in regression models (Kim et al., 2011). 
 
Third, having matched the sample by propensity score stratification, Cox regression 
analyses with propensity score stratification were carried out to compare rates of 
AMI between the propensity-matched case and comparison cohorts. Hazard ratios 
and 95% confidence intervals were obtained for the outcome and were stratified by 
gender and age groups. Adjustments for age of study entry, history of medical 





7.3.1 Samples included 
Among the 91,104 individuals from the PIMC and 300,000 comparison samples 
from the LHID2000, 1,117 individuals (734 had diagnosis of schizophrenia and 156 
had bipolar disorder) appeared in both datasets. There were 2,567 and 2,800 
individuals from the LHID2000 that had been diagnosed with schizophrenia or 
bipolar disorder, respectively.  
 
After applying inclusion and exclusion criteria, there were 208,466 adults from the 
PIMC and LHID2000 datasets included, of whom 19,656 and 5,996 had a diagnosis 
of schizophrenia and bipolar disorder respectively during the 12-year period, with 
182,814 comparison subjects. Among the individuals with mental disorders of 
interest, 18,627 (94.8%) of those with schizophrenia, and 5,975 (99.6%) of those 
with bipolar disorder were contained on the PIMC register – i.e. had received their 
psychiatric diagnosis in the context of a hospitalization episode between 1996 and 
2000. Of the 202,226 people on the LHID, 72 (46.5%) of all 155 patients with 
bipolar disorder were also on the PIMC (i.e. cases that had received hospitalization), 
compared to 164 (12.5%) of all 1,317 patients with schizophrenia. A flow chart 
detailing selection processes is displayed in Figure 7.3.  
 
7.3.2 Missing data 
As specified in Figure 7.3, eighteen individuals were excluded from the beginning of 
data management because of missing information on date of birth. 8,123 individuals 
from the LHID2000 were excluded because they never had any medical visit from 
year 1996 to 2007, and therefore, did not have a date for study entry (defined as first 
medical visit during the follow up period). Finally, 57 individuals were excluded 
before entering the analysis due to missing any of the information on gender, or 
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levels of urbanization or income. 
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Figure 7.2 Flow chart illustrating selection of case and comparison cohorts from patients registered in Taiwan’s National Health 







aThe n for these exclusion criteria add up to more than the total n because some patients met more than one exclusion criterion 
b Including age at last visit > 120 years old (n=2), unreasonable date of last visit (n= 1)
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7.3.3 Sample characteristics 
Table 7.2 summarises the characteristics of the cohorts. Significant differences were 
found in the mean ages at study entry of the three groups (ANOVA F 693.10, df 2, 
p<0.001) and in all categorical variables (including age group) between people with 
and without serious mental illness (all p-values <0.001) from chi-squared tests. On 
observation, individuals with schizophrenia had a higher male predominance and 
lower income, and were more likely have past history of diabetes, hyperlipidaemia 
and alcohol use disorders prior to study entry compared to the comparison group. On 
the other hand, people diagnosed with bipolar disorder had a higher female 
predominance, higher proportions living in more urbanized areas compared to 
schizophrenia, and a higher likelihood of having previous history of the medical 
diagnoses of interest prior to study entry than the comparison group.   
 
In the combined cohorts of 208,466 people, 2,352 (1.13%) had experienced at least 
one AMI episode during the 12-year follow up period: 181 (0.92%) in those with 
schizophrenia, 106 (1.77%) in those with bipolar disorder, and 2,065 (1.13%) in the 
comparison cohort. The mean (SD) age at recorded AMI was 60.6 (16.4) years for 
people with schizophrenia, 65.1 (15.1) years in people with bipolar disorder, and 
66.5 (13.7) years in the comparison cohort. The mean age at the index AMI was 5.9 
(95% CI 3.8~8.0,) years lower for schizophrenia compared to comparison subjects (t 
5.5, df 2244, p <0.001), 1.4 (95% CI -1.2~.4.1) years lower in bipolar disorder 
compared to comparison subjects (t 1.05, df 2169, p =0.29), and 4.5 (95% CI 




Table 7.2 Baseline between-cohort comparison of demographic characteristics and cardiovascular risk factors  




Bipolar disorder  
(n= 5,996)  
Test statistic, degree of 
freedom (df), P value 
Mean (SD) age at study entry 43.7 (15.8) 39.7 (14.6) 46.5 (16.4) F 693.1, df 2, p<0.001 
Age group at study entry (%)       χ2 1501.6, df 8, p<0.001 
     18~34  35.3  46.2  29.4   
     35~44 24.6  25.6  24.8   
     45~54 16.7  13.4  17.0   
     55~64 10.7  6.4  11.3   
     65 and above 12.8  8.5  17.6   
Gender        (%)       χ2 169.9, df 2, p<0.001 
     Men 50.6  54.6  45.9   
     Women 49.4  45.5  54.1   
Levels of urbanization (%)       χ2 291.3, df 8, p<0.001 
     1 (most urbanized) 31.3  28.0  33.4   
     2 29.2  29.6  29.6   
     3 17.5  17.4  14.1   
     4 13.1  13.0  12.2   
     5 (least urbanized) 9.0  12.0  10.8   
Monthly income    (%)       χ2 3993.6, df 6, p<0.001 
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     NT 0 23.3  23.4  27.1   
     NT$ 1~15840 18.6  34.9  24.8   
     NT$ 15841 ~ 25000 39.4  34.8  34.8   
     ≧NT$ 25001 18.7  7.0  13.3   
History of angina (%) 1.9 3.3 12.4 χ2 2844.5, df 2, p<0.001 
History of hypertension (%) 7.3  7.4  23.9  χ2 2234.9, df 2, p<0.001 
History of diabetes          (%) 2.4  5.7  15.0  χ2 3678.9, df 2, p<0.001 
History of hyperlipidemia (%) 2.8  4.3  14.1  χ2 2360.7, df 2, p<0.001 
History of alcohol use disorders (%) 0.3  8.4  17.1  χ2 17974.7, df 2, p<0.001 
Acute myocardial infarction (%) 1.1 0.9 1.8 χ2 29.6, df 2, p<0.001 
History of visiting psychiatric 
department before study entry (%)
2.5 79.1 96.3 χ2 135852, df 2, p<0.001 
Hospital levels of visits before study entry (%)    
    Medical centers 42.2 60.7 80.3 χ2 50224.3, df 2, p<0.001 
    Regional hospitals 46.5 72.2 79.7 χ2 53180.3, df 2, p<0.001 
    District hospitals 61.0 71.8 79.4 χ2 18946.3, df 2, p<0.001 
    Primary care 97.4 92.8 97.1 χ2 1626.4, df 2, p<0.001 
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7.3.4 Results of Cox regression 
Hazard ratios of AMI comparing people with or without serious mental illness were 
calculated from multivariate Cox regression and are summarized in Table 7.3. 
Addition of hypertension, diabetes and hyperlipidaemia diagnoses to the models 
substantially attenuated the hazard ratios for both disorders. Age-modification was 
found in fully adjusted model with hazard ratios for older age x disorder interaction 
terms of 0.88 (95% CI 0.78~0.99, p=0.046) in schizophrenia and bipolar disorder 
0.73 (95% CI 0.61~0.87, p<0.001); indicating a stronger excess risk in younger 
individuals with serious mental illness. Gender- interaction terms in the fully 
adjusted model were male gender x disorder: 0.91 (95% CI 0.66~1.25, p=0.57) and 
0.67 (95% CI 0.45~1.00, p=0.05) for people with schizophrenia and bipolar disorder, 
respectively. Three-way (age group x gender x disorder) interaction terms were tested 
in fully adjusted models. Such interaction was found to be significant in people with 
bipolar disorder (0.93, 95% CI 0.87~0.99, p=0.02) but not in schizophrenia (0.98, 
95% CI 0.93~1.03, p=0.35). 
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Table 7.3 (a) Hazard ratios (HR) of AMI in people with and without schizophrenia  
 
Numbers of 










Unadjusted HR Model 1 Model 2 Model 3 
Male (Age groups )           
  Total male 112 1302 1.11 ( 0.92 ~ 1.35 ) 1.05 ( 0.87 ~ 1.28 ) 1.03 ( 0.85 ~ 1.26 ) 0.90 ( 0.74 ~ 1.01 ) 
     18~44 13 52 1.34 ( 0.92 ~ 1.96 ) 1.06 ( 0.72 ~ 1.56 ) 1.06 ( 0.72 ~ 1.57 ) 0.97 ( 0.65 ~ 1.44 ) 
     45~54 19 133 1.01 ( 0.63 ~ 1.63 ) 0.95 ( 0.59 ~ 1.53 ) 0.93 ( 0.58 ~ 1.51 ) 0.76 ( 0.47 ~ 1.24 ) 
     55~64 19 256 1.01 ( 0.59 ~ 1.73 ) 1.00 ( 0.59 ~ 1.72 ) 0.97 ( 0.57 ~ 1.66 ) 0.82 ( 0.48 ~ 1.42 ) 
     65 and above 61 861 1.01 ( 0.75 ~ 1.35 ) 1.18 ( 0.87 ~ 1.59 ) 1.16 ( 0.86 ~ 1.56 ) 1.01 ( 0.75 ~ 1.37 ) 
Female (Age groups)           
   Total female 69 763 1.42 ( 1.11 ~ 1.82 ) 1.22 ( 0.95 ~ 1.56 ) 1.22 ( 0.95 ~ 1.56 ) 1.02 ( 0.79 ~ 1.32 ) 
     18~44 9 14 2.65 ( 1.52 ~ 4.62 ) 2.34 ( 1.33 ~ 4.09 ) 2.35 ( 1.34 ~ 4.12 ) 2.18 ( 1.23 ~ 3.87 ) 
     45~54 8 42 2.00 ( 1.21 ~ 3.32 ) 1.94 ( 1.16 ~ 3.22 ) 1.95 ( 1.17 ~ 3.26 ) 1.49 ( 0.87 ~ 2.56 ) 
     55~64 18 96 1.11 ( 0.63 ~ 1.95 ) 1.07 ( 0.61 ~ 1.88 ) 1.09 ( 0.62 ~ 1.91 ) 0.93 ( 0.53 ~ 1.66 ) 
     65 and above 34 611 0.88 ( 0.57 ~ 1.37 ) 0.85 ( 0.55 ~ 1.32 ) 0.85 ( 0.55 ~ 1.32 ) 0.69 ( 0.44 ~ 1.08 ) 
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All  (Age groups)           
          Total 181 2065 1.23 ( 1.05 ~ 1.43 ) 1.10 ( 0.95 ~ 1.29 ) 1.09 ( 0.94 ~ 1.27 ) 0.93 ( 0.80 ~ 1.09 ) 
     18~44  22  66 1.67 ( 1.22 ~ 2.29 ) 1.38 ( 1.01 ~ 1.90 ) 1.41 ( 1.03 ~ 1.94 ) 1.29 ( 0.94 ~ 1.79 ) 
     45~54 27 175 1.26 ( 0.89 ~ 1.77 ) 1.20 ( 0.85 ~ 1.69 ) 1.20 ( 0.85 ~ 1.70 ) 0.95 ( 0.67 ~ 1.37 ) 
     55~64 37 352 1.75 ( 1.17 ~ 2.60 ) 0.99 ( 0.67 ~ 1.47 ) 0.98 ( 0.66 ~ 1.45 ) 0.84 ( 0.57 ~ 1.25 ) 
     65 and above 95 1472 1.03 ( 0.70 ~ 1.51 ) 1.06 ( 0.83 ~ 1.35 ) 1.05 ( 0.82 ~ 1.35 ) 0.90 ( 0.70 ~ 1.15 ) 
Model 1: Adjusted for age at study entry  
Model 2: Adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, and hospital levels before study entry 
Model 3: Adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, previous coronary heart disease 
hypertension, diabetes, and hyperlipidaemia 
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Table 7.3 (b) Hazard ratios (HR) of AMI in people with and without bipolar disorder  
 
Numbers of 




Numbers of AMI 




Unadjusted HR Model 1 Model 2 Model 3 
Male (Age groups )           
  Total male 54 1302 0.94 ( 0.72 ~ 1.24 ) 1.10 ( 0.84 ~ 1.44 ) 1.08 ( 0.82 ~ 1.42 ) 0.72 ( 0.54 ~ 0.97 ) 
     18~44 2 52 1.75 ( 0.90 ~ 3.42 ) 1.71 ( 0.87 ~ 3.34 ) 1.75 ( 0.90 ~ 3.42 ) 1.13 ( 0.55 ~ 2.35 ) 
     45~54 7 133 0.93 ( 0.41 ~ 2.09 ) 0.91 ( 0.41 ~ 2.05 ) 0.93 ( 0.41 ~ 2.09 ) 0.52 ( 0.23 ~ 1.22 ) 
     55~64 6 256 1.37 ( 0.75 ~ 2.51 ) 1.37 ( 0.75 ~ 2.51 ) 1.37 ( 0.75 ~ 2.51 ) 0.75 ( 0.39 ~ 1.43 ) 
     65 and above 11 861 0.92 ( 0.63 ~ 1.34 ) 1.00 ( 0.69 ~ 1.47 ) 0.92 ( 0.63 ~ 1.34 ) 0.74 ( 0.50 ~ 1.11 ) 
Female (Age groups)           
   Total female 52 763 1.92 ( 1.45 ~ 2.54 ) 1.69 ( 1.28 ~ 2.25 ) 1.69 ( 1.27 ~ 2.24 ) 0.91 (0.66 ~ 1.26) 
     18~44 2 14 4.45 ( 2.20 ~ 8.99 ) 4.34 ( 2.15 ~ 8.78 ) 4.32 ( 2.13 ~ 8.74 ) 2.40 ( 1.04 ~ 5.55 ) 
     45~54 7 42 2.44 ( 1.23 ~ 4.84) 2.43 ( 1.22 ~ 4.82) 2.40 ( 1.21 ~ 4.78) 1.38 ( 0.63 ~ 3.04) 
     55~64 9 96 2.31 ( 1.37 ~ 3.92 ) 2.27 ( 1.34 ~ 3.85 ) 2.25 ( 1.33 ~ 3.82 ) 0.91 ( 0.48 ~ 1.70 ) 
     65 and above 34 611 1.26 ( 0.79 ~ 2.02 ) 1.06 ( 0.66 ~ 1.70 ) 1.05 ( 0.65 ~ 1.68 ) 0.62 ( 0.37 ~ 1.04 ) 
All  (Age groups)           
  
129
          Total 106 2065 1.27 ( 1.05 ~ 1.54 ) 1.29 ( 1.06 ~ 1.56 ) 1.28 ( 1.05 ~ 1.56 ) 0.77 ( 0.63 ~ 0.96 ) 
     18~44 4 66 2.34 ( 1.45 ~ 3.77 ) 2.24 ( 1.39 ~ 3.62 ) 2.24 ( 1.39 ~ 3.62 ) 1.40 ( 0.82 ~ 2.40 ) 
     45~54 14 175 1.33 ( 0.79 ~ 2.24 ) 1.31 ( 0.78 ~ 2.21 ) 1.31 ( 0.78 ~ 2.20 ) 0.68 ( 0.39 ~ 1.21 ) 
     55~64 15 352 1.75 ( 1.18 ~ 2.60 ) 1.73 ( 1.16 ~ 2.57 ) 1.69 ( 1.13 ~ 2.50 ) 0.83 ( 0.53 ~ 1.29 ) 
     65 and above 73 1472 1.06 ( 0.79 ~ 1.42 ) 1.03 ( 0.76 ~ 1.38 ) 1.03 ( 0.77 ~ 1.38 ) 0.69 ( 0.51 ~ 0.95 ) 
Model 1: Adjusted for age at study entry  
Model 2: Adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, and hospital levels before study entry 
Model 3: Adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, previous coronary heart disease hypertension, 
diabetes, and hyperlipidaemia 
  
Figures 7.3(a) and (b) summarize age and gender stratified models for schizophrenia 
and bipolar disorder. It was observed that risks of AMI in the two serious mental 
illness cohorts were raised in the groups less than 45 years of age for women with 





Figure 7.3 (a) Age-stratified hazard ratios and 95% confidence intervals of AMI 
in men with or without schizophrenia or bipolar disorder (adjusted for age at 




Figure 7.3 (b) Age-stratified hazard ratios and 95% confidence intervals of 
AMI in women with or without schizophrenia or bipolar disorder (adjusted 






Fully adjusted results from sensitivity analyses restricted to AMI ascertained in the 
latter half of the surveillance period were, in essence, identical to those obtained in 
the analyses of the full sample (as shown in Figure 7.4 (a) and (b)).  
  
Figure 7.4 (a) Sensitivity analysis restricting AMI to those ascertained in the 
latter half of the surveillance period: age-stratified hazard ratios and 95% 
confidence intervals of AMI in men with or without schizophrenia or bipolar 
disorder (adjusted for age at study entry, levels of income and urbanization, 
cardiovascular risk factors) 
 
  
Figure 7.4 (b) Sensitivity analysis restricting AMI to those ascertained in the 
latter half of the surveillance period: age-stratified hazard ratios and 95% 
confidence intervals of AMI in women with or without schizophrenia or 
bipolar disorder (adjusted for age at study entry, levels of income and 




7.3.5 Propensity scores calculated from logistic regression and results of Cox 
regression after propensity stratification 
Results applying multivariate logistic regression analyses for the calculation of 
propensity scores using covariates listed in Table 7.1 are shown in Table 7.4. The 
logistic regression models yielded a c-statistic of 0.93 for the validity of 
schizophrenia model, and 0.83 for that of bipolar disorder. These results indicated 
that the covariates from Table 7.1 provided a strong ability to describe the 




Table 7.4 Multivariate logistic regression analysis for calculating propensity scores in patients with schizophrenia (R square = 0.64, c statistic 
= 0.93), or bipolar disorder(R square = 0.28, c statistic = 0.83), vs. control group, and covariates  
  Schizophrenia ( n= 19,656)   Bipolar disorder (n=5,996) 
Variable Odds ratios b SE of b p Odds ratios b SE of b p 
Intercept   -4.22  0.04 <0.001   -5.40  0.06  <0.001 
Age group at study entry                  
     18~34 1  0      1  0      
     35~44 0.79  -0.23  0.03 <0.001 1.00  0.004 0.04  0.91 
     45~54 0.55  -0.60  0.04 <0.001 0.72  -0.33  0.05  <0.001 
     55~64 0.35  -1.05  0.05 <0.001 0.49  -0.72  0.06  <0.001 
     66 and above 0.28  -1.26  0.05 <0.001 0.47  -0.75  0.05  <0.001 
Gender                        
     Men 1.29  0.26  0.02 <0.001 0.89  0.11  0.03  0.002 
     Women 1  0      1  0      
Levels of urbanization                  
     1 (most urbanized) 1  0      1  0      
2 1.13  0.12  0.03 <0.001 0.96  -0.04  0.04  0.23  
3 1.14  0.13  0.04 <0.001 0.84  -0.18  0.05  <0.001  
4 1.29  0.26  0.04 <0.001 0.96  -0.04  0.05  0.44  
     5 (least urbanized) 1.75  0.56  0.04 <0.001 1.20  0.18  0.05  <0.001  
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Monthly income                     
     NT 0 1  0      1  0      
     NT$ 1~15840 1.53  0.43  0.03 <0.001 1.21  0.19  0.42  <0.001 
     NT$ 15841 ~ 25000 0.85  -0.17  0.03 <0.001 0.75  -0.28  0.04  <0.001 
     ≧NT$ 25001     0.34    -1.07    0.05 <0.001    0.66   -0.42     0.05 <0.001 
History of medical disorders before study entry         
   Hypertension       0.62  -0.48  0.05 <0.001 2.83 1.04  0.04  <0.001 
   Diabetes              1.69  0.52  0.06 <0.001 3.97  1.38  0.05  <0.001 
   Hyperlipidemia     0.78  -0.25  0.06 <0.001 2.64  0.97  0.05  <0.001 
   Alcohol use disorders  4.50  1.50  0.09 <0.001 59.35  4.08  0.07  <0.001 
   Angina                 1.99  0.69  0.07 0.69  4.57  1.52  0.05  <0.001 
History of visiting psychiatric department 
before study entry 
126.19 4.84 0.03 <0.001     
Hospital levels of visits before study entry               
    Medical centers 1.47  0.38  0.02 <0.001 4.01  1.39  0.04  <0.001 
    Regional hospitals 1.81  0.59  0.03 <0.001 2.89  1.06  0.03  <0.001 
    District hospitals 1.19  0.17  0.03 <0.001 1.59  0.46  0.04  <0.001 
    Primary care  1  0      1  0     
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Figure 7.5(a) and 7.5(b) illustrate the distribution of the propensity score (or the 
probability that subjects being assigned to the case group) estimated using logistic 
regression by covariates listed in Table 7.1. Patients with diagnosis of schizophrenia 
or bipolar disorder had significantly higher propensity score than those without 
psychiatric diagnosis, which indicated that patients with diagnosis of schizophrenia 
or bipolar disorder had significantly higher probability being assigned to the case 
group before propensity stratification.  
 
Moreover, after such propensity score stratification, patient characteristics of the case 
and comparison groups within each propensity score stratum tended to be similar, 
some of the differences became insignificant (p>0.05) (please see Table 7.5 (a) and 
(b) for propensity stratum in which the differences of patient characteristics became 












Figure 7.5(b) Distribution of estimated propensity scores in people with or 






Table 7.5(a) Stratum in which differences of patient characteristics became 
insignificant between people with or without schizophrenia (‘case’ vs. ‘control’) 






Test statistic, degree 
of freedom (df), P 
value 
Gender, in the strata which ‘case’ and ‘control’ had between 20th 
~ 30th percentile of propensity scores   (%)  χ
2 3.21, df 1, p=0.07 
      Men 39.4  42.9   
      Women 60.6  57.1   
Levels of urbanization, in the strata which ‘case’ and ‘control’ had 
between 30th ~ 40th percentile of propensity scores 
χ2 11.4, df 4, p=0.02 
     1 (most urbanized) 30.0  30.3   
     2 35.8  32.0   
     3 12.3  16.7   
     4 12.4  11.3   
     5 (least urbanized) 9.5  9.8   
History of diabetes, in the strata which ‘case’ and ‘control’ had > 
40th percentile of propensity scores (%) 
χ2 0.39, df 1, p=0.53 
 6.4 6.7  
History of hyperlipidemia, in the strata which ‘case’ and ‘control’ 
between 30th ~ 40th percentile of propensity scores (%) 
χ2 0.03, df 1, p=0.86 
 6.2 6.0  
History of alcohol use disorder, in the strata which ‘case’ and 
‘control’ between 30th ~ 40th percentile of propensity scores (%) 
χ2 1.46, df 1, p=0.23 
 0.0 0.2  
History of angina, in the strata which ‘case’ and ‘control’ between 
30th ~ 40th percentile of propensity scores (%) 
χ2 4.85, df 1, p=0.03 
 7.5 5.4  
History of angina, in the strata which ‘case’ and ‘control’ > 40th 
percentile of propensity scores (%) 
χ2 4.33, df 1, p=0.04 
 3.3 2.5  
Hospital levels of visits before study entry, in the strata which ‘case’ 
and ‘control’ between 30th ~ 40th percentile of propensity scores 
(%) 
χ2 4.15, df 1, 
p=0.04 
Primary care 4.0 5.7  
Acute myocardial infarction, in the strata which ‘case’ and χ2 1.48, df 1, p=0.22 
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‘control’ <20th percentile of propensity scores (%) 
 1.1 1.3  
Acute myocardial infarction, in the strata which ‘case’ and 
‘control’ between 20th ~ 30th percentile of propensity scores 
(%) 
χ2 0.09, df 1, p=0.76 
 2.0 1.9  
Acute myocardial infarction, in the strata which ‘case’ and 
‘control’ between 30th ~ 40th percentile of propensity scores 
(%) 
χ2 0.28, df 1, p=0.60 




Table 7.5(b) Stratum in which differences of patient characteristics became 
insignificant between people with or without bipolar disorder (‘case’ vs. 







degree of freedom 
(df), P value 
Age group at study entry, in the strata which ‘case’ and ‘control’ 
had between 20th ~ 30th percentile of propensity scores   (%)  χ
2 1.76, df 3, p=0.62
     18~44  50.2  48.0   
     45~54 15.9  15.6   
     55~64 15.1 16.1  
     >64 years 18.7 20.3  
Age group at study entry, in the strata which ‘case’ and ‘control’ 
had between 30th ~ 40th percentile of propensity scores   (%)  χ
2 2.62, df 3, p=0.45
     18~44  49.6  50.8   
     45~54 25.4  27.0   
     55~64 9.8 8.9  
     >64 years 15.2 13.3  
Gender, in the strata which ‘case’ and ‘control’ had between 20th ~ 
30th percentile of propensity scores   (%)  χ
2 0.71, df 1, p=0.40
      Men 44.8  46.6   
      Women 55.2  53.4   
Gender, in the strata which ‘case’ and ‘control’ had between 30th ~ 
40th percentile of propensity scores   (%)  χ
2 0.80, df 1, p=0.06
      Men 40.6  40.1   
      Women 59.42  59.9   
Levels of income, in the strata which ‘case’ and ‘control’ had 
between 20th ~ 30th percentile of propensity scores 
χ2 0.18, df 3, p=0.98
     NT 0 26.3  25.7   
     NT$ 1~15840 28.7  28.7   
     NT$ 15841 ~ 25000 30.4  31.2   
     ≧NT$ 25001 14.6  14.4   
Levels of income, in the strata which ‘case’ and ‘control’ had 
between 30th ~ 40th percentile of propensity scores 
χ2 0.93, df 3, p=0.82
     NT 0 27.5  28.6   
     NT$ 1~15840 13.3  12.6   
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     NT$ 15841 ~ 25000 37.1  37.8   
     ≧NT$ 25001 22.2  21.0   
Levels of urbanization, in the strata which ‘case’ and ‘control’ had 
between 20th ~ 30th percentile of propensity scores 
χ2 2.39, df 4, p=0.66
     1 (most urbanized) 31.9  33.6   
     2 28.8  29.3   
     3 15.0  15.4   
     4 12.1  10.8   
     5 (least urbanized) 12.2  10.8   
Levels of urbanization, in the strata which ‘case’ and ‘control’ had 
between 30th ~ 40th percentile of propensity scores 
χ2 2.57, df 4, p=0.63
     1 (most urbanized) 37.7  37.4   
     2 26.1  27.7   
     3 17.3  18.1   
     4 10.8  8.9   
     5 (least urbanized) 8.1  8.0   
Levels of urbanization, in the strata which ‘case’ and ‘control’ had > 
40th percentile of propensity scores 
χ2 5.82, df 4, p=0.21
     1 (most urbanized) 36.2  34.2   
     2 29.9  30.5   
     3 11.9  12.3   
     4 11.9  12.0   
     5 (least urbanized) 10.2  10.9   
History of hypertension, in the strata which ‘case’ and ‘control’ had 
< 20th percentile of propensity scores (%) 
χ2 0.08, df 1, p=0.78
 2.5 2.7  
History of hypertension, in the strata which ‘case’ and ‘control’ had 
between 30th ~ 40th percentile of propensity scores (%) 
χ2 3.62, df 1, p=0.06
 11.1 8.6  
History of diabetes, in the strata which ‘case’ and ‘control’ had 
between 20th ~ 30th percentile of propensity scores (%) 
χ2 0.22, df 1, p=0.64
 3.1 2.8  
History of diabetes, in the strata which ‘case’ and ‘control’ had 
between 30th ~ 40th percentile of propensity scores (%) 
χ2 3.18, df 1, p=0.08
 4.3 2.8  
History of hyperlipidemia, in the strata which ‘case’ and ‘control’ 
had < 20th percentile of propensity scores (%) 
χ2 2.91, df 1, p=0.09
 0.8 0.3  
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History of hyperlipidemia, in the strata which ‘case’ and ‘control’ 
had between 20th ~ 30th percentile of propensity scores (%) 
χ2 3.20, df 1, p=0.07
 4.9 3.3  
History of angina, in the strata which ‘case’ and ‘control’ between 
20th ~ 30th percentile of propensity scores (%) 
χ2 3.91, df 1, p=0.05
 1.9 0.8  
Hospital levels of visits before study entry, in the strata which ‘case’ 
and ‘control’ had between 30th ~ 40th percentile of propensity scores 
(%) 
χ2 1.00, df 1, 
p=0.32 
District hospital 70.6 72.5  
Hospital levels of visits before study entry, in the strata which ‘case’ 
and ‘control’ had between 20th ~ 30th percentile of propensity scores 
(%) 
χ2 0.54, df 1, 
p=0.46 
Primary care 97.9 98.4  
Hospital levels of visits before study entry, in the strata which ‘case’ 
and ‘control’ had between 30th ~ 40th percentile of propensity 
scores (%) 
χ2 0.994, df 1, 
p=0.33 
Primary care 98.3 98.8  
Hospital levels of visits before study entry, in the strata which ‘case’ 
and ‘control’ > 40th percentile of propensity scores (%) 
χ2 0.0002, df 
1, p=0.99 
Primary care 98.7 98.7  
Acute myocardial infarction, in the strata which ‘case’ and ‘control’ 
had between 20th ~ 30th percentile of propensity scores (%) 
χ2 0.0001, df 1, 
p=0.99 
 1.5 1.5  
Acute myocardial infarction, in the strata which ‘case’ and ‘control’ 
between 30th ~ 40th percentile of propensity scores (%) 
χ2 2.75, df 1, p=0.10
 1.3 2.2  
Acute myocardial infarction, in the strata which ‘case’ and ‘control’ 
between 30th ~ 40th percentile of propensity scores (%) 
χ21.37, df 1, p=0.24
 2.2 1.9  
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Results from adjusted Cox regression models after propensity stratification are 
summarized in Table 7.6. Similar to the main analysis, addition of history of 
coronary artery diseases, hypertension, diabetes and hyperlipidaemia to the models 
substantially attenuated the hazard ratios for both serious mental illnesses. Figures 
7.6 (a) and (b) summarize the fully adjusted age and gender stratified models for 
schizophrenia and bipolar disorder after propensity stratification. It was observed that 
risks of AMI in the two case cohorts were raised in two younger age groups for 
women, but were more equivocal for men. Gender x disorder, age group x disorder, 
and three-way (age group x gender x disorder) interaction terms were tested in fully 
adjusted models and were not found to be significant (p-values >0.10) in people with 
or without schizophrenia. However, age-modification was found in the fully adjusted 
model in people with bipolar disorder with the older age x disorder interaction term 
of 0.76 (95% CI 0.63~0.91, p=0.003). In addition, although no gender interaction 
was found (interaction term 0.68, 95% CI 0.46~1.02, p=0.06), three-way (age group 
x gender x disorder) interaction was found to be significant in people with bipolar 
disorder in the fully adjusted model (interaction term 0.93, 95% CI 0.88~0.99, 
p=0.02).  
 
Considering independent influences on the AMI outcome, the strongest associations 
in final models were for cardiovascular risk factors in schizophrenia (i.e. coronary 
artery diseases: HR 2.29 (95% CI 1.92~2.73), p<0.001; hypertension: HR 1.63 (95% 
CI 1.43~1.85), p<0.001). Similarly, associations for cardiovascular risk factors in 
bipolar disorder were: coronary artery diseases: HR 1.95 (95% CI 1.58~2.40), 
p<0.001 and hypertension: HR 1.46 (95% CI 1.25~1.69), p<0.001). 
 
On testing interactions with age, there were significant negative terms for women 
with schizophrenia (HR: 0.96 (95% CI 0.94~0.99, p=0.001) and bipolar disorder (HR: 
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0.97 (95% CI 0.95~1.00, p=0.02), indicating a stronger excess risk in younger 
women with this disorder. 
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Table 7.6 (a) Additional analysis: Hazard ratios (HR) of AMI in people with and without schizophrenia after propensity stratification  
 Unadjusted HR Model 1 Model 2 Model 3 
Male (Age groups )         
  Total male 1.00 ( 0.76 ~ 1.32 ) 0.94 ( 0.71 ~ 1.24 ) 0.91 ( 0.69 ~ 1.20 ) 0.88 ( 0.66 ~ 1.18 ) 
     18~44 1.10 ( 0.57 ~ 2.12 ) 0.91 ( 0.47 ~ 1.76 ) 0.88 ( 0.45 ~ 1.71 ) 0.88 ( 0.45 ~ 1.72 ) 
     45~54 0.88 ( 0.45 ~ 1.71 ) 0.81 ( 0.41 ~ 1.58 ) 0.78 ( 0.40 ~ 1.54 ) 0.76 ( 0.38 ~ 1.53 ) 
     55~64 1.03 ( 0.49 ~ 2.19 ) 1.01 ( 0.48 ~ 2.15 ) 0.97 ( 0.46 ~ 2.05 ) 0.96 ( 0.43 ~ 2.12 ) 
     65 and above 0.95 ( 0.63 ~ 1.41 ) 1.02 ( 0.69 ~ 1.52 ) 1.00 ( 0.67 ~ 1.49 ) 0.96 ( 0.64 ~ 1.45 ) 
Female (Age groups)         
   Total female 1.34 ( 0.95 ~ 1.88 ) 1.11 ( 0.79 ~ 1.54 ) 1.11 ( 0.80 ~ 1.55 ) 1.07 ( 0.75 ~ 1.52 ) 
     18~44 2.88 ( 1.20 ~ 6.89 ) 2.49 ( 1.03 ~ 5.99 ) 2.48 ( 1.04 ~ 6.89 ) 2.72 ( 1.14 ~ 6.50 ) 
     45~54 1.67 ( 0.79 ~ 3.51) 1.57 ( 0.75 ~ 3.32) 1.59 ( 0.75 ~ 3.38) 1.53 ( 0.66 ~ 3.54) 
     55~64 1.08 ( 0.54 ~ 2.15 ) 1.03 ( 0.52 ~ 2.06 ) 1.06 ( 0.54 ~ 2.10 ) 1.13 ( 0.55 ~ 2.32 ) 
     65 and above 0.95 ( 0.55 ~ 1.64 ) 0.86 ( 0.51 ~ 1.47 ) 0.85 ( 0.50 ~ 1.45 ) 0.78 ( 0.45 ~ 1.36 ) 
All  (Age groups)         
          Total 1.12 ( 0.90 ~ 1.38 ) 0.99 ( 0.80 ~ 1.22 ) 0.98 ( 0.79 ~ 1.21 ) 0.94 ( 0.75 ~ 1.17 ) 
     18~44 1.43 ( 0.85 ~ 2.38 ) 1.19 ( 0.70 ~ 2.02 ) 1.16 ( 0.68 ~ 1.97 ) 1.16 ( 0.68 ~ 2.00 ) 
     45~54 1.09 ( 0.67 ~ 1.78 ) 1.06 ( 0.65 ~ 1.74 ) 1.03 ( 0.63 ~ 1.70 ) 0.99 ( 0.58 ~ 1.67 ) 
     55~64 1.05 ( 0.64 ~ 1.73 ) 1.03 ( 0.62 ~ 1.70 ) 0.98 ( 0.59 ~ 1.62 ) 1.00 ( 0.59 ~ 1.70 ) 
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     65 and above 0.95 ( 0.69 ~ 1.31 ) 0.95 ( 0.69 ~ 1.31 ) 0.99 ( 0.65 ~ 1.51 ) 0.89 ( 0.64 ~ 1.23 ) 
Model 1: stratified by propensity score levels and adjusted for age at study entry  
Model 2: stratified by propensity score levels and adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, 
and hospital levels before study entry 
Model 3: stratified by propensity score levels and adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, 
previous coronary heart disease hypertension, diabetes, and hyperlipidaemia 
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Table 7.6 (b) Additional analysis: Hazard ratios (HR) of AMI in people with and without bipolar disorder after propensity stratification  
 Unadjusted HR Model 1 Model 2 Model 3 
Male (Age groups )         
  Total male 0.80 ( 0.60 ~ 1.06 ) 0.83 ( 0.62 ~ 1.09 ) 0.81 ( 0.62 ~ 1.08 ) 0.69 ( 0.52 ~ 0.92 ) 
     18~44 1.13 ( 0.56 ~ 2.30 ) 1.11 ( 0.55 ~ 2.25 ) 1.16 ( 0.57 ~ 2.36 ) 1.01 ( 0.49 ~ 2.09 ) 
     45~54 0.67 ( 0.29 ~ 1.53 ) 0.63 ( 0.27 ~ 1.45 ) 0.64 ( 0.28 ~ 1.46 ) 0.51 ( 0.22 ~ 1.21 ) 
     55~64 0.97 ( 0.52 ~ 1.81 ) 0.95 ( 0.51 ~ 1.76 ) 0.91 ( 0.50 ~ 1.70 ) 0.74 ( 0.39 ~ 1.43 ) 
     65 and above 0.76 ( 0.52 ~ 1.12 ) 0.82 ( 0.56 ~ 1.21 ) 0.81 ( 0.55 ~ 1.19 ) 0.73 ( 0.49 ~ 1.09 ) 
Female (Age groups)         
   Total female 1.36 ( 1.02 ~ 1.82 ) 1.23 ( 0.92 ~ 1.64 ) 1.23 ( 0.92 ~ 1.64 ) 0.92 ( 0.67 ~ 1.26 ) 
     18~44 3.52 ( 1.67 ~ 7.40 ) 3.44 ( 1.63 ~ 7.22 ) 3.35 ( 1.60 ~ 7.04 ) 2.21 ( 0.95 ~ 5.13 ) 
     45~54 1.91 ( 0.94 ~ 3.88) 1.87 ( 0.92 ~ 3.80) 1.91 ( 0.93 ~ 3.91) 1.43 ( 0.65 ~ 3.19 ) 
     55~64 1.53 ( 0.86 ~ 2.64 ) 1.48 ( 0.86 ~ 2.55 ) 1.46 ( 0.85 ~ 2.51 ) 0.93 ( 0.50 ~ 1.72 ) 
     65 and above 0.87 ( 0.54 ~ 1.40 ) 0.79 ( 0.49 ~ 1.27 ) 0.79 ( 0.49 ~ 1.28 ) 0.65 ( 0.39 ~ 1.09 ) 
All  (Age groups)         
          Total 1.03 ( 0.84 ~ 1.25 ) 1.00 ( 0.82 ~ 1.22 ) 0.98 ( 0.80 ~ 1.20 ) 0.77 ( 0.62 ~ 0.95 ) 
     18~44 1.99 ( 1.20 ~ 3.30) 1.92 ( 1.16 ~ 3.17) 1.93 ( 1.17 ~ 3.20) 1.38 ( 0.80 ~ 2.39) 
     45~54 1.12 ( 0.65 ~ 1.90 ) 1.07 ( 0.63 ~ 1.83 ) 1.10 ( 0.65 ~ 1.88 ) 0.69 ( 0.39 ~ 1.24 ) 
     55~64 1.24 ( 0.83 ~ 1.87 ) 1.21 ( 0.80 ~ 1.81 ) 1.20 ( 0.80 ~ 1.80 ) 0.83 ( 0.53 ~ 1.30 ) 
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     65 and above 0.81 ( 0.60 ~ 1.10 ) 0.81 ( 0.60 ~ 1.10 ) 0.81 ( 0.60 ~ 1.09 ) 0.69 ( 0.51 ~ 0.95 ) 
Model 1: stratified by propensity score levels and adjusted for age at study entry  
Model 2: stratified by propensity score levels and adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, and 
hospital levels before study entry 
Model 3: stratified by propensity score levels and adjusted for gender (where not stratified), age at study entry, levels of income, levels of urbanization, previous 
coronary heart disease hypertension, diabetes, and hyperlipidaemia
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Figure 7.6 (a) Additional analysis: Age-stratified hazard ratios and 95% 
confidence intervals of AMI in men with or without schizophrenia or bipolar 
disorder (stratified by propensity score levels and adjusted for age at study 
entry, levels of income, levels of urbanization, previous coronary heart disease 




Figure 7.6 (b) Additional analysis: Age-stratified hazard ratios and 95% 
confidence intervals of AMI in women with or without schizophrenia or bipolar 
disorder (stratified by propensity score levels and adjusted for age at study 
entry, levels of income, levels of urbanization, previous coronary heart disease 








In this large analysis of national health care records, schizophrenia was not 
associated with increased risk of AMI in the total sample or in most sub-groups. 
Bipolar disorder was associated with increased risk of AMI following adjustment for 
sociodemographic factors but with lower risk of AMI when further adjusted for 
cardiovascular risk factors. One sub-group of young women (below 45 years) with 
schizophrenia and bipolar disorder were found to have a significantly increased risk 
of AMI over a 12-year surveillance period than counterparts without SMI. Results 
did not change substantially after propensity stratification, although bipolar disorder 
was primarily associated with either no change or decreased AMI risk following this 
method of adjustment.     
 
7.4.2 No significant association between schizophrenia and risk of AMI  
This investigation of the risk of AMI in people with SMI was carried out on the 
largest database of psychiatric inpatients to date, comparing these with a nationally 
representative sample of comparison cohort. Although there was some evidence of 
isolated excess risk in younger women, contrary to the study hypothesis no increased 
risk of AMI was found in people with schizophrenia for the sample overall. This null 
finding is consistent with some studies (Curkendall et al., 2004; Laursen et al., 2011; 
Lin et al., 2008; Truyers et al., 2011) but is not in line with other positive 
associations summarised in Chapter 2. One possible explanation is that the sample 
with SMI in this cohort were more severely affected by their psychotic disorder, so 
that those who survived into mid- and late-life were healthier in other ways. Also, 
other non-AMI causes of death might be responsible for the recognised excess 
mortality in people with SMI in Taiwan (Chen WJ et al., 1996; Chen YH et al., 2010) 
resulting in further selection bias through survival (Truyers et al., 2011). In addition, 
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it is important to bear in mind that there might be over-adjustment resulting in an 
obscured association in fully adjusted models (Model 3), since cardiovascular risk 
factors (hyperlipidaemia, hypertension, diabetes) may lie on the causal pathway 
between mental disorder and AMI risk. 
 
A further reason might be that the Taiwanese population is relatively protected with 
respect to cardiovascular outcomes compared to populations in Western countries. 
Although the incidence rate of AMI in Taiwan rose from 51 to 108 per 100,000 
population per year in men and 27 to 50 per 100,000 population per year in women 
from year 1996 to 2007 (Department of Health in Taiwan, 2008; Peng, 2009), these 
figures remain lower than those from the UK, where the incidence rate declined from 
230 to 154 per 100,000 population per year in men and 95 to 66 per 100,000 
population per year in women from year 2002 to 2007 (Birkhead J, 1999; Smolina K, 
2012). Better cardiovascular risk profiles have also been reported in the Taiwanese 
population (prevalence of hypertension ranging from 13~21%; dyslipidemia: 6~20%; 
hyperglycemia: 7~8%; and overweight: 24~38%)(Bureau of Health Promotion, 
Department of Health in Taiwan, 2008) than that in European countries (prevalence 
of hypertension ranging from 35~48%; dyslipidemia: 27~70%; hyperglycemia: 
5~12%; and overweight: 24~63%)(Nichols M, 2012). Hence, it is possible that the 
disparities of cardiovascular risk profiles and incidence of AMI between people with 
or without SMI are not as large as those in Western settings.  
 
Another explanation to bear in mind is the possibility of under-detection of AMI in 
people with SMI (Laursen et al., 2011), particularly when the diagnosis of AMI could 
only be ascertained from these administrative data recorded by treating physicians 
for claim purposes. That is, in order for the diagnosis of AMI to be given, patients 
must have had medical contacts and sought medical help. Patients with mental 
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disorders have been reported to be a group that experiences barriers to seeking 
medical help compared with the general population (Felker et al., 1996). Previous 
research has reported possible insufficient physical or laboratory examinations 
required for the ascertainment of AMI, and under-referral for relevant treatment 
(Laursen et al., 2011). Underlying causes for difficulty accessing medical care in 
people with SMI cited by previous research have included lack of communication 
skills (Worley et al., 1990), refusal of recommended consultations (Kampmeier, 
1977; McConnell et al., 1992), and physicians’ negative reactions (Groves, 1978), 
none of which could be investigated in this particular dataset.  
 
In addition, it should also be borne in mind that patients with negative symptoms, 
and those who had never presented to hospital for psychiatric treatment might be 
missed in the analysis. This may be relevant if these missing people lived a more 
unhealthy lifestyle associated with higher cardiovascular risk, such as through 
smoking, obesity and physical inactivity, secondary to negative symptoms of social 
withdrawal and self-neglect. Given the elevated standardized mortality ratios 
(ranging from 3.7~7.6) in deaths due to cardiovascular diseases for SMI in Taiwan 
(Chen WJ et al., 1996), comparable to those in Western countries (SMR: 2.1~6.0) 
(Kamara et al., 1998; Osby et al., 2001; Osby et al., 2000; Rasanen et al., 2003; 
Valenti et al., 1997), the possibility of under-recognition should be considered (Chen 
WJ et al., 1996) and further research is required.   
 
7.4.3 Elevated risk of AMI in women with SMI, younger than 45 years of age 
Despite the overall null association between the risk of AMI in people with SMI, this 
investigation revealed that the risk of AMI was significantly modified by age in 
people with schizophrenia and bipolar disorder. The age modification was still 
prominent after propensity stratification in people with bipolar disorder. More 
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specifically, in contrast to the recognised higher risk of coronary artery disease in 
men compared with women in premenopausal age ranges observed in most 
community populations, the cardioprotective effect in younger women was 
apparently attenuated in people with SMI. This is the first study to report age and 
gender modification of the risk of AMI in people with bipolar disorder; and is in 
agreement with another study of people with schizophrenia reporting elevated risk of 
cardiovascular disease in women under age 59 (Bresee et al., 2010). A large 
component of the reduced risk of coronary artery disease in premenopausal women is 
thought to be derived from a relatively favourable lipid profile with higher levels of 
high-density lipoprotein cholesterol (Bergemann et al., 2005). However, studies have 
suggested that people with schizophrenia may live with an unhealthy lifestyle from 
an early age (Allison et al., 1999), with predisposition to higher levels of 
intra-abdominal or visceral fat (Thakore et al., 2002) or higher susceptibility to poor 
glycaemic control (Bellivier, 2005) before any initiation of psychotropic medication. 
Besides, schizophrenia is a chronic disorder with up to 50% of those affected 
receiving long-term treatment with atypical antipsychotics (Newcomer, 2005), and a 
larger volume of research has suggested that the well-recognized side effects of 
weight gain or metabolic syndrome associated with these drugs should be of concern 
(Bobes et al., 2010; Newcomer, 2005). In people with SMI receiving long-term 
antipsychotic treatment, elevation in body weight or visceral adiposity might increase 
the risk of cardiovascular diseases through changes in insulin resistance (Newcomer 
et al., 2002), levels of triglycerides and cholesterol profiles (Meyer & Koro, 2004) or 
blood pressure (Newcomer, 2005). It is therefore important to establish mechanisms 
underlying the apparent negation of this protective effect (Bresee et al., 2010), 
perhaps through metabolic syndrome, cigarette smoking, lack of exercise, or 
decreased levels of estradiol as indicated in previous research (Bresee et al., 2010; 




7.4.4 Risk of AMI in patients with bipolar disorder 
Relatively little research has investigated the risk of AMI in people with bipolar 
disorder. Previous studies have examined such associations either cross-sectionally 
(Kilbourne et al., 2004), or longitudinally but with smaller numbers of bipolar 
patients (Callaghan et al., 2009; Lin et al., 2008), and none to date have compared 
AMI risk and its correlates between bipolar disorder and schizophrenia. In this study, 
a risk effect was observed in the total sample of people with bipolar disorder that was 
independent of socio-demographic factors in the conventional Cox model. However, 
the excess risk was attenuated in the propensity stratification model, and reversed in 
both models once cardiovascular risk factors were included as covariates. These 
findings were different from those in schizophrenia where the associations were 
mostly null. The findings would be consistent with a risk effect of bipolar disorder on 
AMI which was largely mediated by worse cardiovascular risk profile; however this 
conclusion can only be tentative, because temporal relationships between bipolar 
disorder and cardiovascular risk factors could not be determined within the short 
follow-up period (although, given the typical ages of onset, bipolar disorder is more 
likely to precede cardiovascular risk factors). Considering the reversal in the 
direction of association in the fully adjusted model, it was possible that the diagnosis 
of bipolar disorder conferred some protection after taking all other factors into 
account, possibly because of higher levels of medical contact and recognition of risk 
factors. Alternatively, the findings might reflect the survival bias discussed 
previously. Of note, regarding potential differences in causal pathways between the 
two disorders, it has been suggested that behavioral or adverse physiological changes 
(such as increased platelet aggregation and decreased heart rate variability) during 
depressive or manic episodes (Katon, 2003; Kilbourne et al., 2007) might mediate at 
least some of the association with increased risk of cardiovascular diseases in young 
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women with bipolar disorder. Finally, although the association between AMI and 
bipolar disorder was attenuated when AMI early in the observation period was 
excluded, this was unlikely to be accounted for by effects of previous AMI episodes 
because these are likely to be rare, and may simply reflect loss of statistical power.  
 
7.4.5 Strengths and limitations 
Strengths of this study include the very large prospective dataset drawn from a 
national sample with sufficient statistical power to estimate the associations of 
interest with a high level of precision. Also relevant is the fact that this dataset comes 
from a near-universal healthcare provision system, and so can be reasonably claimed 
to be nationally representative. A key limitation is that findings were drawn from 
administrative rather than research datasets – in particular, the diagnoses were 
clinician-initiated and do not necessarily generalize to research diagnostic criteria, 
and there might be potential under reporting of true cases of AMI and mental 
disorders. For this reason diagnostic groups were deliberately chosen which were 
relatively broad and unambiguous. There were also compensating advantages in the 
higher generalisability of clinical (rather than research) diagnoses to naturalistic 
clinical environments. However, misclassification of case and comparison groups 
should be considered as probable to some extent. In terms of exposure, it is important 
to bear in mind that the case cohorts predominantly represented relatively severely 
affected subgroups of people with schizophrenia or bipolar disorder since the 
majority had been hospitalized and there were insufficient numbers of individuals 
drawn from the LHID2000 dataset alone (i.e. those without hospitalization) to 
analyze separately. This issue is particularly pertinent for bipolar disorder where a 





Considering the outcome, it is important to bear in mind that this refers to incident 
hospitalizations with AMI as a primary clinical diagnosis. Evidence from 
electrocardiography and cardiac enzymes would be required for this according to 
standard clinical practice in Taiwan; however, the outcome does not capture sudden 
cardiac deaths outside hospital or instances of AMI which did not result in 
hospitalization (however, it would include instances of AMI resulting in early 
inpatient mortality if sufficient prior investigations had been carried out to ascertain 
AMI as the cause of this). A further limitation is that there was no information on 
lifetime history of mental disorders and cases could only be ascertained on the basis 
of medical contact during the follow-up window. Measurement errors in both 
exposure and outcome ascertainments will have obscured rather than exaggerated the 
associations of interest and therefore should be considered as potential explanations 
for associations which were expected but not found.  
 
Considering confounding, although it was possible to adjust for demographic status 
and certain medical disorders, information was not available on other determinants of 
vascular risk status such as smoking and exercise habits, blood pressure levels, 
obesity or body size. These are therefore left as potential causal pathways between 
exposure and outcome on which it is not possible to comment. However, similar to 
Western studies where greater prevalence of cigarette smoking, obesity, and physical 
inactivity were found in people with SMI (Brown, 2000; Robson, 2007; Vancampfort, 
2012), epidemiological studies in Taiwan have also reported a higher prevalence of 
current cigarette smoking in 70.9% of male and 11.5% of female inpatients with 
schizophrenia (Liao et al., 2002), compared to 46.8% of men and 4.3% of women in 
the general population in Taiwan (Wen et al., 2001), and a 2.51~2.74 fold higher 
prevalence of obesity in outpatients with schizophrenia receiving antipsychotic 
compared to Taiwanese reference population (Hsiao, 2004). Thus, the effect of 
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smoking, obesity, and physical inactivity on the increased risk of developing AMI in 
SMI requires consideration, particularly given findings such as the fall in the 
prevalence of cigarette smoking in the Scottish general population accounting for a 
36% decrease in cardiovascular mortality between 1975 and 1994 (Capewell et al., 
1999). In contrast, the prevalence of smoking and cardiovascular mortality was not 
found to have fallen in people with schizophrenia in the UK (Brown, 2010; The 
Information Centre, 2006), emphasizing that reducing cigarette smoking in people 
with SMI might still be the most important prevention strategy for cardiovascular 




DIAGNOSTIC PROCEDURES, REVASCULARIZATION, AND INPATIENT 
MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS 




To investigate, within a system that has tried to eliminate economic barriers to 
healthcare, the equality of intervention receipts, outcome of inpatient mortality or 
recurrence following the first acute myocardial infarction (AMI) among patients with 
serious mental illness (SMI). Hypotheses were that invasive coronary interventions, 
including catheterization and revascularization, would be lower in cases compared to 
controls, and that the adverse outcomes of inpatient mortality, AMI recurrence, and 
subsequent hospitalization due to other cardiovascular diseases would be higher in 




The case samples were patients with schizophrenia or bipolar disorder from the case 
cohorts (described in Chapter 6.2 ~ 6.3) who had an AMI episode between 1996 and 
2007. The first such AMI episode was defined as the ‘index episode’. 
 
8.2.2 Controls 
The control samples were people from the comparison cohort (described in Chapter 
6.2 ~ 6.3) who had an AMI episode between 1996 and 2007. The first such AMI 
episode was defined as the ‘index episode’. 
 
8.2.3 Main outcome variables 
The main outcome variables on intervention after AMI are described in Chapter 
6.6~6.7, and displayed in Table 6.4. If the discharge date of first AMI hospitalization 
matched the admission date of the next hospitalization, records of intervention 
receipts in these hospitalizations were merged and managed as care for the same 
AMI episode. We also investigated 30-day inpatient mortality as an outcome and 
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separately investigated rates of revascularization among those who have received 
catheterization.  
 
Additional analyses included examining whether the following diagnoses 
co-occurred on the hospital discharge note after the index AMI episode as proxy 
measures of AMI severity (shown in Table 8.1): congestive heart failure, cardiogenic 
shock, conduction disorders, including second- or third-degree atrioventricular block, 





Table 8.1 ICD-9-CM codes for complications during the index AMI episode 
ICD-9-CM codes 
Diagnosis for previous or co-occurring 
cardiovascular diseases  
428.XX Congestive heart failure   
785.XX Cardiogenic shock   
426.XX Atrioventricular block   
427.XX Cardiac dysrhythmias   
518.XX Chronic respiratory failure   
 
 
Finally, the following adverse outcomes were compared: 30-day inpatient mortality, 
proportions of re-admission with a second AMI episode, and subsequent 
hospitalization due to heart failure or cardiogenic shock within and after one year of 
the index AMI. 
 
The following covariates (described in Chapter 6.5) were considered: demographic 
characteristics, cardiovascular risk factors (previous diagnoses of hypertension, 
diabetes, hyperlipidaemia, and alcohol use disorders prior to AMI). In addition the 
following factors were considered that might affect the receipt of diagnostic 
procedures or revascularization: previous history of cardiac diseases (coronary artery 
disease, heart failure, cardiogenic shock, respiratory failure, acute pulmonary edema, 
or any conduction disorder), and hospital properties (hospital level, geographical 
location, urbanization level, and teaching status, all obtained and classified using 
methods from previous research (Lin et al., 2006)). Figure 8.1 summarises the 
analysis plan. 
 
8.2.4 Statistical analysis 
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SAS version 9 for Windows (SAS Institute, Cary, NC) was used for data 
management and analysis. All covariates, including demographic characteristics and 
cardiovascular risk factors were initially compared between the cohorts using χ2 and 
Student t tests. Next, intervention receipt and inpatient mortality after AMI were 
calculated and compared between cohorts. Logistic regression analyses were carried 
out to examine the independent effects of having schizophrenia or bipolar disorder on 
the outcomes of intervention receipts, inpatient mortality, co-occurring diagnoses of 
complications, re-admissions of AMI, or subsequent hospitalization due to heart 
failure or cardiogenic shock within and after one year of the index AMI. Odds ratios 
were calculated with 95% confidence intervals. The analysis was divided into four 
stages. In the first stage, procedures of any catheterization or revascularization were 
modeled as dependent variables with respect to their associations with psychiatric 
diagnosis, adjusting for demographic and clinical covariates. Second, among people 
who were offered catheterization, similarly adjusted logistic regression analyses were 
carried out to examine the subsequent revascularization as an outcome. Third, odds 
of 30-day mortality were compared between people with or without severe mental 
disorders and adjusted not only for the above covariates but also for receipt of any 
catheterization or revascularization as potential mediators. Fourth, odds of 
re-admissions due to second AMI, or hospitalizations due to heart failure or 
cardiogenic shock within and after one year among those who discharged alive from 
their index AMI episode were analyzed.  
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Figure 8.1 Concept of analysis for evaluating the intervention receipts, inpatient 
mortality, and inpatient complication following an AMI in people with or 











• Status of having serious mental illness 
or not 
• Demographic characteristics 
- Gender 
- Age 
- Levels of monthly household 
income 
- Levels of urbanization 
• Hospital properties (the hospital where 
patient was first diagnosed with AMI) 
- Teaching status 
- Levels of hospital 
- Levels of urbanization of hospitals 




- Alcohol use disorder 
• Previous history of cardiac diseases 
prior to AMI 
- Coronary heart diseases 
- Heart failure 
- Cardiogenic shock 
- Respiratory failure 
- Acute pulmonary edema 
- Any conduction disorders 
• Hospital properties of which the 
diagnosis of AMI was given 
- Hospital level 
- Urbanization level  
Outcome variables 
 
•Status of receiving particular intervention 
or not 
- Diagnostic catheterization 
- PTCA 
- CABG 
• Inpatient mortality 
• Status of having the following 
complications during the hospitalization 
of the index AMI episode 
- Heart failure 
- Cardiogenic shock 
- Respiratory failure 
- Acute pulmonary edema 
- Any conduction disorders 
• Status of having any re-admissions of a 
second AMI episode 
• Status of having any subsequent 
hospitalization due to heart failure or 




8.3.1 Sample characteristics 
After applying inclusion/exclusion criteria, a total of 3,361 adult patients with 
incident AMI between 1996 and 2007 were identified, of whom 591 (17.6%) and 243 
(7.2%) had a diagnosis of schizophrenia and bipolar disorder respectively, with 2,527 
controls. Of cases with schizophrenia and bipolar disorder, 24 (4.1%) and 45 (18.5%) 
respectively were present on the LHID2000 dataset alone, implying that they had not 
received mental health impatient care before 2000. Table 8.2 summarises the 
characteristics of the cohorts. The mean (SD) age at recorded AMI was 57.1 (15.4) 
years for people with schizophrenia, 64.2 (15.4) years in people with bipolar disorder, 
and 66.8 (13.8) years in the comparison cohort. Significant differences were found 
between cohorts in the mean ages of first AMI episode between three groups 
(ANOVA F 110.5, df 2, p<0.001) and in almost all categorical variables apart from 
history of previous cardiac diseases) between people with and without serious mental 
illness (all p-values <0.05). Patients with schizophrenia had a lower income level and 
were more likely to be diagnosed with diabetes, hyperlipidaemia, and alcohol use 
disorders prior to index AMI compared with the controls. Regarding intervention 
receipt, 24.1% (n=811) of all sample members received catheterization during their 
index AMI episode. Among these, 73.3% (n=595) received PTCA and 8.4% (n=68) 
received CABG. Less than 2% (n=9) received both procedures. Both mental disorder 
groups were less likely to receive diagnostic procedures (i.e. catheterization) and 
revascularization (i.e. PTCA and CABG) of AMI, or to be diagnosed in medical 
centers or teaching hospitals (all p<0.001 from chi-square test, df 1). 
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Table 8.2 Between-cohort comparison of demographic and health / healthcare characteristics  
No serious mental 
illness  
Schizophrenia Bipolar disorder P value    
(n= 2,527) ( n= 591) ( n= 243 )   
Mean (SD) age at index AMI episode 66.8 (13.8) 57.1 (15.4) 64.2 (15.4) <0.001 
Age group (%)         
     18~35 5.7  15.2  6.2  <0.001 
     36~45 13.7  22.5  12.4   
     46~55 17.6  21.2  14.4   
     56~65 26.4  16.9  18.5   
     66~75 26.7  15.6  27.2   
     76 and above 10.1  8.6  21.4   
Gender (%)       0.02 
     Men 64.9  60.1  58.4   
     Women 35.1  39.9  41.6   
Levels of urbanization (%)       0.02 
     1 (least urbanized) (reference group) 13.6  14.2  4.5   
     2 15.6  17.1  21.8   
     3 15.0  13.0  15.6   
     4 29.6  32.0  29.2   
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     5 (most urbanized) 26.2  23.7  28.8   
Average monthly income NT$ (SD) 11138.0 (14781.1) 6442.5 (11472.8) 7074.7 (13195.8) <0.001 
Monthly income (%)       <0.001 
     NT$ 0       (reference group) 32.0  25.9  34.2   
     NT$ 1~15840 23.8  50.0  41.2   
     NT$ 15841 ~ 25000 35.7  20.1  18.1   
     ≧NT$ 25001  8.5  4.2  6.6   
Hypertension (%) 10.3  52.6  50.6  <0.001 
Diabetes (%) 22.4  38.4  31.7  <0.001 
Hyperlipidemia (%) 19.9  27.6 27.6  <0.001 
Alcohol use disorders (%) 0.7  16.8  9.5  <0.001 
History of previous cardiac diseases (%) 21.3  21.2  25.1  0.37 
Hospital level at AMI diagnosis (%)       <0.001  
    Medical centers   30.7  20.5  31.7   
    Regional hospitals  32.0  29.1  22.6   
    District hospitals 25.5  43.7  35.8   
    Others (reference group) 11.8  6.8  9.9   
Teaching hospital at AMI diagnosis (%) 62.6  49.6  54.3  <0.001 
Urbanization of hospital at AMI diagnosis (%)       <0.001 
     1 ( least urbanized ) (reference group) 4.4  8.1  2.1   
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2 13.4  17.3  11.1   
3 11.5  12.9  11.1   
4 37.9  33.8  42.4   
     5 ( most urbanized ) 32.9  27.9  33.3   
Cardiac complications after AMI (%) 19.3 18.3 18.1 0.80 
Receipt of catheterization (%) 27.9  12.2  14.0  <0.001  
Receipt of any PTCA or CABG (%) 23.9  9.0  12.8  <0.001  





8.3.2 Catheterization and revascularization following AMI in people with 
serious mental illness 
Adjusted associations between case status and receipt of catheterizations and 
revascularization are summarized in Table 8.3(a) and 8.3(b) Reduced likelihood of 
receiving these procedures persisted in the two case groups after adjusting for 
different covariates. Among those who were offered catheterization, people with 
mental disorder were less likely to receive revascularization, although this fell short 







Table 8.3(a) Odds ratios of catheterizations and revascularizations following AMI 
in people with and without schizophrenia (n=3118)  




  Odds ratio Odds ratio 
Unadjusted OR 0.36 ( 0.28 ~ 0.47 ) 0.31 ( 0.23 ~ 0.42 )
Model 1: adjusted for demographic  
   characteristics (age of index AMI, 
 gender, levels of income and  
urbanizations)  
0.35 ( 0.27 ~ 0.46 ) 0.30 ( 0.22 ~ 0.41 )
Model 2: adjusted for demographic    
characteristics, cardiovascular risk 
factors, and previous cardiac history 
0.33 ( 0.24 ~ 0.46 ) 0.31 ( 0.22 ~ 0.45 )
Model 3: adjusted for demographic    
characteristics, cardiovascular risk 
factors, previous cardiac history, and
hospital properties  
0.38 ( 0.27 ~ 0.53 ) 0.35 ( 0.24 ~ 0.51 )
Model 4: adjusted for demographic   
characteristics, cardiovascular risk 
factors, previous cardiac history,  
hospital properties, and inpatient  
complications 







Table 8.3(b) Odds ratios of catheterizations and revascularizations following AMI 
in people with and without bipolar disorder (n=2770)  




  Odds ratio Odds ratio 
Unadjusted OR 0.42 ( 0.29 ~ 0.61 ) 0.47 ( 0.32 ~ 0.69 )
Model 1: adjusted for demographic  
   characteristics (age of index AMI, 
 gender, levels of income and  
urbanizations)  
0.42 ( 0.29 ~ 0.61 ) 0.47 ( 0.32 ~ 0.70 )
Model 2: adjusted for demographic    
characteristics, cardiovascular risk 
factors, and previous cardiac history 
0.36 ( 0.23 ~ 0.54 ) 0.42 ( 0.27 ~ 0.65 )
Model 3: adjusted for demographic    
characteristics, cardiovascular risk 
factors, previous cardiac history, and 
hospital properties  
0.38 ( 0.24 ~ 0.59 ) 0.47 ( 0.30 ~ 0.74 )
Model 4: adjusted for demographic   
characteristics, cardiovascular risk 
factors, previous cardiac history,  
hospital properties, and inpatient  
complications 






Table 8.4 Odds ratios of revascularization after AMI among people who received 
catheterization   
  Receipt of revascularization 
  Schizophrenia (n=72) 
vs. control (n=705) 
Bipolar disorder (n=34) 
vs. control (n=705) 
 Odds ratio Odds ratio 
Unadjusted OR 0.58 ( 0.34 ~ 1.01 ) 0.73 ( 0.32 ~ 1.64 ) 
Model 1: adjusted for demographic  
   characteristics (age of index AMI, 
 gender, levels of income and  
urbanizations)  
0.53 ( 0.30 ~ 0.93 ) 0.72 ( 0.32 ~ 1.64 ) 
Model 2: adjusted for demographic    
characteristics, cardiovascular risk 
factors, and previous cardiac history 
0.60 ( 0.30 ~ 1.20 ) 0.68 ( 0.28 ~ 1.66 ) 
Model 3: adjusted for demographic    
characteristics, cardiovascular risk 
factors, previous cardiac history, and
hospital properties  
0.59 ( 0.29 ~ 1.17 ) 0.67 ( 0.27 ~ 1.66 ) 
Model 4: adjusted for demographic   
characteristics, cardiovascular risk 
factors, previous cardiac history,  
hospital properties, and inpatient  
complications 
0.59 ( 0.29 ~ 1.18 ) 0.68 ( 0.28 ~ 1.68 ) 
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8.3.3 30-day inpatient mortality in people with or without schizophrenia and 
bipolar disorder 
Table 8.5 summarizes 30-day inpatient mortality and onset of cardiovascular 
complications. Patients with schizophrenia were found to have significantly higher 
inpatient mortality (chi-square 19.4, df 1, p <0.001) than controls, despite the fact 
that both mental disorder groups had similar frequencies of complications compared 
to the controls.  
 
Odds ratios of inpatient mortality in people with or without mental disorder are 
analyzed further in Table 8.6. Adjustments resulted in strengthened associations with 
schizophrenia (principally following adjustment for demographic factors), and 
attenuated associations with bipolar disorder. Associations with cardiovascular 
complications remained non-significant after adjustment apart from that between 















    
n = 2527 n = 591 chi-square (DF) p n = 243 chi-square (DF) p 
Inpatient mortality (%) 5.54  10.49  19.37 (1) <0.001 7.00  0.88 (1) 0.35  
New-onset of any cardiovascular 
complication during the index AMI 
episode (%) 
19.27  18.27  0.31 (1) 0.58 18.11  0.19 (1) 0.66  
   Heart failure 8.31  7.28  0.69 (1) 0.41 7.82  0.07 (1)  0.79  
   Cardiogenic shock 7.00  7.28  0.05 (1) 0.82 5.76  0.53 (1) 0.47  
   Respiratory failure 7.48  8.97  1.48 (1)  0.22 6.58  0.26 (1)  0.61  
   Acute pulmonary edema  3.32  2.54  0.96 (1)  0.33 3.70  0.10 (1)  0.75  






Table 8.6 Odds ratios of inpatient mortality following AMI in people with and 
without serious mental illness 
  Schizophrenia vs. 
control 
Bipolar disorder vs. 
control 
 Odds ratio Odds ratio 
Unadjusted OR  2.00 ( 1.46 ~ 2.73 ) 1.28 ( 0.76 ~ 2.16 ) 
Model 1: adjusted for demographic 
characteristics (age of index AMI, 
gender, levels of income and 
urbanizations)  
2.68 ( 1.92 ~ 3.74 ) 1.34 ( 0.79 ~ 2.28 ) 
Model 2: adjusted for demographic 
characteristics, cardiovascular risk 
factors, and previous cardiac 
history  
2.62 ( 1.77 ~ 3.90 ) 1.20 ( 0.67 ~ 2.14 ) 
Model 3: adjusted for demographic 
characteristics, cardiovascular risk 
factors, previous cardiac history, 
and hospital properties  
2.79 (1.87 ~ 4.17 ) 1.21 ( 0.68 ~ 2.18 ) 
Model 4: adjusted for demographic 
characteristics, cardiovascular risk 
factors, previous cardiac history, 
hospital properties, and inpatient  
complications 
2.97 ( 1.93 ~ 4.58 ) 1.30 ( 0.70 ~ 2.43) 
Model 5: adjusted for demographic 
characteristics, cardiovascular risk 
factors, previous cardiac history, 
hospital properties, inpatient 
complications, and any receipt of 
catheterization or revascularization




 Table 8.7 Odds ratios of cardiovascular complication being diagnosed during the index AMI episode in people with and without serious 
mental illness  
  Schizophrenia group vs. comparison group Bipolar group vs. comparison group 
  Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR 
New onset of any cardiovascular 
complications during the index 
AMI episode 
0.94 ( 0.74 ~ 1.18 ) 1.06 ( 0.82 ~ 1.37) 0.93 ( 0.66 ~ 1.30 ) 0.75 ( 0.53 ~ 1.07 ) 
New onset of heart failure during 
the index AMI episode 
0.87 ( 0.62 ~ 1.22 ) 0.99 ( 0.68 ~ 1.44 ) 0.94 ( 0.57 ~ 1.53 ) 0.78 ( 0.47 ~ 1.30 ) 
New onset of cardiogenic shock   
during the index AMI episode 
1.04 ( 0.74 ~ 1.47 ) 1.20 ( 0.83 ~ 1.75 ) 0.81 ( 0.46 ~ 1.42 ) 0.67 ( 0.38 ~ 1.18 ) 
New onset of respiratory failure   
during the index AMI episode 
1.22 ( 0.89 ~ 1.68 ) 1.52 ( 1.07 ~ 2.15 ) 0.87 ( 0.51 ~ 1.48 ) 0.70 ( 0.41 ~ 1.20 ) 
New onset of acute pulmonary     
edema during the index AMI 
episode 
0.76 ( 0.43 ~ 1.32 ) 0.82 ( 0.45 ~ 1.50 ) 1.12 ( 0.56 ~ 2.25 ) 1.19 ( 0.57 ~ 2.46 ) 
Adjusted for age of first AMI, gender, levels of income and urbanization, cardiovascular risk factors of hypertension, diabetes, 




8.3.4 Hospitalizations due to AMI, heart failure, or cardiogenic shock within 
and after one year of the index AMI episode 
There were no significant elevations in the odds ratios of re-admissions due to 
second AMI episode or due to heart failure in patients with psychiatric diagnosis, 
however, the odds of re-admission due to cardiogenic shock were significantly higher 
in the psychiatric groups after adjustment. (Table 8.8(a) ~8.8(b))
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Table 8.8(a) Re-admissions due to second episode of AMI, heart failure, cardiogenic shock, or other conduction 
problems  










    
n = 2527 n = 591 chi-square (DF) p n = 243 chi-square (DF) p 
Re-admission of second AMI after one 
month and before a year after the 
discharge of index AMI (%) 
2.18  2.37  0.082 (1) 0.77 3.29  1.24 (1) 0.27  
Re-admission of second AMI one year after 
the discharge of index AMI (%) 
3.09  2.03  1.91 (1) 0.17 3.29  0.03 (1) 0.86  
New onset of heart failure after the 
discharge of index AMI (%) 
15.79  12.86  3.18 (1) 0.07 15.64  0.004 (1)  0.95  
New onset of cardiogenic shock after the 
discharge of index AMI (%) 
5.74  7.28  2.00 (1) 0.16 9.88  6.63 (1) 0.01  
New onset of conduction problems1 after 
the discharge of index AMI (%) 
4.04  3.72  0.12 (1)  0.73 2.47  1.45 (1)  0.23  
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Table 8.8(b) Odds ratios of re-admissions due to AMI or other cardiovascular complications after the index AMI episode in people with 
and without serious mental illness  
  Schizophrenia group vs. comparison group Bipolar group vs. comparison group 
  Unadjusted OR Adjusted OR2 Unadjusted OR Adjusted OR2 
Re-admission of second AMI after 
one month and before a year after 
the discharge of index AMI 
1.09 ( 0.60 ~ 1.98 ) 1.05 ( 0.52 ~ 2.12 ) 1.53 ( 0.72 ~ 3.25 ) 1.22 ( 0.53 ~ 2.81 ) 
Re-admission of second AMI one 
year after the discharge of index 
AMI 
0.65 ( 0.35 ~ 1.20 ) 0.78 ( 0.38 ~ 1.61 ) 1.07 ( 0.51 ~ 2.24 ) 1.64 ( 0.46 ~ 2.38) 
New onset of heart failure after the 
discharge of index AMI 
0.79 ( 0.61 ~ 1.02 ) 0.96 ( 0.70 ~ 1.32 ) 0.99 ( 0.69 ~ 1.42 ) 1.19 ( 0.80 ~ 1.79 ) 
New onset of cardiogenic shock 
after the discharge of index AMI 
1.29 ( 0.91 ~ 1.84 ) 2.29 ( 1.48 ~ 3.55 ) 1.80 ( 1.14 ~ 2.83 ) 2.19 ( 1.32 ~ 3.64 ) 
New onset of conduction disoreder1 
after the discharge of index AMI 
0.92 ( 0.58 ~ 1.47 ) 1.13 ( 0.64 ~ 2.01 ) 0.60 ( 0.26 ~ 1.39 ) 0.69 ( 0.29 ~ 1.66 ) 
1Including ventricular tachycardia, ventricular fibrillation, atrioventricular block, and cardiac arrest 




8.4.1 Summary of the findings 
In this analysis of national population-based administrative records, people with 
schizophrenia and bipolar disorder were found to have a significantly decreased 
likelihood of catheterizations and revascularizations during an AMI hospital episode 
than people without those mental disorders. Inpatient mortality remained three times 
higher in patients with schizophrenia compared to controls after adjusting for 
intervention receipt amongst other covariates. However, no evidence was found for 
raised inpatient mortality in patients with bipolar disorder. Only the complication of 
respiratory failure was significantly higher in patients with schizophrenia. Although 
no differences in the recurrence of AMI compared to general population, subsequent 
hospitalizations due to cardiogenic shock after discharge of index AMI was higher 
in patients with schizophrenia and bipolar disorder. 
 
8.4.2 Decreased likelihood of intervention receipt in schizophrenia and bipolar 
disorder 
The finding that both the schizophrenia and bipolar disorder groups were less than 
half as likely to receive invasive coronary interventions than controls is supported 
by previous research reporting odds ratios ranging from 0.27 to 0.93 (Druss et al., 
2000; Jones LE & Carney, 2005; Kisely et al., 2009; Lawrence DM et al., 2003; 
Mitchell & Lawrence, 2011; Young & Foster, 2000). Thus, this finding raised the 
possibility of severe inequalities in service receipt following AMI for patients with 
SMI, although accepting that the case samples had relatively high morbidity as they 
were enriched by people who had received inpatient mental health care. Levels of 
severity for the index AMI episode, as far as these could be estimated from the data 
available, were similar between people with or without mental disorder and 




Several reasons have been suggested to underlie reduced medical care receipt in 
people with mental disorders. These include socioeconomic disadvantage and 
physician bias (Petersen et al., 2003; Schulman et al., 1999), inaccurate decisions 
(Graber et al., 2000; Petersen et al., 2003), and patient and/or family preferences, 
levels of adherence, or quality of therapeutic alliances (DiMatteo et al., 2000; 
Petersen et al., 2003). Reduced access to appropriate health insurance has also been 
cited (Druss & Rosenheck, 1998). The healthcare context for the findings presented 
here should therefore be considered. Economic disparities in Taiwan are less likely 
to be an underlying factor because of a healthcare system which has near-universal 
coverage comparable to systems in the UK and Canada (Kisely et al., 2009) and 
which entails very low out-of-pocket expenses or no cost sharing for people with 
serious mental illness at the point of delivery. As has been found in other settings 
(Druss et al., 2000), rates of revascularization among patients who underwent 
catheterization did not differ significantly between those with and without mental 
disorders (although a disadvantage for the schizophrenia group came close to 
significance), suggesting that the reduced access lay more at the point of 
investigation rather than at the point of management. Previous research has 
considered a variety of factors potentially underlying physician decision-making in 
people with mental disorders including perceived non-compliance, smoking habits, 
or cooperation with post-operative care as a reason for reduced cardiovascular 
interventions (Penn & Martin, 1998; Schulman et al., 1999). Although the nature of 
the data analyzed did not allow in-depth evaluation of physician behaviour, it is 
noteworthy that substantial inequalities were still found in a healthcare system that 
remunerates physicians on the basis of procedure receipt with no maximum limit on 
the total services a physician can provide and be paid for each month when 
appropriate managements were given. Conscious or unconscious judgments by 
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physicians concerning procedures performed in people with severe mental disorder 
may still be one of the reasons for the observed inequality.  
 
In Taiwan, since 95% of people with serious mental illness live with friends, 
families, or other relatives (Hou et al., 2008; Song, 1999), it is important to consider 
the role that families play in healthcare decision making (Chou et al., 1992; Hou et 
al., 2008; Wu CC, 1993). As a consequence, it is also important to investigate 
further whether any inequality in intervention access might have arisen because of 
adequacy of information provided to facilitate decision-making where capacity is 
lacking (Druss et al., 2000), and to clarify the extent to which family empowerment 
and education interventions could improve the situation are also in need. 
 
8.4.3 Raised inpatient mortality during AMI admission in patients with 
schizophrenia but not bipolar disorder 
The 2-fold increased likelihood of 30-day inpatient mortality in people with 
schizophrenia was substantially stronger than that reported by previous literature 
(where odds ratios have ranged from 1.19 to 1.56) (Abrams et al., 2009; Kisely et al., 
2009; Kurdyak et al., 2012). Patients with bipolar disorder on the other hand showed 
no significant mortality elevation, although this group were relatively small in size 
and, as mentioned, the hierarchical classification system may have resulted in 
selected cases. Findings should therefore be interpreted with caution, and further 
research is still required to establish reasons for the discrepancy in mortality and the 
disadvantage of intervention receipt for the two mental disorders, potentially 
exploring different levels of cognitive function, judgment, affective symptoms, or 
behavioural, and social performances between the two groups. It is also possible that 
there were underlying differences in vulnerability or vascular risk factors, since it 
was only possible to adjust for known and recorded disorders. As mentioned earlier, 
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cardiovascular outcomes in bipolar disorder have received much less research than 
those in schizophrenia and the findings here suggest discrepancies in outcome which 
may benefit from further investigation. One possible explanation may lie in attitudes 
to illness and help-seeking. Previous studies have found that despite higher objective 
levels of comorbidity, patients with schizophrenia report fewer physical symptoms 
or disorders than controls (Dworkin, 1994; Jeste et al., 1996; Phelan et al., 2001). 
Higher pain tolerance (Vahia et al., 2008) or lower sensitivity to pain because of 
antipsychotic use (Jeste et al., 1996) in schizophrenia might also be responsible. It is 
possible that delayed diagnosis or treatment might have occurred because 
communication failures (Dworkin, 1994; Mitchell & Lawrence, 2011; Robson & 
Gray, 2007), and it is important that medical personnel are more aware of the 
underlying disadvantage and the need to pay more attention to potential disease 
signs perhaps particularly in the context of active psychotic symptoms or where 
medically indicated treatments are refused (Phelan et al., 2001). 
 
8.4.4 Significant elevation in the odds ratios of re-admissions due to cardiogenic 
shock 
The result that the adjusted odds ratio of re-admissions due to cardiogenic shock 
after the first AMI episode was significantly higher in patients with serious mental 
illness compared with general population reflects the need of early recognition and 
treatment of this poor prognostic factor among psychiatric patients, especially since 
cardiogenic shock is the most common cause of death in patients hospitalized with 
AMI, and is associated with a poor prognosis and 50 ~ 80% mortality rates 
(Hollenberg et al., 1999; Topalian et al., 2008). Although there were no significant 
differences in re-admissions due to second AMI episode, heart failure or other 
conduction problems between people with or without serious mental illness, it 
should be borne in mind the possibility that the second AMI episode or other 
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cardiovascular complications went unrecognized by clinical attention in patients 
with psychiatric disorders, or patients died outside the hospital, and thus these 
diagnoses have not been detected. However, since 9.3% of recurrent myocardial 
infarction or 19.7% of ischemia were found to precipitate cardiogenic shock 
(Hochman et al., 2000; Topalian et al., 2008), it is important to educate patients 
discharged from an AMI episode and their families to aware the development of 
significant chest pain or other symptoms of AMI and to seek medical evaluations or 
interventions as soon as possible. 
 
8.4.5 Strengths and Limitations 
 
As well as the relatively large, nation-wide samples with statistical power 
advantages, a particular strength of the analysis lies in the fact that the data 
contained detailed records of relevant cardiovascular diagnoses and intervention 
receipts. An important limitation is that covariates of interest were confined to those 
represented in the dataset and information was not available, for example, on 
investigation results, specific symptom profiles, or the presence or not of previous 
AMI before 1996. Also, as mentioned in Chapter 7, it should be borne in mind that 
the generalisability of this study is limited to patients with schizophrenia or bipolar 
disorder who had previously received psychiatric inpatient care, and so are likely to 
represent groups with relatively severe mental disorder. Third, since a hierarchical 
algorithm was adopted, favoring a diagnosis of schizophrenia over bipolar disorder, 
cases with bipolar disorder were relatively restricted. Finally, there might be an issue 
with multiple analyses carried out in this study. However, adjustments in all models 
were decided a priori, and outcomes of intervention receipts, inpatient mortality, 
and one-year re-admissions were all part of the clinically meaningful processes and 




ASSOCIATION OF ACUTE MYOCARDIAL INFARCTION AND 
ANTIPSYCHOTIC USE IN PEOPLE WITH SCHIZOPHRENIA AND 





Taking advantage of a sizeable sample of patients with serious mental illness (SMI) 
derived from the large comprehensive national health insurance database, a 
case-crossover design was applied to investigate the associations between acute 
myocardial infarction (AMI) and recent antipsychotic use among people with SMI. 
Hypotheses were that antipsychotic exposure, especially typical antipsychotic, 
would be more common in the ‘case’ period compared to the ‘control’ period, and 
that the average dose of antipsychotic would be higher in the ‘case’ period compared 
to the ‘control’ period. The reason for hypothesizing that there would be more 
typical antipsychotic exposure in the ‘case’ period than in the ‘control’ period was 
because the short-term pathway leading to AMI might be associated with typical 
antipsychotic agents via conduction deficits (Vieweg, 2002; Wang, 2002; Wang, 
2007) rather than cardiometabolic effects. Finally, different from the definition of 
‘case cohort’ or ‘control cohort’ in Chapters 7~8, the ‘case period’ and ‘control 
period’ terms used in this chapter stand for the time periods ‘proximal’ or ‘distal’, 
respectively, to the index AMI episode.  
 
9.2 Method 
9.2.1 Study cohort 
The study cohort were patients with schizophrenia or bipolar disorder from the 
PIMC and the LHIRD2000 (details described in Chapter 6.2~ 6.3) who had an 
episode of AMI in between 1996 to 2007. 
 
9.2.2 Elements of the study design 
As illustrated in Figure 9.1, a case-crossover design was applied in this study. This 
is a variant of the matched case-control design, but compares exposure status within 
individuals rather than between individuals: specifically between time periods 
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proximal and distal to the event of interest. The design provides a powerful means of 
removing the influence of between-individual differences as confounders (since 
individuals are their own controls) and is particularly suited to the investigation of 
short-term effects of exposures on the risk of acute outcomes (Maclure, 1991). In the 
study described here, a 60-day case and control time periods were chosen a priori, 
in order to be comparable to the study by Pariente et al. which quantified the 
incidence of AMI in pre-defined periods of 1~30 (acute), 31~60 (intermediate), 
61~90 (prolonged) days after the first dispense of antipsychotic compared to the 
reference period (Pariente et al., 2012). Here in this study, the exposure status to 
antipsychotic was ascertained during the 60 day period prior to the index AMI 
episode and was compared with that during the preceding 60 days (i.e. 61-120 days 
prior to AMI) (see Figure 9.2). To check for consistency and to take account of any 
potential seasonal effect, an additional sensitivity analysis was carried out 
comparing the primary 60 day ‘case’ period to a 60 day ‘control’ period precisely 
one year previously. 
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Figure 9.1 Application of the case-crossover design in the study 
 
 
The ratio of discordant pairs between the number of patients exposed in the case 









9.2.3 Sample characteristics 
Information was extracted from the database on demographic status (age and 
gender), and the presence or not of any diagnoses indicating increased 
cardiovascular risk (coronary artery diseases (ischemic heart diseases, angina 
pectoris, chronic ischemic heart disease or coronary atherosclerosis), 
cerebrovascular diseases, hypertension, diabetes, or hyperlipidaemia).  
 
9.2.4 Antipsychotic exposure 
From the ‘Medical Expenditure and Prescription Claims subset’ of the NHIRD, 
records were identified of antipsychotic prescription instances during the case or 
control time windows as the primary exposure (Anatomical Therapeutic Chemical 
(ATC) classification system: ATC code: N05A antipsychotic agents, as summarized 
in Chapter 6.7 and Table 6.5). In order to quantify an individual’s average daily 
dose, the Defined Daily Dose [DDD, or ‘the assumed average maintenance dose per 
day for a drug used for its main indication in adults’ (WHOCC, 2009), which had 
been previously applied in this database (Wu CS et al., 2011)], was calculated for 
each antipsychotic agent. This measure was applied in the following ways: 
1. The summed total dose over the 12 months prior to AMI was calculated by 
adding up all the prescribed doses of antipsychotic agents within the 12- months 
period.  
2. Average daily doses during case and control periods were calculated by using 
cumulative doses divided by cumulative exposure days.  
3. The above two variables were further categorised into low and high ranges 
applying median values as the cut point for this.  
 
Typical antipsychotics were defined as chlorpromazine, chlorprothixene, flupentixol, 
fluphenazine, haloperidol, levomepromazine, melperon, periciazine, perphenazine, 
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pimozide, pipamperone, prochlorperazine, promazine, thioridazine, and 
zuclopenthixol, and atypical antipsychotics were defined as amisulpride, clozapine, 
olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, and aripiprazole (Enger 
et al., 2004; Farah, 2005; Meltzer, 2004).  
 
9.2.5 Time-variant confounding factors 
Confounding in a case-crossover study principally arises from other factors which 
may differ between case and control exposure periods (i.e. alternative explanations 
for any observed variation in the exposure). Hence, despite no more confounding 
effects of between-individual differences, other time-variant factors, such as 
prescriptions of antidepressants (tricyclics in particular), or cardiovascular 
medications (antithrombotic, antidiabetic, diuretic, antihypertensive, and lipid 
lowering agents) have been shown to have cardio-toxic (Glassman, 1998) or 
cardio-protective (Nakagawa et al., 2006) effects. Therefore, the following 
covariates were defined for the case and control time periods, and were adjusted in 
this respect (also see Table 6.5 for ATC codes, (WHO, 2009)): 
 
 i) general healthcare contacts, quantified as the number of non-psychiatric 
outpatient visits;  
ii) prescriptions of any antidepressant for at least one day.  
iii) The presence of any cardiovascular medications (antithrombotic, antidiabetic, 
diuretic, antihypertensive, and lipid lowering agents) within each period was also 
calculated. 
 
9.2.6 Statistical analysis 
SAS version 9 for Windows (SAS Institute, Cary, NC) was used for data 
management and analysis. Matched pair analyses were carried out, pairing the case 
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and control time windows by each individual’s unique identifier. Primary analyses 
compared any antipsychotic agent exposure as a binary variable between case and 
control time periods using conditional logistic regression models (PHREG 
procedure in SAS) to generate matched odds ratios from numbers of discordant pairs, 
followed by adjustment for potential confounders as described above. Sub-analyses 
on individuals with schizophrenia and bipolar disorder were then carried out 
separately, stratifying for the following factors: age at AMI (above and below 
median), gender, presence or not of a cardiovascular risk factor preceding the AMI, 
and the summed total antipsychotic dose (DDD above and below median value) for 
all antipsychotic prescriptions over the 12 months preceding the AMI. Interaction 
terms between antipsychotic exposure and these variables were tested. The 
frequencies of psychiatric hospitalization between case and control periods were 
also compared to contextualize findings. Further conditional logistic regression 
analyses were carried out to compare levels of average daily dose (DDD above and 
below median value), and use of typical vs. atypical antipsychotic agents between 
case and control periods. The test of whether there was a positive correlation 
between increased risk of AMI and higher average daily dose was examined by 
Wald chi-square test based on groups of low or high average daily dose (DDD) 
defined according to median value. Analyses were repeated using the second control 
period (12-15 months [366-425 days] before AMI) to check for consistency.  
 
Finally, because matched odds ratios for exposure status (i.e. presence/absence of 
antipsychotic use) were derived only from discordant pairs (i.e. people with an 
exposure in one time period and without that exposure in the other), further analyses 
compared the average daily dose (DDD) of antipsychotic as a continuous variable 
between the two time periods in patients who had received antipsychotic agents at 




After applying inclusion/exclusion criteria, a total of 834 cases with serious mental 
illness and incident AMI between 1996 and 2007 were identified: 591 (70.9%) with 
schizophrenia and 243 (29.1%) with bipolar disorder. Table 9.1 summarizes sample 
characteristics. For all patients with antipsychotic exposure in the case period 
(n=384), the median average daily dose during this period was 0.50 DDD (25th and 
75th percentiles 0.25 and 0.92 respectively); for all patients with antipsychotic 
exposure in the control period (n=364), the median average daily dose during this 




Table 9.1. Characteristics of the analyzed samples 
  Schizophrenia 
( n= 591) 
Bipolar disorder
( n= 243 ) 
Statistic, Degree of 
freedom (df), p value
Mean (SD) age at index AMI episode 57.1 (15.4) 64.2 (15.4) F 36.6, df 1, p<0.001 
Gender (% female) 39.9  41.6  χ2 0.19, df 1, p=0.66 
Levels of urbanization (%)   χ2 19.3, df 4, p<0.001 
   1 (most urbanized) 23.7 28.8  
2 32.0 29.2  
3 13.0 15.6  
4 17.1 21.8  
5 (least urbanized) 14.2 4.5  
Monthly income    (%)   χ2 9.16, df 3, p<0.05 
   NT 0 25.9 34.2  
   NT$ 1~15840 50.0 41.2  
NT$ 15841 ~ 25000 20.1 18.1  
 ≧NT$ 25001 4.2 6.6  
Non-psychiatric medical visits the year before the AMI  F 17.8, df 1, p<0.001 
    0 times 5.4 0.8  
    1~22 times (below median) 51.3 35.8  
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    ≧ 23 times (above median) 43.3 63.4  
Any previous cardiovascular risk factors prior to 
AMI (%) 
78.7 82.7 χ2 1.74, df 1, p=0.19 
   Hypertension        54.3  60.5  χ2 2.67, df 1, p=0.10 
   Diabetes            38.6  33.3  χ2 2.03, df 1, p=0.18 
   Hyperlipidemia      28.1  30.0  χ2 0.32, df 1, p=0.63 
Alcohol use disorders  13.4 8.6 χ2 3.64, df 1, p=0.07 
   History of previous coronary heart diseases  44.2  56.4  χ2 10.3, df 1, p<0.01 
History of previous cerebrovascular diseases  6.4 6.2 χ2 0.02, df 1, p=0.89 
Total defined daily dose (DDD) of antipsychotic use 
in the 12 months prior to AMI  
  χ2 60.1, df 1, p<0.001 
   Total DDD <=67.7 (n = 255) 41.0  82.7   
   Total DDD > 67.7 (n = 255) 59.0  17.3   
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9.3.1 Antipsychotic exposures in case and control periods 
Table 9.2 summarizes the results of case-crossover analyses on AMI and recent 
antipsychotic use in the 834 individuals with serious mental illness. For patients with 
antipsychotic exposure only in the case period (n=65), the median average daily dose 
during this period was 0.40 DDD (25th and 75th percentiles 0.19 and 0.63 
respectively); for patients with antipsychotic exposure only in the control period 
(n=45), the median average daily dose during this period was 0.25 DDD (25th and 
75th percentiles 0.17 and 0.81 respectively). Daily antipsychotic doses were therefore 
mostly below the recommended average maintenance dose in both periods. People 
who were male, diagnosed with schizophrenia, had no cardiovascular diagnoses, and 
were exposed to lower total dose of antipsychotic within the year prior to index AMI, 
were found to be significantly more likely to have antipsychotic exposure in the case 
period compared to the control period.  
 
Table 9.3 further summarizes the differences in average daily dose (above/below 
median DDD) and types of antipsychotic prescribed between case and control 
periods among patients with at least one antipsychotic prescription instance within 
the 12 months prior to AMI. Results showed no significant associations between 
average daily dose and AMI. However, there were more typical antipsychotic being 
prescribed in the case period compared to the control period. No significant 
differences were found in the frequency of psychiatric admissions between case and 
control periods (adjusted OR: 1.33, 95% CI: 0.84~2.08).    
 
Regarding the stronger association between recent antipsychotic use and AMI in 
people with no previous cardiovascular disease diagnosis, average antipsychotic 
DDD during the case period was compared between people with and without 
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previous cardiovascular diagnoses but no significant differences were found (t 0.05, 
df 63, p=0.96). 
 
Moreover, on further comparing the average daily dose between case and control 
periods in people with antipsychotic use in both (n=319), 32.9% of people had a 
higher average daily dose in the case period, 32.6% of people had a higher average 
daily dose in the control period, and 34.5% had the same average daily dose during 
both periods. A matched t-test found no significant difference in average daily dose 





Table 9.2 Case-crossover analyses investigating the association between AMI and recent antipsychotic use, stratified by 
patient characteristics 
  Any antipsychotic use in case (1-60 days) and control 
(61-120 days) periods prior to AMI (n) 
Association between recent antipsychotic 
use and AMI (OR, 95%CI)a 
  Use only 
in case 
period 
Use only in 
control period




Unadjusted Adjusted model b 
Total sample 65 45 319 405 1.44 (0.99 ~ 2.11) 1.42 (0.97 ~ 2.08) 
Psychiatric diagnosis       
Schizophrenia (n= 591) 49 29 270 243 1.69 (1.07 ~ 2.67) 1.66 (1.05 ~ 2.63) 
Bipolar disorder (n= 243) 16 16 49 162 1.00 (0.50 ~ 2.00) 0.98 (0.49 ~ 1.98) 
Gender       
   Female ( n = 337 ) 28 27 127 155 1.04 (0.61 ~ 1.76) 1.04 (0.61 ~ 1.76) 
   Male ( n = 497 ) 37 18 192 250 2.06 (1.17 ~ 3.61) 1.98 (1.12 ~ 3.48) 
Age (years)       
   18~60 (n = 433) 34 21 199 179 1.62 (0.94 ~ 2.79) 1.60 (0.93 ~ 2.76) 
   >60  (n = 401) 31 24 120 226 1.29 (0.76 ~ 2.20) 1.25 (0.73 ~ 2.14) 
Previous cardiovascular risk factors     
    No (n= 168) 17 3 58 90 5.67 (1.66 ~ 19.33) 5.71 (1.67 ~ 19.53)
    Yes (n = 666) 48 42 261 315 1.14 (0.76 ~ 1.73) 1.11 (0.73 ~ 1.68) 
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Summed antipsychotic dose (DDD) over the 12 months prior to AMI (n=510, excluding people who had not received any 
antipsychotic in the previous year) 
    <=67.7 (n = 255) 52 30 104 69 1.73 (1.11 ~ 2.72) 1.71 (1.09 ~ 2.68) 
    >67.7 (n = 255) 13 15 215 12 0.87 (0.41 ~ 1.82) 0.86 (0.41 ~ 1.81) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects 
exposed only in the control period) and conditional logistic regression.   




Table 9.3. Risk of AMI and antipsychotic use within the 60-day risk period, by average defined daily dose and types of antipsychotic use among patients 
with at least one antipsychotic prescription instance within the 12 months prior to AMI (n=510) 
 
 Any antipsychotic use in case (1-60 days) and control (61-120 
days) periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
 Use only in 
case period  
Use only in 
control period 
Use in both 
periods  
Non-use in 
both periods  
Unadjusted Adjusted model 1b 
Average daily dose (DDD) per day during exposed period (excluding people who had not received any antipsychotic in the previous year) 
 Above median   36 27 144 303 1.33 (0.81 ~ 2.20) 1.33 (0.81 ~ 2.19) 
Type(s) of antipsychotic used during exposure period (excluding people who had not received any antipsychotic in the previous year) 
   Only typical      59 39 249 163 1.51 (1.01 ~ 2.27) 1.50 (1.00 ~ 2.25) 
   Only atypical     13 10 122 365 1.40 (0.44 ~ 4.41) 1.42 (0.45 ~ 4.48) 
   Combined  7 5 51 447 1.40 (0.44 ~ 4.41) 1.45 (0.46 ~ 4.61) 
a Calculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the 
control period) and conditional logistic regression.   
bAdjustment for non-psychiatric outpatient visits in the 60-day exposure periods  
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9.3.2 Sub-analyses in patients with schizophrenia 
Antipsychotic use prior to AMI was then analyzed separately in people with 
schizophrenia and bipolar disorder. As summarized in Table 9.4, in people with 
schizophrenia more recent antipsychotic prescription was associated with AMI after 
adjusting for potential confounders, suggesting a 60% increased risk. 
 
Having tested for statistical interactions, the association between AMI and more 
recent antipsychotic prescription was stronger in men (interaction term coefficient 
3.43, 95% CI 1.29~9.14, p=0.014), in those without prior cardiovascular diagnoses 
(0.20, 0.04~0.93, p=0.041), and in patients with lower overall antipsychotic 
exposure over the previous year (0.61, 0.21~1.76, p=0.36), but there was no 




Table 9.4. Case-crossover analyses investigating the association between AMI and recent antipsychotic use in patients with schizophrenia (n=591) 
  Any antipsychotic use in case (1-60 days) and control (61-120 days) 
periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
 Use only in 
case period 
Use only in 
control period 
Use in both 
periods  
Non-use in both 
periods    
Unadjusted Adjusted modelb 
Total sample (n=591) 49 29 270 243 1.69 (1.07 ~ 2.67) 1.60 (1.01 ~ 2.55) 
Gender       
   Women ( n = 236 ) 19 20 106 91 0.95 (0.51 ~ 1.78) 0.93 (0.49 ~ 1.77) 
   Men ( n = 355 ) 30 9 164 152 3.33 (1.58 ~ 7.02) 3.10 (1.46 ~ 6.58) 
Age (years)       
   18~60 (n = 346) 30 16 182 118 1.88 (1.02 ~ 3.44) 1.81 (0.98 ~ 3.35) 
   >60  (n = 245) 19 13 88 125 1.46 (0.72 ~ 2.96) 1.37 (0.68 ~ 2.80) 
Previous cardiovascular risk factors      
No (n= 126) 12 2 50 62 6.00 (1.34 ~ 26.79) 7.00 (1.49 ~ 32.91) 
Yes (n = 465) 37 27 220 181 1.37 (0.83 ~ 2.25) 1.26 (0.76 ~ 2.09) 
Summed antipsychotic doses (DDD) over the 12 months prior to AMI (n=400, excluding people who had not received any antipsychotic in the previous year) 
Below median (n = 200) 38 20 97 45 1.90 (1.11 ~ 3.27) 1.90 (1.10 ~ 3.31) 
Above median (n = 200) 11 9 173 7 1.22 (0.51 ~ 2.95) 1.14 (0.46 ~ 2.80) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the control 
period) and conditional logistic regression.   
bAdjustment for non-psychiatric outpatient visits and antidepressant use in the 60-day exposure periods  
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Further analyses for patients with schizophrenia who had at least one antipsychotic 
prescription (Table 9.5) found no significant association between risk of AMI and 
recent exposure to higher antipsychotic average daily dose (i.e. above the 0.61 
median DDD) after adjustment, nor was there a dose-response relationship (Wald 
chi-square = 1.08, df=1, p trend = 0.30). It seemed that the odds ratios for typical 
agents were significantly higher than those for atypical agents, although patients 
with discordant time periods for atypical antipsychotic agents were too small for 
further interpretation. The odds of any psychiatric admission were not found to 
differ between the case and control periods (OR=1.32, 95% CI 0.78 ~ 2.22).  
 
Comparing the average daily dose between case and control periods in concordant 
pairs (i.e those who received antipsychotic prescription in both periods) of 
schizophrenia, a matched t-test revealed no significant difference (t = -0.43, df =269, 
p = 0.66). 
 
A series of exploratory analyses were carried out to investigate further the primary 
finding in the group with schizophrenia. Additional adjustment for changes in 
cardiovascular medication use did not substantially alter the primary association 
(further adjusted odds ratio 1.56, 95% CI 0.98~2.48). Analyses using the alternative 
control period (1 year previously) are summarized in Table 9.6 and indicate a 
stronger association between AMI and recent antipsychotic exposure. 
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Table 9.5 Risk of AMI and antipsychotic use within the 60-day risk period, by average defined daily dose and types of antipsychotic use among 
schizophrenia with at least one antipsychotic prescription instance within the 12 months prior to AMI (n=400) 
  Any antipsychotic use in case (1-60 days) and control (61-120 
days) periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
  Use only in 
case period 
Use only in 
control period 
Use in both 
periods  
Non-use in both 
periods   
Unadjusted Adjusted model 1b 
Average daily dose during exposed period     
Above median 28 26 124 222 1.08 (0.63 ~ 1.84) 1.07 (0.63 ~ 1.83) 
Type(s) of antipsychotic used during exposure period     
    Only typical 45 26 213 116 1.73 (1.07 ~ 2.81) 1.71 (1.06 ~ 2.78) 
    Only atypical        10 6 102 282 1.67 (0.61 ~ 4.59) 1.63 (0.59 ~ 4.49) 
    Combined  6 4 44 346 1.50 (0.42 ~ 5.32) 1.47 (0.41 ~ 5.23) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the control 
period) and conditional logistic regression.   





Table 9.6. Sensitivity analyses comparing the case period to the control period one year prior to the AMI in people with schizophrenia 
  Any antipsychotic use in case (1-60 days) and control 
(366-425 days) periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
 Use only in 
case period 
Use only in 
control period 
Use in both 
periods  
Non-use in 
both periods  
Unadjusted Adjusted modelb 
Total sample (n=591) 95 45 224 227 2.11 (1.48 ~ 3.01) 4.20 (2.29 ~ 7.68) 
Gender       
   Women ( n = 236 ) 38 21 87 90 1.81 (1.06 ~ 3.08)  4.46 (1.60 ~ 12.43) 
   Men ( n = 355 ) 57 24 138 138 2.38 (1.47 ~ 3.83) 4.19 (1.96 ~ 8.95) 
Age (years)       
   18~60 (n = 346) 54 25 158 109 2.16 (1.34 ~ 3.47) 3.56 (1.75 ~ 7.23) 
   >60  (n = 245) 41 20 66 118 2.05 (1.20 ~ 3.50)  6.81 (2.07 ~ 22.33) 
Previous cardiovascular risk factors    
No (n= 126) 21 4 41 60  5.25 (1.80 ~ 15.29)  6.30 (1.71 ~ 23.24) 
Yes (n = 465) 74 41 183 167 1.81 (1.23 ~ 2.64) 3.89 (1.91 ~ 7.91) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the control 
period) and conditional logistic regression.   
bAdjustment for non-psychiatric outpatient visits and antidepressant use in the 60-day exposure periods  
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9.3.3 Sub-analyses in patients with bipolar disorder 
As shown in Table 9.7, there was no association between AMI and recent 
antipsychotic use in patients with bipolar disorder either before or after adjustment. 
However, it should be borne in mind that the case numbers for stratified analyses in 
bipolar group might be too small to be interpretable. No significant modifications by 
gender (interaction term coefficient 0.58, 95%CI 0.14~2.37, p=0.45), age group 
(0.95, 95%CI 0.54~1.70, p=0.87), prior cardiovascular risk factors (0.18, 95%CI 
0.02~1.74, p=0.14), or summed dose of antipsychotic prescription within the year 




Table 9.7. Case-crossover analyses investigating the association between AMI and recent antipsychotic use in patients with bipolar (n=243) 
  Any antipsychotic use in case (1-60 days) and control (61-120 days) 
periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
 Use only in case 
period  
Use only in 
control period 
Use in both 
periods  
Non-use in both 
periods    
Unadjusted Adjusted modelb 
Total sample (n=243) 16 16 49 162 1.00 (0.50 ~ 2.00) 0.98 (0.49 ~ 1.98) 
Gender       
   Women ( n =101 ) 9 7 21 64 1.29 (0.48 ~ 3.45) 1.29 (0.48 ~ 3.49) 
   Men ( n = 142 ) 7 9 28 98 0.78 (0.29 ~ 2.09) 0.74 (0.27 ~ 2.02) 
Age (years)       
   18~60 (n = 87) 4 5 17 61 0.80 (0.22 ~ 2.98) 0.80 (0.21 ~ 3.01) 
   >60  (n = 156) 12 11 32 101 1.09 (0.48 ~ 2.47) 1.06 (0.47 ~ 2.43) 
Previous cardiovascular risk factors      
No (n= 42) 5 1 8 28 5.00 (0.58 ~ 42.8) 4.47 (0.51 ~ 39.2) 
Yes (n = 201) 11 15 41 134 0.73 (0.34 ~ 1.60) 0.75 (0.34 ~ 1.64) 
Summed antipsychotic dose (DDD) over the 12 months prior to AMI (n=110, excluding people who had not received any antipsychotic in the previous year) 
Below median (n = 55) 9 12 10 24 0.75 (0.32 ~ 1.78) 0.73 (0.30 ~ 1.74) 
Above median (n = 55) 7 4 39 5 1.75 (0.51 ~ 5.98) 1.76 (0.51 ~ 6.04) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the control 
period) and conditional logistic regression.   
bAdjustment for non-psychiatric outpatient visits and antidepressant use in the 60-day exposure periods  
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In patients with bipolar who received at least one prescription of antipsychotic 
within the year prior to AMI, further analyses (Table 9.8) found no significant 
differences between risk of AMI and exposures to lower or higher antipsychotic 
summed dose (above the 0.24 median DDD) or typical vs. atypical antipsychotic 
after adjustment. No significant trend of dose-response relationship (Wald 
chi-square = 1.25, df=1, p trend = 0.27) was observed. Among concordant pairs of 
people with bipolar disorder (n=49), no significant difference were found in average 
daily dose between case and control periods (t = -0.97, df =48, p = 0.34). 
 
Similar to people with schizophrenia, results of additional analyses using a more 
distant control period one year previously revealed stronger associations between 






Table 9.8 Risk of AMI and antipsychotic use within the 60-day risk period, by average defined daily dose 
and types of antipsychotic use among bipolar with at least one antipsychotic prescription instance within the 
12 months prior to AMI (n=110) 
  Any antipsychotic use in case (1-60 days) 
and control (61-120 days) periods prior to 
AMI (n) 
Association between recent antipsychotic 
use and AMI (OR, 95%CI)a 











Unadjusted Adjusted model 1b
Average daily dose during exposed period     
Above median 11 8 22 69 1.38 (0.55 ~ 3.42) 1.38 (0.55 ~ 3.42)
Type(s) of antipsychotic used during exposure period     
    Only typical 14 13 36 47 1.08 (0.51 ~ 2.29) 1.08 (0.51 ~ 2.29)
    Only atypical     3 4 20 83 0.75 (0.17 ~ 3.35) 0.75 (0.17 ~ 3.36)
    Combined  1 1 7 101 1.00 (0.06 ~ 15.99) 1.00 (0.06 ~ 17.62)
a Calculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to 
subjects exposed only in the control period) and conditional logistic regression.   






Table 9.9. Sensitivity analyses comparing the case period to the control period one year prior to the AMI in people with bipolar disorder 
  Any antipsychotic use in case (1-60 days) and control (366-425 
days) periods prior to AMI (n) 
Association between recent antipsychotic use and AMI 
(OR, 95%CI)a 
 Use only in 
case period 
Use only in 
control period 
Use in both 
periods  
Non-use in 
both periods  
Unadjusted Adjusted modelb 
Total sample (n=243) 36 18 29 160 2.00 (1.14 ~ 3.52) 6.22 (2.07 ~ 18.71) 
Gender       
   Women ( n =101 ) 16 9 14 62 1.78 (0.79 ~ 4.02)  23.91 (2.40 ~ 238.1) 
   Men ( n = 142 ) 57 24 138 138 2.22 (1.01 ~ 4.88) 3.43 (0.93 ~ 12.59) 
Age (years)       
   18~60 (n = 87) 12 4 9 62 3.00 (0.97 ~ 9.30) 6.56 (1.28 ~ 33.55) 
   >60  (n = 156) 24 14 20 98 1.71 (0.89 ~ 3.31) 6.46 (1.39 ~ 30.05) 
Previous cardiovascular risk factors    
No (n= 42) 9 2 4 27  4.50 (0.97 ~ 20.83)  14.38 (1.84 ~ 112.4) 
Yes (n = 201) 27 16 25 133 1.69 (0.913 ~ 3.13) 3.53 (0.90 ~ 13.83) 
aCalculated by McNemar’s procedure for matched analyses (the ratio of subjects exposed only in the case period to subjects exposed only in the control 
period) and conditional logistic regression.   
bAdjustment for non-psychiatric outpatient visits and antidepressant use in the 60-day exposure periods  
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9.3.4 Differences between patients with schizophrenia and bipolar disorder 
Considering differences between schizophrenia and bipolar disorder, atypical 
antipsychotic use within the 12 months prior to AMI was found to be more frequent 
in patients with schizophrenia than in those with bipolar disorder (11.5% and 6.4% 
respectively; chi-square = 4.73, DF=1, p=0.030), and the quantity of antipsychotic 
use over the 12 months prior to AMI was higher (mean (SD) summed DDDs 54.1 
(90.3) and 13.8 (20.1) respectively; t =2.42, DF=8, p=0.042). The mean (SD) daily 
doses (DDD) of antipsychotic during the case period were 0.62 (0.52) in patients 
with schizophrenia and 0.25 (0.15) in those with bipolar disorder (t =2.77, DF=63, 
p=0.007). However, there were no marked differences in psychiatric hospitalization 
(9.0% and 7.0% respectively; chi-square = 0.88, DF=1, p=0.351) or combination of 
psychiatric hospitalization and antipsychotic prescription (5.9 % and 5.6 % 





9.4.1 Summary of main findings 
There has long been speculation about antipsychotic agents as one of the potential 
reasons for higher risk of cardiovascular disease in people with SMI (Brauer et al., 
2011). In this study, after adjusting for other potentially time-varying confounders, 
there was a 60% increased odds of recent antipsychotic exposure before AMI in 
people with schizophrenia in primary analyses, but the same was not observed in 
those with bipolar disorder. Within the group with schizophrenia, the association was 
significantly stronger in men, in people without previous cardiovascular diagnoses 
and in those with lower overall antipsychotic exposure during the 12 months 
preceding the AMI. However, AMI was not associated with the average dose of 
recent antipsychotic, so far as this could be ascertained, and it was not associated 
with an increase in the dose in people who were receiving antipsychotics during both 
comparison periods.   
 
The key finding was that antipsychotic exposure was significantly more common in 
the ‘case’ period compared to the ‘control’ period in patients with schizophrenia. The 
importance of the timing was further supported in the additional analyses when the 
control period was separated from the case period. Although the statistical 
significance of the association was reduced after further adjustment for changes in 
cardiovascular medication, the odds ratio did not change substantially and the 
inclusion of this covariate might represent over-adjustment since initiation of 
cardiovascular medication might have been an early sign of the incipient outcome. In 
agreement with the hypothesis stated in Chapter 5 that exposures of typical 
antipsychotic would be more common in the ‘case’ period than in the ‘control 
period’, it was revealed in Table 9.5 that typical antipsychotic agents have been used 
more commonly only in the case period than in the control period in people with 
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schizophrenia. Regarding possible mechanisms, the known longer-term 
cardiovascular risks associated with atypical antipsychotic use mediated through 
insulin resistance and obesity (Newcomer, 2007) would not be captured in this 
particular research design which focused on investigating shorter-term relationships. 
These might be associated with other vascular processes (Pariente et al., 2012) or 
conduction deficits, as have been proposed as potential causes of sudden cardiac 
death (Straus et al., 2004; Suvisaari et al., 2009) and have been reported in 
association with typical antipsychotic agents (Suvisaari, 2009; Vieweg, 2002; Wang, 
2007). It is important to bear in mind that, despite the positive association observed 
between recent antipsychotic exposure and AMI, since underlying mechanisms are 
still unclear, and the association might be accounted for by protopathic bias (i.e. the 
psychotic/physical state that led to the antipsychotic prescription), the interpretation 
of the key finding needs caution. Causal pathways and possible impacts clearly 
require further elucidation, particularly as the benefits of antipsychotic medication 
are likely to outweigh any increased risk of AMI, as described in previous literature 
demonstrating that lower mortality is associated with antipsychotic use in people 
with SMI (Tiihonen, 2009; Tiihonen, 2012).   
 
As well as the primary association itself, the finding that the risk of AMI is higher in 
people with lower overall antipsychotic exposure over the 12 months prior to AMI 
suggests that new initiation of antipsychotic may be associated particularly with 
increased risk. Unfortunately the data available (based on prescription) did not allow 
investigation of specific administration patterns, for example, peak single doses and 
emergency administrations. There was also no measure of adherence to prescribed 
medication. Although overall dose during the 60 day exposure periods did not differ 
or modify the association of interest, it is possible that patterns of administration 
might have varied which would need investigating in a database with information on 
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administration rather than prescription. Another question which is difficult to address 
conclusively is the extent to which the risk factor for AMI being observed is the 
antipsychotic agent itself or the symptoms being treated. Against the latter possibility, 
there was no difference found in inpatient care between the case and control periods; 
however, no data were available on specific symptom severity. It should be noted 
that the highest risk groups were found to be men with schizophrenia who had been 
relatively antipsychotic-naïve over the preceding 12 months. The author feels that, 
taken together, these facts are more consistent with an effect of treatment rather than 
underlying disorder on AMI; however, further investigation is clearly required.  
 
Contrary to expectations, the association between antipsychotic and AMI was found 
to be weaker rather than stronger in people with previous diagnoses of cardiovascular 
disease or cardiovascular risk factors compared to those without. An important 
consideration is that these data reflected recorded diagnoses and no data were 
available on measurements such as actual blood pressure or cholesterol levels. In 
particular, the group who had not received any cardiovascular diagnosis might have 
contained people with unrecognized morbidity who might be a group at particular 
risk, again an important issue requiring further investigation. If the antipsychotic 
agent itself can be considered a risk factor for AMI, one possible explanation for the 
observation is that administration may have been more cautious in people with 
known risk factors for cardiovascular disease. No evidence was found for differences 
in averaged antipsychotic doses; however, as previously mentioned, these may not 
reflect the pattern of administration such as the maximum single dose given.  
 
In contrast to schizophrenia, associations between AMI and recent antipsychotic use 
appeared absent in bipolar disorder. Potential reasons for the discrepancy between 
the two mental disorders might be the difference in disease presentation and 
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prescription patterns of psychotropics: for example, the inclusion of other 
pharmacotherapy such as lithium or anticonvulsants for acute care, either instead of 
antipsychotic agents or as a partial replacement so that lower single doses were 
required. However, it is important to note that an association remained between 
bipolar disorder and more recent antipsychotic exposure when the case period was 
compared to a control period one year previously. An association is therefore still 
possible which for some reason was not present with a more contiguous control 
period, perhaps because of other causal pathways. It should also be borne in mind 
that because of the hierarchical algorithm applied, the sample with bipolar disorder 
were smaller in size and might be skewed to include less prominently psychotic 
syndromes. Thus, the result of negative findings in bipolar patients described here 
may not apply to all bipolar patients. However, further analysis broadening the 
sample by including 250 more people who had been diagnosed with both bipolar 
disorder and schizophrenia showed results similar to the primary finding for bipolar 
disorder (adjusted OR = 1.14, 0.70~1.87).  
  
9.4.2 Strengths and Limitations 
From knowledge to date, this is the first study to date using a case-crossover design 
to investigate the association between recent antipsychotic exposure and risk of acute 
myocardial infarction. The specific focus on patients with serious mental illness and 
the national sample are also novel features. Strengths of this study include the 
relatively large samples of people with clinically diagnosed mental disorders who 
experienced a hospitalized AMI, drawn from a data resource with near-universal 
national coverage. Data availability included prescriptions of antipsychotic and other 
medications. The case-crossover design has substantial advantages, compared to a 
traditional cohort study, of removing the influence of between-individual 
confounding although (as will be discussed) time-varying confounders within 
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individuals do require consideration. Sensitivity analyses altering the control period 
additionally supported the robustness of the primary finding.  
 
Limitations include the fact that the majority of cases were drawn from a sub-register 
identifying people who had previously received inpatient mental health care and 
therefore the analysed sample represent cases with relatively severe illness which 
should be borne in mind when considering generalisability. In addition, the outcome 
was hospitalized AMI and would not include episodes which did not result in 
inpatient care or sudden deaths outside the hospital. Furthermore, as discussed earlier, 
there was limited depth of information about symptomatology. However, 
measurement errors in case or outcome ascertainments will have obscured rather than 
exaggerated the associations of interest. Finally, the study was limited in its ability to 
differentiate between individual antipsychotic agents (for example, on the basis of 
their receptor-binding profiles) because of insufficient statistical power. 
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CHAPTER 10  
GENERAL CONCLUSIONS AND IMPLICATIONS 
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10.1 Summary of key findings 
This thesis comprised investigations of three objectives: comparing risk of acute 
myocardial infarction (AMI) in people with/without serious mental illness (SMI), 
comparing intervention receipts following an AMI episode between these groups, 
and investigating short-term associations between AMI and recent antipsychotic 
exposure within the serious mental illness group. Key findings relevant to study 
objectives and hypotheses are listed below. 
 
Objective 1: ‘To investigate the relative risk of acute myocardial infarction 
among patients with serious mental illness’  
 
(1) Hypothesis: Compared with the national population, people with SMI will have a 
higher risk of acute myocardial infarction, independent of age, sex, previous 
history of cardiovascular risk factors, and levels of monthly income and 
urbanization levels. 
 
Summary of key findings: 
This hypothesis was only partly supported. Comparing 25,652 individuals with 
SMI and 182,814 individuals from the general population, no associations 
between exposure and outcome were found in the samples as a whole. However, 
age and gender stratified analyses showed a significant two-fold excess risk of 
AMI associated with SMI in women younger than 45 years of age.   
 
Objective 2: ‘To explore the intervention receipts, outcome of inpatient 
mortality or recurrence following the first acute myocardial infarction among 




Comparing outcomes following AMI between people with a previous history of SMI 
(cases) and those without such a history (controls), the hypotheses were as follows:  
 
(1) Diagnostic catheterization will be lower in cases compared to controls. 
 
Summary of key findings: 
This hypothesis was fully supported. People with SMI (case cohort) were less 
than half as likely to receive catheterization compared to controls (odds ratios 
(OR)= 0.37 and 0.38 in fully adjusted model for individuals with schizophrenia 
and bipolar disorder, respectively).  
 
(2) Receipt of revascularization will be lower in cases compared to controls. 
 
Summary of key findings: 
This hypothesis was fully supported. People with SMI (case cohort) were less 
than half as likely (OR=0.35 and 0.47 in fully adjusted model for individuals 
with schizophrenia and bipolar disorder, respectively) to receive 
revascularization compared to controls. 
 
(4) Receipt of revascularization after catheterization will be lower in cases compared 
to controls. 
 
Summary of key findings: 
This hypothesis was partly supported. The odds of receiving revascularization 
after catheterization were 0.59~0.68 times lower in people with serious mental 





(5) Inpatient complications following acute myocardial infarction will be higher in 
cases compared to controls. 
 
Summary of key findings: 
This hypothesis was not supported. Prevalences of inpatient complications 
following an AMI were not significantly higher in people with serious mental 
illness, except for respiratory failure in people with schizophrenia.  
 
(6) The 30-day inpatient mortality following an AMI will be higher in cases 
compared to controls.  
 
Summary of key findings: 
This hypothesis was partly supported. The 30-day inpatient mortality following 
an acute myocardial infarction was 2.68 times significantly higher in people with 
schizophrenia compared to controls, but was not significantly higher in people 
with bipolar disorder. 
 
(7) Recurrence of AMI within and after one year following discharge will be higher 
in cases compared to controls. 
 
Summary of key findings: 
This hypothesis was not supported. The odds of re-admissions due to a second 
AMI after one month or after a year following discharge were not significantly 
higher in people with serious mental illness in the fully adjusted model.  
 
(8) Hospitalizations due to other cardiovascular diseases within and after a year after 
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discharge will be higher in cases compared to controls.  
 
Summary of key findings: 
This hypothesis was only partly supported. Odds of hospitalizations due to other 
cardiovascular diseases within and after a year following discharge were not 
significantly higher in people with serious mental illness in the fully adjusted 
model, except for hospitalization due to new onset of cardiogenic shock in people 
with schizophrenia and people with bipolar disorder. 
 
Objective 3: ‘To investigate the associations between acute myocardial 
infarction and recent antipsychotic use among people with serious mental 
illness’ 
 
Comparing a more recent (case) with a more distant (control) time period in people 
with serious mental illness who experienced an acute myocardial infarction, the 
hypotheses were as follows:  
 
(1) Antipsychotic exposure will be more common in the case time period compared 
to the control time period. 
 
Summary of key findings: 
This hypothesis was partly supported. Recent antipsychotic exposure before the 
occurrence of index AMI episode was found to be more common in people with 
schizophrenia, but not in people with bipolar disorder. However, the association 
was significant for both disorders when the case period was compared with a 
control period 12 months previously. The association in schizophrenia was 




(2) The average dose of antipsychotic will be higher in the case period compared to 
the control period. 
 
Summary of key findings: 
Contrary to the hypothesis, the average dose of antipsychotic prescription was 
not significantly higher in the case period, either in people with schizophrenia or 
bipolar disorder. Trends suggesting a dose-dependent relationship were also not 
observed.   
 
(3) Use of typical antipsychotic will be more common in the case period compared to 
the control period. 
 
Summary of key findings: 
This hypothesis was partly supported in people with schizophrenia, but not in 
people with bipolar disorder. The result showed that typical antipsychotic agents 
were prescribed more often in the case period than in the control period.  
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10.2 Summary of core methodological issues 
10.2.1 Key strengths of this study 
Taking the advantage of this large, population-based sample, the research described 
in this thesis possessed sufficient statistical power - an important methodological 
challenge in studies of serious mental illness and AMI because of the difficulties 
encountered in many settings in obtaining numbers large enough to draw meaningful 
results. In addition, this thesis analysed nationally-representative data with the high 
generalisability of a naturalistic clinical environment.  
 
10.2.2 Methodological considerations 
The main methodological limitations are considered below under the headings of 




Results that are statistically significant (i.e. applying the conventional definition of a 
p-value less than 0.05) indicated an acceptably low risk of Type I error, (also known 
as a false rejection of the null hypothesis, or a ‘false-positive’ finding) (Stewart, 
2008). However, this assumption concerns an association between a single primary 
exposure and outcome, and the possibility of Type I error should still be borne in 
mind when considering multiple and secondary or subgroup analyses. For instance, 
in Chapter 7, the positive association between SMI and increased risk of AMI found 
in the subgroup of young women might have arisen by chance, although this 
subgroup analysis was planned a priori, based on an assumption age and gender 
might have modifying effects on the association of interest. The pattern of stronger 
associations in younger people was also observed consistently across the age range 
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of the sample, rather than being confined to a single subgroup which reduces the 
likelihood of this error. The multiple outcomes investigated in Chapter 8 would 
increase the chance of Type I error, although these were again conducted based on a 
logical, a priori approach to consequences of post-AMI care. In Chapter 9, stratified 
analyses were exploratory but kept to a relatively small number, and interaction tests 
were examined rather than just reporting significant findings within a subgroup.  
 
Type II error describes the incorrect acceptance of a null hypothesis (i.e. a ‘false- 
negative’ finding) and may arise either because of a lack of statistical power or 
measurement error. Lack of statistical power can be considered in relation to the 
relatively small numbers of AMI instances in younger age groups investigated in 
Chapter 7, some of the more rare outcomes in Chapter 8, and possibly the null 
association between more recent antipsychotic use and AMI among people with 
bipolar disorder described in Chapter 9. In this respect, a post hoc power analysis 
calculated using the PS program (Dupont, 1992) showed a required number of 500 
case patients needed in order to achieve a 70% power with an alpha (probability of 
Type 1 error) of 0.05.  
 
Bias 
As discussed in the previous chapters, there are potentially important considerations 
regarding selection bias. The first concerns the potential misclassification of true 
cases (patients with SMI), because the study sample was drawn from an 
administrative dataset without validated interviews and the application of research 
diagnostic criteria. Second, people with AMI who died outside a hospital would not 
have been captured as having outcome events in Chapter 9 and would not have been 
included in the samples analysed in Chapters 10 and 11. Third, the sample size of 
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the bipolar group was relatively small and cautions should be taken when 
generalising the results due to the hierarchical classification algorithm applied as 
well as any misdiagnosis of cases as unipolar depression. Fourth, the majority of the 
case cohorts examined were individuals with SMI who had received hospitalization 
in mental health units, thus the generalisability may be limited to people more 
severely affected by these diagnoses. The effect of this particular selection process 
on findings of interest is difficult to predict; on the one hand, those with more severe 
symptomatology may be at higher risk of adverse outcomes because of effects of 
acute illness; on the other hand, they would have received more medical contact than 
those less well recognised and the latter group might have more negative 
symptomatology and poorer outcomes due to self-neglect. Fifth, in terms of 
information bias, although recall bias would not be an issue, patients’ medical 
records were only available within a specified time window and it was not possible 
to assume that the index AMI was the first occurrence; neither was it possible to 
consider past psychiatric history or the duration of each mental disorder of interest 
though efforts were made in sensitivity analyses to address this.  
 
Confounding 
As described previously, although basic demographic characteristics (such as gender, 
age, levels of income and urbanization of residence) and previous diagnosed 
cardiovascular risk factors could be obtained and investigated as covariates, other 
information relevant to vascular risk (such as smoking status, physical activity, 
obesity, and psychosocial factors) was not available in this routine administrative 
record. Thus, the possibility of residual confounding still remains. For instance, in 
Chapter 7, although unmeasured, it is possible that the higher prevalence of 
cigarette smoking and unhealthy lifestyles among young women with SMI in Taiwan 
(Liao, 2002) might be responsible for the observed positive association. Similarly, of 
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relevance to findings in Chapter 8, previous research has discussed the possibility of 
medical professionals’ reluctance to offer some post-AMI procedures to smokers due 
to concerns about potential adverse effects of cigarette smoking on post-operative 
care (Daumit et al., 2006; Kisely et al., 2009; Mallik et al., 2005; McDonald et al., 
2003). The possible effects of these unhealthy lifestyle factors on the 
decision-making process of medical personnel should therefore be considered when 
interpreting findings. Another key confounder might be patients’ actual cognitive 
function and their ability to express opinions or to comprehend instructions during 
hospitalization following AMI. This might explain some of the worse outcomes for 
patients with schizophrenia compared to those with bipolar disorder. Finally, in 
Chapter 9, the effects of unmeasured personal characteristics as confounders were 
not as influential as in Chapters 8 and 9 because comparisons were made between 
two different time periods within the same individual. However, it is still important 
to bear in mind that there are other possible time-varying confounders that might 
account for the associations of interest but which could not be measured from the 
data available. Of particular importance is the remaining question of whether it is 
antipsychotic agents or the symptoms or behaviours being treated which are 
responsible for an apparent raised short-term risk of AMI.  
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10.3 Summary of issues that cut across three result chapters 
10.3.1 Components of disadvantage 
Although cardiovascular mortality is higher in people with SMI in Taiwan compared 
to controls (Chen WJ et al., 1996; Chen YH et al., 2010), findings for risk of AMI 
incidence in this study did not explain this for schizophrenia, apart from the 
relatively rare occurrence in young women, and were complex for bipolar disorder, 
highly dependent on other factors included in regression models. However, as 
discussed in Chapter 7, the incident AMI in this study only reflected recognized and 
hospitalized AMI and thus this risk might have been underestimated. On the other 
hand, people with SMI were found to be less likely to receive invasive coronary 
interventions; and for schizophrenia at least, inpatient mortality was higher. From 
these findings, it is possible that the higher risk of an end-point such as mortality is 
more explained (in Taiwan at least) by less adequate care (or possibly sudden 
non-hospitalized AMI) rather than AMI incidence itself. A recently reported 
Australian investigation of cancer outcomes in SMI appeared to draw similar 
conclusions – i.e. that higher cancer mortality was not due to higher overall cancer 
incidence but to delayed presentation and less adequate intervention(Kisely, Crowe, 
et al., 2012). On the other hand, findings reported in Chapter 9 were consistent with 
a role of antipsychotic agents, within schizophrenia at least, as a short-term 
precipitant. 
 
10.3.2 Differences between mental disorders 
A second common finding concerned differences between schizophrenia and bipolar 
disorder. These were not always observed: for example, the reduced odds of 
intervention receipt in both mental disorders. However, there were several 
differences in other findings. First, as stated in Chapter 7, although in both mental 
disorders, the excess risk of AMI was higher in women less than 45 years of age, 
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such risk association disappeared in young women with bipolar disorder in the 
sensitivity analysis when early AMI was excluded. Second, despite having similarly 
increased odds of developing cardiovascular complications, the 30-day inpatient 
mortality following the index AMI was significantly higher in patients with 
schizophrenia, whereas no significant difference between those with bipolar disorder 
and the comparison group was found. Third, as described in Chapter 9, associations 
between AMI and recent antipsychotic exposure was found in people with 
schizophrenia but was not present for bipolar disorder in the primary analyses. The 
aforementioned differences between two mental disorders might reflect again the 
degree of health disadvantage is more severe in people with schizophrenia. Although 
interpretation should be made with caution due to the much smaller sample size in 
bipolar disorder, it would be worth investigating whether differences in disease 
presentation during the acute psychotic episode or patterns and strategies of 
antipsychotic initiation are the potential factors for the disparity, both in associations 
with antipsychotic exposure and in post-AMI outcome.   
 
10.3.3 Acute and chronic risk effects with different causal pathways 
The results from Chapter 7 where young women with SMI were found to have 
elevated risk of AMI, can be contrasted with those from Chapter 9 where recent 
antipsychotic exposure was associated with AMI particularly in male patients with 
schizophrenia without previous cardiovascular risk factors. One possible explanation 
is that the risk of AMI, at least in people with schizophrenia, is mediated through 
different causal pathways with respect to short-term and long-term risks. Interactions 
of disease severity, behavioral disruptions, drug compliance, identification of 
underlying cardiovascular risk factors, with physicians’ prescription patterns between 




10.4.1 Public health implications 
As discussed in previous chapters, the raised risk of AMI in young women with 
schizophrenia and bipolar disorder could only be partially explained by demographic 
characteristics and cardiovascular comorbidities. Although derived from subgroup 
analyses, the worrying pronounced increase in AMI risk in young women is relevant 
from a public health perspective because health education, encouragements of 
changes in lifestyle might be indicated, or as evidence suggests, a reduction in the 
prevalence and impact of cardiovascular risk factors through offering advice and/or 
information for health promotion alongside recovery-focused support from mental 
health nurses (Hardy et al., 2012; Tosh et al., 2011). Potentially relevant in this 
respect, a recent study concluded that the legally framed ‘community treatment 
orders’ in Western Australia (under which, patients with serious mental illness are 
required to accept psychiatric treatments) were able to reduce mortality from 
physical causes such as cancer, cardiovascular, and central nervous system disorders 
through increasing contacts to health services or better access to medical resources in 
patients with mental illness (Kisely, Preston, et al., 2012). 
 
With respect to the elevated inpatient mortality after AMI in schizophrenia, and 
decreased odds of intervention receipts following an AMI, although it is not possible 
to control the occurrence of misfortune or prevent all environmental stressors, health 
inequity threatening the physical health of people with SMI should be minimized. 
Policy implications should be considered with respect to legal frameworks around 
the decision-making process of treatment administration, promoting equality in 
physical healthcare for people with chronic severe mental disorders. Educational 
programmes to raise the awareness in medical personnel of underlying disadvantages 




10.4.2 Clinical implications 
As well as public health interventions to improve cardiovascular risk factors at a 
population level and increase awareness of health inequalities, there are other 
potentially more direct implications for clinical services. Considering results from 
Chapter 7, it is important to bear in mind that the finding of no increased risk of 
AMI in this study might have arisen through under-detection or under-referral for 
physical disorders in people with SMI in Taiwan. Thus, there remains a need to 
provide equal access to cardiovascular screening (Osborn et al., 2003; Pitman et al., 
2011; Osborn et al., 2011) and relevant treatments to people with SMI in order to 
prevent excess incidence of AMI.  
 
The finding that patients with either mental disorder were half as likely to receive 
catheterization or revascularization procedures following the index AMI is clearly 
concerning, particularly considering that the Taiwan health system is a relatively 
accessible and un-rationed healthcare system. Although it is possible that there are 
reasons beyond anyone’s control why these standard procedures were not feasible, 
the decision-making process of medical personnel still merits further consideration. 
If the reasons for low intervention receipt include refusal of treatment from people 
with serious mental illness or their family, medical personnel may still need to 
consider how they address and discuss the contents of the intervention process and 
prognosis. In particular, they should consider strategies for people with these mental 
disorders, employing more effective communications and a more humanistic 
approach. Specific measures might included maintaining patients’ engagement in 
receiving medical care, better understanding of clients’ and caregivers’ situations or 
concerns, provision of emotional support, working with existing strengths, and 
conveying hope for the long-term (Bellack, 2006; Browne et al., 2008; Eldridge et al., 
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2011; Horsfall et al., 2010). Attitudes toward specific treatment and whether all the 
relevant information has been revealed and contemplated sufficiently by patients or 
their families should all be taken into consideration, especially when previous 
literature has demonstrated great success in providing health services when 
incorporating the participation of clinicians and family members (Dixon, 1999b).  
 
Another method to reduce barriers of access to medical care in patients with SMI 
might be to enhance collaborations between mental health services and primary care. 
Previous research has suggested that improved receipt of preventive measures, fewer 
visits to emergency departments, and greater improvement in quality and outcomes 
of medical care can be achieved by more closely integrating mental health and 
primary care (Druss, 2001b; Dombrovski, 2004; Pincus, 2003). Additional benefits 
have been derived from training psychiatrists to provide primary medical care 
(Dobscha, 2001), and from building ‘collaborative models of care’ which introduce 
internal or family medicine clinicians to mental health clinics or inpatient units 
(Silberman, 1999). Such collaborations or information changes (Horvitz-Lennon et 
al., 2006) to bridge the gap between general medicine and services more typically 
received by patients with SMI are currently lacking in the health care system in 
Taiwan and thus might be a future direction to work on.   
 
Since undetected medical comorbidities occurring during hospitalizations 
(Cradock-O’Leary et al., 2002; Daumit, 2006) might be a reason for the elevated 
inpatient mortality in schizophrenia which was not fully explained by decreased 
likelihood of intervention receipt, it is important that medical personnel i) are more 
aware of potential underlying communication difficulties, ii) evaluate patients with 
SMI on regular basis (Laursen, 2009), iii) use specific monitoring equipment 
(Eldridge et al., 2011), and iv) pay more attention to the early identification of 
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potential disease signs, perhaps particularly in the context of active psychotic 
symptoms or where medically indicated treatments are refused. In addition, 
principles of remaining ‘ALERT’ when assessing patients with SMI highlighted by 
The Royal College of Psychiatrists in the UK have also been suggested (Hardy et al, 
2012). The five priorities of ‘ALERT’ (The Royal College of Psychiatrists, 2009) are 
as follows: 
• Awareness of the link between physical and mental health  
• Liaison mental health services in all general hospitals 
• Engaging patients and carers in health services 
• Re-organization, commissioning, and quality standards (e.g. liaison mental health 
services should be commissioned and reviewed against agreed specific service 
standards).  
• Training and education for all health-care professionals.   
 
An implication for mental health services, related to findings from Chapter 9 in 
particular, is that medical personnel should be cautious in considering cardiovascular 
side effects or early pre-AMI symptomatology when initiating antipsychotic 
treatment, especially in men with schizophrenia. Moreover, as discussed in the same 
chapter, the finding of a stronger association between AMI and recent antipsychotic 
exposure in the group with no previous cardiovascular risk factors also suggests a 
need for more rigorous medical attention to identify risk profiles for AMI among 
people with serious mental illness, potentially moving beyond simply asking about 
known diagnoses. 
 
10.4.3 Research implications 
Regarding the main result in Chapter 7 where elevated risk of AMI was found in 
young women with schizophrenia or bipolar disorder, future investigations need to 
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focus on clarifying causal pathways, particularly focusing on gender differences in 
people with severe mental disorders within these age ranges. An example of this 
might be the potential increase in hypercoagulability in women with SMI who use 
contraceptive pills and/or who are current smokers (Daumit, 2006). Given the 
recognised increased risk of cardiovascular mortality and substantially reduced life 
expectancy in people with major mental disorders, research is also required into how 
much this is accounted for by AMI risk and incidence and how much by subsequent 
interventions received by people with mental disorders who experience an AMI.  
 
As discussed in Chapter 8, the clear excess of inpatient mortality during AMI 
episodes in patients with schizophrenia but not bipolar disorder despite similar 
complication rates during hospitalization suggests that psychotic disorders should not 
be combined for analyses in this area. Further research exploring underlying reasons 
for these differences in outcome between patients with schizophrenia and bipolar 
disorder may need to be conducted. On the other hand, given the substantially 
reduced life expectancy in people with major mental disorders, research also 
suggests a need to understand further the clinical interactions and relationships 
between patients, their caregivers, and medical providers. For example, previous 
qualitative studies found that conceptualisations of stroke illness and ageing, 
socio-economic factors, resource allocation, and information provision were main 
themes affecting inequity in stroke care (Mold, 2003). Also, process-typed, 
qualitative research has explored the interface at clinical level, such as how the 
motivation, attitudes, and expectations to treat AMI in people with SMI among 
health care professionals might be influenced (Becker & Kaufman, 1995; Pound & 
Ebrahim 1997). Likewise, there is a need for better understanding of interactions 
with patient themselves and how conceptualizations may interact and affect the 




As mentioned previously in Chapter 4 and discussed in Chapter 9, from the 
literature to date, this is the first study to investigate the association between AMI 
and recent antipsychotic exposure in SMI, applying a case-crossover design. What 
this method tests are essentially short-term precipitating actions related to the 
exposure, rather than long term risk, which should be borne in mind when 
interpreting results. Although it is still too early to draw conclusions about changes in 
antipsychotic treatment guidelines, the primary association in schizophrenia still 
supports a need for further investigation of potential risk effects and close monitoring 
of patients particularly during antipsychotic initiation. As well as this, potential 
thrombotic effects (Parker, 2010), and other physical changes during the psychotic 
state still warrant future exploration, such as dehydration, immobility, or increased 
cigarette smoking, which in turn might cause a pro-inflammatory response, platelet 
aggregation, or vessel spasm (Hagg & Spigset, 2002; Zornberg & Jick, 2000), 
leading to AMI in addition to any short-term effects of antipsychotic medication. 
Finally, the modifying factors identified (gender, diagnosis, cardiovascular risk and 
previous antipsychotic use) support the development and evaluation of personalized 
risk prediction models as well as providing potential avenues for further investigation 
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Appendix 1 Detailed lists of data files applied from the NHIRD 
The following application lists of compact discs are based on the information provided 
from the website of NHIRD  (http://www.nhri.org.tw/nhird)  




Serial number of 
the compact disc 
that contained 
data 
Name of the file 
(in Mandrin) 
English description of the file 





Psychiatric Ambulatory care (as the 
‘CD’ files mentioned in chapter 6) 
expenditures by visits, prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Profiles of psychiatric patients (as the 
‘ID’ file mentioned in chapter 6), 
psychiatric Inpatient expenditures (as 
the ‘DD’ files mentioned in chapter 6) 






Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 







Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 






Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
1999 TN88PSY04 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
1999 TN88PSY05 精神疾病病患 住院醫療費用清單
明細檔，精神疾病病患 住院醫療費
用醫令清單明細檔 
Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 
admissions, prescriptions and 
treatment files 
2000 TN89PSY01 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2000 TN89PSY02 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2000 TN89PSY03 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2000 TN89PSY04 精神疾病病患 住院醫療費用清單
明細檔 
Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 
admissions files 
2000 TN89PSY05 精神疾病病患 住院醫療費用醫令
清單明細檔 
Psychiatric inpatient prescriptions and 
treatment files 
2001 TN90PSY01 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2001 TN90PSY02 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
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明細檔 and treatment files 
2001 TN90PSY03 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2001 TN90PSY04 精神疾病病患 住院醫療費用清單
明細檔 
Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 
admissions files 
2001 TN90PSY05 精神疾病病患 住院醫療費用醫令
清單明細檔 
Psychiatric inpatient prescriptions and 
treatment files 
2001 TN90PSY06 精神疾病病患 住院醫療費用醫令
清單明細檔 
Psychiatric inpatient prescriptions and 
treatment files 
2002 TN91PSY01 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2002 TN91PSY02 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2002 TN91PSY03 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2002 TN91PSY04 精神疾病病患 住院醫療費用清單
明細檔 
Psychiatric Inpatient expenditures by 
admissions files 
2002 TN91PSY05 精神疾病病患 住院醫療費用醫令
清單明細檔，精神疾病病患 承保資
料 
Profiles of psychiatric patients, 
psychiatric inpatient prescriptions and 
treatment files 
2003 TN92PSY01 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2003 TN92PSY02 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2003 TN92PSY03 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 




Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 




2004 TN93PSY01 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2004 TN93PSY02 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 
2004 TN93PSY03 精神疾病病患 門診處方及治療明
細檔，精神疾病病患 門診處方醫令
明細檔 
Psychiatric Ambulatory care 
expenditures by visits prescriptions 
and treatment files 




Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 






Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 






Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 






Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 






Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 








Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 





Psychiatric Ambulatory care 
expenditures by visits prescriptions 






Profiles of psychiatric patients, 
psychiatric Inpatient expenditures by 
admissions, prescriptions and 
treatment files 





Patient profiles (as the ‘ID’ files 
mentioned in chapter 6), Ambulatory 
care (as the ‘CD’ files mentioned in 
chapter 6) expenditures by visits 
prescriptions and treatments, Inpatient 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles , Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
(as the ‘DD’ files mentioned in chapter 
6) by admissions, prescriptions and 
treatment files 
1999 RN10_1999_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 
prescriptions and treatments 







expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2004 RN10_2004_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN10_2005_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 




Patient profiles, Ambulatory care 






and treatments, Inpatient expenditures 






Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
1999 RN20_1999_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 










Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2004 RN20_2004_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN20_2005_2 門診處方醫令明細檔 
Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2007 RN20_2007_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 





Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 




Patient profiles, Ambulatory care 






and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
1999 RN01_1999_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions files, Prescription files 
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2004 RN01_2004_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN01_2005_2 門診處方醫令明細檔 Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 






Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
1999 RN06_1999_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 









Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2004 RN06_2004_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN06_2005_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 







expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2007 RN06_2007_1 門診處方醫令明細檔 
Ambulatory care expenditures by visits 





Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
1999 RN14_1999_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 




Patient profiles, Ambulatory care 






and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2004 RN14_2004_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN14_2005_2 門診處方醫令明細檔 
Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 






Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 







expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
1999 RN19_1999_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions files, Prescription files 
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2004 RN19_2004_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
2005 RN19_2005_2 門診處方醫令明細檔 
Ambulatory care expenditures by visits 







Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 








Patient profiles, Ambulatory care 
expenditures by visits prescriptions 
and treatments, Inpatient expenditures 
by admissions, prescriptions and 
treatment files 
Registry for catastrophic illness (severe mental or physical illness) patients  
1996 
AN8501 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness (as the ‘HV’ file 
mentioned in chapter 6) 
1997 AN8601 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
1998 
AN8701 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
1999 
AN8801 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2000 
AN8901 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2001 
AN9001 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2002 
AN9102 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2003 
AN9202 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2004 
AN9302 重大傷病證明明細檔 Profiles of patients with severe mental 




AN9402 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2006 
AN9502 重大傷病證明明細檔 Profiles of patients with severe mental 
or physical illness  
2007 
AN9602 重大傷病證明明細檔 Profiles of patients with severe mental 




Appendix 2 Lists of variables used for the analysis from four main subsets of 
Registry for beneficiaries (‘ID’), Ambulatory care expenditures by visits (‘CD’), 
Inpatient expenditures by admissions (‘DD’), Registry for catastrophic illness 
(severe mental or physical illness) patients subsets (‘HV’), and Ambulatory care 
prescriptions and treatments by visits (‘OO’) 
 
 
Number Variable name English description of the variable 
Registry for beneficiaries (‘ID’) 
1 ID Individual ID number 
2 INS_ID The ID number of the ‘Insured person’ 
3 INS_ID_TYPE 
Whether the person is the one that pays the 
premium or is the dependent of ‘insured person’. 
(*so if a person is the dependent, then his ID will 
not be his INS_ID) 
4 INS_AMT ‘Insured amount’: the proxy measure for monthly 
income 
5 ID_BIRTHDAY Date of birth 
6 ID_SEX Gender 
7 INS_RELATION The relationship with the ‘insured person’ 
8 AREA_NO_I The code for place of residence 
9 ID_IN_TYPE 
Status of being registered to National Health 
Insurance 
10 ID_IN_DATE Date of registration 
11 ID_OUT_TYPE 
Status of being withdrawal from National Health 
Insurance 
12 ID_OUT_DATE Date of withdrawal 
Ambulatory care expenditures by visits (‘CD’) 
1 FEE_YM Month and date of the claim 
2 
APPL_TYPE Application made for regular claims or for auditing 
purposes 
3 HOSP_ID ID number of the hospital making the claim 
4 APPL_DATE Date of applying for the claim 
5 CASE_TYPE Ambulatory care, emergency care, or inpatient care
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6 SEQ_NO Sequential number  
11 FUNC_TYPE Department the ambulatory care visit (eg. 
cardiology, or psychiatry) 
12 FUNC_DATE Date of visiting the ambulatory care  
13 TREAT_END_DATE Date of finishing the ambulatory care visit 
14 ID_BIRTHDAY Date of birth 
11 ID Individual ID number 
19 ACODE_ICD9_1 Main disease code using ICD-9-CM 
20 ACODE_ICD9_2 Second disease code using ICD-9-CM 
21 ACODE_ICD9_3 Third disease code using ICD-9-CM 
22 ICD_OP_CODE Procedure codes using ICD-9-OP-code 
23 DRUG_DAY Total days of prescriptions 
24 PRSN_ID ID number of the physician 
37 ID_SEX Gender 
Inpatient expenditures by admissions (‘DD’) 
1 FEE_YM Month and date of the claim 
2 
APPL_TYPE Application made for regular claims or for auditing 
purposes 
3 HOSP_ID ID number of the hospital making the claim 
4 APPL_DATE Date of applying for the claim 
5 CASE_TYPE Ambulatory care, emergency care, or inpatient care
6 SEQ_NO Sequential number  
7 ID Individual ID number 
8 ID_BIRTHDAY Date of birth 
12 FUNC_TYPE Department the inpatient admission (eg. cardiology, 
or psychiatry) 
13 IN_DATE Date of admission  
14 OUT_DATE Date of discharge 
15 APPL_BEG_DATE Start date of the inpatient reimbursement claim 
16 APPL_END_DATE End date of the inpatient reimbursement claim 
17 E_BED_DAY Admission days in acute ward 
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18 S_BED_DAY Admission days in chronic ward 
19 PRSN_ID ID number of the physician 
23 TRAN_CODE 
Result of this admission: 1. discharged; 2. 
hospitalization continues; 3. change to ambulatory 
care; 4. Inpatient mortality; 
5.Against advice discharge; 6. Transfer to another 
hospital; 7. Change name; 8. Run away; 9. 
Committed suicide; 0: others  
24 ICD9CM_CODE Main disease code using ICD-9-CM 
25 ICD9CM_CODE_1 Second disease code using ICD-9-CM 
26 ICD9CM_CODE_2 Third disease code using ICD-9-CM 
27 ICD9CM_CODE_3 Fourth disease code using ICD-9-CM 
28 ICD9CM_CODE_4 Fifth disease code using ICD-9-CM 
29 ICD_OP_CODE Main procedure codes during this admission 
30 ICD_OP_CODE_1 Second procedure codes during this admission 
31 ICD_OP_CODE_2 Third procedure codes during this admission 
32 ICD_OP_CODE_3 Fourth procedure codes during this admission 
33 ICD_OP_CODE_4 Fifth procedure codes during this admission 
70 ID_SEX Gender 
Registry for catastrophic illness (severe mental or physical illness) patients subsets 
(‘HV’) 
1 ID Individual ID number 
2 DISE_CODE Disease code using ICD-9-CM 
3 HV_TYPE Types of severe mental or physical illness 
4 ID_BIRTHDAY Date of birth 
5 ID_SEX Gender 
6 APPL_DATE Date of applying for the claim 
7 APPL_TYPE Application made for regular claims or for auditing 
purposes 
8 HOSP_ID ID number of the hospital making the claim 
9 PRSN_ID ID number of the physician 
Ambulatory care prescriptions and treatments by visits (‘OO’) 
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1 FEE_YM Month and date of the claim 
2 
APPL_TYPE Application made for regular claims or for auditing 
purposes 
3 HOSP_ID ID number of the hospital making the claim 
4 APPL_DATE Date of applying for the claim 
5 CASE_TYPE Ambulatory care, emergency care, or inpatient care
6 SEQ_NO Sequential number  
8 DRUG_NO The number of drug prescribed 
9 DRUG_USE Drug dose prescribed by the physician 
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